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Abstract  
  
The Gram-negative saprophyte Burkholderia pseudomallei is the causative agent of 
melioidosis, an infectious disease which is endemic in Southeast Asia and northern 
Australia.  This bacterium possesses many virulence factors which are thought to 
contribute to its survival and pathogenicity.  Six genes BPSL2033, BP1026B_I2784, 
BP1026B_I2780, BURPS1106A_A0094, BURPS1106A_1131 and BURPS1710A_1419 
were identified earlier in a screen by PCR-based subtractive hybridization, using a 
virulent clinical isolate of B. pseudomallei and a laboratory-acquired attenuated strain of 
the same isolate of B. pseudomallei.  Therefore, the first objective of this study was to 
extensively characterize these genes at the molecular level, as well as one additional 
gene BPSL3147 identified by other investigators.  Through a reverse genetic approach, 
single-gene knockout mutants were successfully constructed by using site-specific 
insertion mutagenesis and confirmed by PCR.  Likewise, complemented strains were 
successfully obtained by reintroducing an intact copy of the defective gene into the 
corresponding mutant strains.  BPSL2033::Km and BURPS1710A_1419::Km mutants 
showed reduced survival inside macrophage RAW 264.7 cells and also low attenuation 
level in the virulence of nematode infection model.  However, BPSL2033::Km only 
demonstrated a weak statistical significance (p=0.049) of intracellular survival 
compared to the wild type at 8 hour post infection in macrophage infection study but 
BURPS1710A_1419::Km showed a p-value of 0.165.  Nevertheless, complemented 
strains of both genes were able to partially restore the gene defect both in vitro and in 
vivo studies, thus suggesting that they individually play a minor role in the virulence of 
B. pseudomallei.  Lack of a universally acceptable antigen for serodiagnosis of 
infections caused by B. pseudomallei is another clinical challenge.  The second 
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objective of this study was to search for an immunogen via a shotgun expression library 
created from clinically confirmed local virulent isolates of B. pseudomallei.  After 2 
rounds of immunoscreening with sera from melioidosis patients, 6 sero-positive clones 
expressing immunogenic polypeptides were sequenced and their identities were: 
BPSS1904 (benzoate 1,2-dioxygenase beta subunit), BURPS1710b_0454 (a putative 
200 kDa antigen p200), BPSS1856 (phosphotransferase enzyme family protein), 
BPSS0897 (short chain dehydrogenase), BPSL3130 and BPSS1757 (hypothetical 
proteins).  These immunogenic polypeptides were then purified and transferred to an 
ELISA platform for further large scale screening.  Experimental screening using 60 
melioidosis positive and 123 non-melioidosis sera allowed the identification of 2 
immunogenic polypeptides BPSS1904 and BPSL3130 with diagnostic potential, which 
demonstrated sensitivities of 75% and 90%, and specificities of 90.24% and 88.62%, 
respectively.  The results suggest that both are potential candidate antigens for the 
serodiagnosis of infections caused by B. pseudomallei.  In summary, the present study 
suggests that BPSL2033 and BURPS1710A_1419 genes to be associated with virulence 
of B. pseudomallei, while immunogenic polypeptides BPSS1904 and BPSL3130 were 
shown to be potential antigens for the serological diagnosis of its infection. 
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Abstrak  
  
Burkholderia pseudomallei merupakan sejenis bakteria gram-negatif yang bersifat 
saprofit.  Bakteria ini adalah agen penyebab melioidosis iaitu penyakit berjangkit yang 
berleluasa di Asia Tenggara dan utara Australia.  Ia berupaya menghasilkan pelbagai 
faktor kevirulenan yang membantu dalam kemandirian dan kepatogenan.  Enam gen 
BPSL2033, BP1026B_I2784, BP1026B_I2780, BURPS1106A_A0094, 
BURPS1106A_1131 dan BURPS1710A_1419 telah dikenal pasti terlebih dahulu oleh 
‘PCR-based subtractive hybridization’ dalam saringan menggunakan pencilan klinikal 
virulen B. pseudomallei dan pencilan makmal yang teratenuasi.  Oleh itu, objektif 
pertama penyelidikan ini merupakan pencirian gen-gen tersebut serta satu gen tambahan 
BPSL3147 yang telah dikenal pasti oleh penyelidik lain pada peringkat molekul.  
Melalui cara genetik terbalik, mutan-mutan ‘knockout’ gen tunggal telah berjaya dibina 
dengan menggunakan mutagenesis kemasukan (insertion) spesifik dan disahkan oleh 
PCR.  Di samping itu, komplemen bagi setiap mutant juga berjaya dibina dengan 
memperkenalkan semula satu salinan gen yang berkenaan ke dalam strain mutan 
masing-masing.  Mutan BPSL2033::Km dan BURPS1710A_1419::Km telah 
menunjukkan pengurangan kemandirian dalam makrofaj RAW 264.7 dan tahap atenuasi 
yang rendah dalam model jangkitan nematod.  Walau bagaimanapun, hanya 
BPSL2033::Km menunjukkan perbezaan statistik signifikan yang lemah (p=0.049) 
selepas 8 jam selepas infeksi dalam makrofaj berbanding dari strain jenis liar, manakala 
BURPS1710A_1419::Km menunjukkan nilai p=0.165.  Walau bagaimanapun, 
komplemen bagi kedua-dua gen dapat memulihkan kecacatan gen sekurang-kurangnya 
sebahagiannya dalam kajian in vitro dan in vivo.  Keputusan ini menunjukkan bahawa 
kedua-dua gen memainkan peranan minor dalam kevirulenan dalam B. pseudomallei 
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secara individu.  Kekurangan antigen universal yang boleh diterima untuk serodiagnosis 
jangkitan disebabkan oleh B. pseudomallei adalah satu lagi cabaran klinikal.  Oleh itu, 
objektif kedua penyelidikan ialah mencari immunogen melalui ‘shotgun expression 
library’ yang dibina daripada pencilan klinikal tempatan B. pseudomallei.  Selepas 2 
saringan dengan meggunakan sera daripada pesakit melioidosis, 6 klon positif 
mengekspresi polipeptida imunogenik telah didapati dan identiti adalah seperti berikut: 
BPSS1904 (benzoate 1,2-dioxygenase beta subunik), BURPS1710b_0454 
(‘putative’200 kDa antigen p200), BPSS1856 (enzim phosphotransferase keluarga 
protein), BPSS0897 (dehidrogenase rantaian pendek), dan BPSL3130 dan BPSS1757 
(protein andaian).  Kemudian, kesemua immunogen ditulen dan dipindahkan ke 
platform ELISA untuk saringan secara besar-besaran.  Pemeriksaan yang menggunakan 
60 melioidosis positif sera dan 123 sera bukan melioidosis telah membolehkan 
pengecaman 2 polipeptida iaitu BPSS1904 dan BPSL3130 yang berpotensi diagnostik, 
iaitu masing-masing mempunyai sensitiviti 75% dan 90%, dan  spesifikasi 90.24% dan 
88.62%.  Keputusan ini menunjukkan bahawa kedua-dua adalah calon antigen yang 
berpotensi untuk digunakan dalam serodiagnosis jangkitan yang disebabkan oleh B. 
pseudomallei. Secara keseluruhannya, kajian ini telah menunjukkan bahawa gen 
BPSL2033 dan BURPS1710A_1419 adalah berkaitan dengan kevirulenan B. 
pseudomallei, manakala polipeptida imunogenik BPSS1904 dan BPSL3130 merupakan 
antigen potensi untuk diagnosis serologi bagi jangkitan ini. 
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Chapter 1   
Introduction 
 
 
Burkholderia pseudomallei is a gram negative bacillus, motile, facultative anaerobe and 
an environmental saprophyte.  It is readily recovered from the soil and surface waters in 
endemic areas, i.e., South-east Asia and Northern Australia (Wiersinga et al., 2012).   
 
This bacterium possesses a remarkable capacity to infect humans and animals, causing 
melioidosis which is an important cause of sepsis in the tropics.  Infections occur after 
contact with contaminated soil and water through cutaneous lesions, by inhalation of 
contaminated dust, or ingestion of contaminated water (Cheng and Currie, 2005).  The 
clinical presentation of the disease is protean, which range from acute to chronic 
pneumonia, localized infection involving only one organ, disseminated septicemia 
disease involving multiple organs, and septic shock (Puthucheary, 2009).   
 
It has a huge genome, 7.25 megabase pairs (Mbp), represented by two chromosomes, 
one 4.07 Mbp and the other 3.17 Mbp (Holden et al., 2004).  The sequenced genomic 
data was reported in a study by Holden et al (2004) previously and has been published 
in databases.  The availability of this allows researchers to carry out comparative 
genomics study for identification of gene(s) encoding virulence determinants, in order 
to understand pathogenesis and provide further insights into microbial diversity and 
evolution.   
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Our previous study had used subtractive hybridization technique to distinguish and 
determine possible differences between a virulent clinical isolate B. pseudomallei and 
its attenuated strain of B. pseudomallei (Puthucheary et al., 2012a).  Interestingly, there 
were 6 strain-specific DNA fragments in the “virulent” clinical isolate of B. 
pseudomallei (v) which were absent in the “attenuated” strain of the same isolate B. 
pseudomallei (av) and could therefore be considered as potential virulence determinants, 
however, their roles in virulence are still unknown. 
 
The first objective of this study was to extensively characterize these putative virulence 
determinants using methods combining gene knockout, cell line and nematode models 
infection studies.  Apart from the candidate genes identified from our previous study, 
one additional gene, BPSL3147 predicted as a putative lipoprotein detected by other 
researchers (Cuccui et al., 2007) was also included into our candidate list due to its 
potential as lipoprotein.  Insertion inactivation mutants were constructed in the parent B. 
pseudomallei strain (Bp-CMS) involved integration of a plasmid into the chromosome 
via homologous recombination through single crossover event.  This method required 
an internal fragment homologous to the gene of interest cloned into a suicide vector 
pUT-Km carrying a kanamycin resistance cassette.  Murine macrophage cell line 
RAW264.7 and Caenorhabditis elegans were used as in vitro and in vivo models, 
respectively, for elucidating pathogenic mechanisms involved in B. pseudomallei 
infections.  
 
Challenges in the clinical setting are associated with the fact that melioidosis is difficult 
to diagnose clinically due to the wide range of presenting symptoms.  Culture still 
represents the gold standard for the confirmation of the disease melioidosis, but it is 
slow and it takes a minimum of 24-48 hours.  The development of a rapid and accurate 
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serodiagnostic test is therefore needed for the detection of B. pseudomallei infection and 
would complement currently available diagnostic methods.  However, the lack of a 
well-established universally acceptable antigen for serologic diagnosis of melioidosis 
infection is a major obstacle.  It is of paramount importance that the ideal antigen 
consists of all or most of the relevant immunogens that are recognized by a patient 
infected with B. pseudomallei.   
 
So, a second objective of this study sought to identify immunogenic polypeptides of B. 
pseudomallei and evaluation of their diagnostic potential.  A shotgun genomic 
expression library was constructed using the NovaTope system from clinically 
confirmed local virulent isolates of B. pseudomallei, each of which expresses a small 
peptide derived from the protein under study.  The library is screened by colony blot 
detection assay using pooled sera from melioidosis positive patients as the probe and 
immunodominant polypeptides that gave the best signals were selected for further 
experiments. ELISA detection assay using individual samples was then performed in 
order to find the most significant candidate that could improve the accuracy and 
reliability of serologic diagnostic methods for infections with B. pseudomallei. 
 
Thereby, the new knowledge generated in my study is expected to advance our 
understanding of the molecular mechanism of action of newly identified putative 
virulence determinants in B. pseudomallei infections and add new candidate(s) for 
serodiagnostic test that could support the diagnosis of melioidosis.   
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  Chapter 2   
Burkholderia pseudomallei and melioidosis 
 
 
2.1  History 
Burkholderia pseudomallei, a gram-negative soil saprophyte was first described by 
Whitmore in 1911 when he and his assistant isolated this organism from morphine 
addicts in Rangoon, Burma (Stanton and Fletcher, 1932).  It caused a glanders-like 
disease, now termed melioidosis.  It was named from the Greek words “melis” meaning 
“a distemper of assess” and “eidos” meaning resemblance in 1921 by Staton and 
Fletcher (Stanton and Fletcher, 1921).  Since its discovery, it has been described using a 
variety of names, generally well known as Pseudomonas pseudomallei, but until 1992, 
it was reclassified into a new genus, Burkholderia (Yabuuchi et al., 1992).   
 
2.2  Burkholderia pseudomallei 
2.2.1  Bacteriology  
B. pseudomallei is a motile, small (1 to 5 µm in length and 0.5 to 1 µm in diameter), 
facultatively anaerobic, non-spore forming bacterium that having a safety-pin like 
appearance (Cheng and Currie, 2005).  Its natural habitats are wet soils, agricultural 
soils, stream, pools, stagnant water, and paddy fields in endemic areas (Bruce, 2002).  
 
B. pseudomallei can be cultured on many microbial media in the laboratory, but 
Ashdown’s selective medium is commonly used and the organism shows differing 
colonial morphology, with mostly small, smooth, glistening purple colonies initially (24 
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h), changing to rough, dry or wrinkled colonies on further incubation (48 h) (Cheng and 
Currie, 2005).  Interestingly, the organism develops seven unique colony morphotypes 
(type I to VII) (Figure 2.1) which are associated with phenotypes that alter the ability of 
B. pseudomallei to survive in adverse environmental conditions (Chantratita et al., 2007; 
Tandhavanant et al., 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1.  Seven unique B. pseudomallei colony morphotypes on Ashdown’s             
                        agar.  (Chantratita et al., 2007) 
 
 
 
 
 
     Type I                 Type II                Type III              Type IV     
     Type V                Type VI               Type VII                
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B. pseudomallei is oxidase positive.  It utilizes glucose via oxidative pathway, and does 
not assimilate arabinose.  It can survive in a variety of conditions, including niches of 
varied temperature (24ºC to 32ºC), acidic environments (pH 4.5 for up to 70 days) 
(Cheng and Currie, 2005), detergents solutions (Gal et al., 2004), and even in nutrient-
deficient liquid environments for period of up to 28 days (Robertson et al., 2010). 
 
2.2.2  Genome 
In 2004, the genome of B. pseudomallei strain K96243 had been fully sequenced, 
annotated, and published (Holden et al., 2004).  This bacterium has a huge genome, 
7.25 megabase pairs (Mbp), represented by two chromosomes, one 4.07 Mbp and the 
other 3.17 Mbp (Holden et al., 2004).  A large chromosome encodes 3,460 coding 
sequences (CDSs) required for housekeeping functions including metabolism, motility, 
cell wall and protein biosynthesis.  On the other hand, the second small chromosome 
encodes 2,395 CDSs associated with adaptation and survival in different niches (Holden 
et al., 2004; Wiersinga et al., 2006).  
 
Intriguingly, approximately 6.1% of the genome is made up of 16 putative genomic 
islands (GIs).  GIs are referred to as regions having distinct G+C content compared to 
general genome backbone and usually contain mobility genes (e.g. insertion sequence 
elements), and/or genes known to be involved in facilitating genetic recombination (e.g. 
inegrase, transposase, and recombinase genes) (Nandi and Tan, 2012;  Tuanyok, 2012).    
These GIs have probably been acquired via horizontal gene transfer and they are absent 
in the closely related species, genome of the B. thailandensis and B. mallei (Holden et 
al., 2004).   Tuanyok and co-workers further expanded this information as 71 distinct 
GIs have been identified by comparing genomic sequences of B. pseudomallei K96243 
to other 4 B. pseudomallei strains, 1710b, 1106a, MSHR668, and MSHR305 (Tuanyok 
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et al., 2008).  These genome analyses, provide a scaffold for researchers to understand 
its microbial diversity and evolution, as well as bacterial pathogenesis.   
 
2.2.3  Epidemiology and prevalence 
B. pseudomallei is widely distributed in the tropics, mainly between the latitudes of 20º 
North and 20º South (Cheng and Currie, 2005).  Endemic region for melioidosis include 
northern Australia, Southeast Asia, Papua New Guinea, most of the Indian subcontinent 
and southern China, Hong Kong and Taiwan (Figure 2.2), and most prominently in 
northeast Thailand, northern Australia, Singapore and parts of Malaysia (Currie et al., 
2008; Wiersinga et al., 2012).  In additional, sporadic cases of melioidosis have recently 
reported in Brazil (Rolim et al., 2005), Belgium (Ezzedine al., 2007), Indian Ocean 
(Currie et al., 2008) and Denmark (Badran et al., 2010), underscores an emerging global 
problem. 
 
In northeast Thailand, the annual incidence of disease is estimated to be 12.7 cases per 
100,000 population between 1997 and 2006 (Limmathurotsakul et al., 2010).  While in 
the Top End of the Northern Territory, the annual incidence of 19.6 cases per 100,000 
population was reported over a 14-year period from 1989 to 2003, a peak rate at 41.7 
cases per 100,000 individuals in 1998 associated with high annual rainfall and two 
severe weather events: tropical cyclone Les (January) and tropical cyclone Thelma 
(December) (Currie et al., 2004).  The annual incidence in Singapore was defined as 1.7 
cases per 10,000 between 1989 and 1996 (Heng et al., 1998). 
 
In Malaysia, melioidosis was first described in animals and human from Kuala Lumpur 
in 1913 and 1917 (Stanton and Fletcher, 1921).  The disease were subsequently reported 
in several states, i.e., Kuala Lumpur (Puthucheary et al., 1992), Pahang (How et al., 
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2005), Johor Bahru (Pagalavan, 2005), Kedah (Hassan et al., 2010) and Kelantan (Deris 
et al., 2010) but the true incidence of melioidosis in Malaysia is relatively unknown.  
Most recently, a remarkably high annual incidence was reported in the state of Kedah 
with a report of 16.35 cases per 100,000 individuals and a case-fatality rate of 33.8% 
(Hassan et al., 2010).  Based on the analysis of 145 cases reported between 2005 to 
2008, the authors reported that the age of patients ranged from seven days to 83 years 
with the male to female ratio of 3:1 and Malays had the highest incidence compared to 
other ethnic groups, namely, Chinese and Indian (Hassan et al., 2010).   
 
Overall, the mortality of melioidosis varies widely the endemic area as demonstrated in 
Table 2.1. 
Table 2.1  Mortality rates of melioidosis. 
No Country Period Mortality 
rate 
References 
1 Malaysia 1976 to 1991 65% Puthucheary et al., 1992 
2 Northern Territory 1989 to 1999 19% Currie et al., 2000a 
3 North Queensland 1996 to 2004 25% Malczewski et al., 2005 
4 Thailand 1986 to 2004 49% Limmathurotsakul et al., 2006 
5 Singapore 1989 to 2007 16% Lo et al., 2009 
 
 
 
 
 
 Chapter 2 
9 
 
 
 
 
 
 
 
 
 
 
 
           
   Figure 2.2. Global map showing the categories of distribution of melioidosis and B. pseudomallei.  
                                    (Wiersinga et al., 2012)
 Chapter 2 
10 
2.2.4  Transmission  
B. pseudomallei infection can be acquired by inhalation, entry through cutaneous 
lesions and by ingestion; however, the relative contribution of each route remains 
unclear (Cheng and Currie, 2005). 
 
Inhalation is reported a primarily route of acquisition, based on the finding that 
helicopter crews in the Vietnam War had increased incidence of disease, likely due to 
inhalation of soil and dust containing B. pseudomallei following aerosolization by 
circulating rotor blades (Howe et al., 1971).  Another example was from Malaysia as a 
case report demonstrated a 24-year-old Malaysian female with acute non-fatal 
septicemia melioidosis after inhaling infective dust during a blast injury (Wang et al., 
1993).  Moreover, Currie and Jacups (2003) described that inhalation transmission in 
endemic areas during heavy rainfall not only contribute to melioidosis, but also a shift 
to the pneumonic presentation of disease, and this was further supported by the recent 
observation from northern Australia (Cheng et al., 2008) and Singapore (Lo et al., 2009).   
 
Inoculation is the commonest route of disease transmission by direct contact of 
contaminated soil and water through skin abrasions or wounds.  B. pseudomallei can be 
readily isolated from moist soil and still water in endemic areas such as paddy fields, 
palm fields, cleared fields as well as drains and ditches (Wiersinga et al., 2006).  A high 
incidence of melioidosis was observed in rice paddies workers and their working 
families, who rarely wear protective clothing (Wiersinga et al., 2006).  The organism is 
believed to be drawn to the surface during the monsoonal rains leading to an increased 
number of melioidosis cases which has been reported in Thailand (Suputtamongkol et 
al., 1994) and Australia (Currie and Jacups, 2003), however, a weaker or no correlation 
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was found in Malaysia and Singapore, respectively (Hassan et al., 2010; Heng et al., 
1998; Sam and Puthucheary, 2007). 
 
Another route of infection is through ingestion.  In animals such as sheeps and pigs, this 
route has been implicated by findings of ingestion of contaminated food (Stanton & 
Fletcher, 1921) and contaminated water (Choy et al., 2000; Millan et al., 2007).   In the 
context of human melioidosis, ingestion of contaminated water is considered as a 
potential risk (Currie et al., 2001; Inglis et al., 2000a).  An example of ingestion 
transmission involved victims of the Asian Tsunami in 2004, where melioidosis was 
seen as a life threatening infection to those ingested to B. pseudomallei-contaminated 
water (Kongsaengdao et al., 2005). 
 
Person-to-person transmission has been reported but is extremely rare.  These cases 
occurred via sexual contact (McCormick et al., 1975), mother-to-child spread (Abbink 
et al., 2001), breast milk transmission (Ralph et al., 2004), perinatal transmission 
(Halder et al., 1998) and another report involved two siblings, one of which had cystic 
fibrosis (Holden et al., 2004).  In addition, neonatal cases of melioidosis have been 
reported from United States of America, Thailand, Malaysia, United Kingdom and India 
(Noyal et al., 2009).  
 
2.2.5  Risk factors 
Numerous studies have shown that patients with particular underlying conditions are at 
risk of B. pseudomallei infection: 88% in Australia (Currie et al., 1993), 77.4% in 
Singapore (Heng et al., 1998), 76% in Malaysia (Puthucheary et al., 1992), and 53% in 
Thailand (Suputtamongkol et al., 1994).  
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The risk factors for melioidosis include diabetes mellitus, renal dysfunction, alcoholism, 
chronic lung disease, steroid therapy, occupational exposure, trauma and parental drug 
abuse (Cheng and Currie, 2005; Puthucheary, 2009; Wiersinga et al., 2006).  The  
contribution of each underlying conditions to melioidosis remains unclear, but these 
conditions are suggested lead to immune deficits such as phagocytic defects, diminished 
humoral and cellular response and diminished cytokine production, therefore, enhancing 
the ability of B. pseudomallei to survive within the host (Puthucheary, 2009). 
 
The most notable risk factor was diabetes mellitus and the case rates have been recorded 
57% in Thailand (Limmathurotsakul et al., 2006), 56.6% in Malaysia (Hassan et al., 
2010), 48% in Singapore (Lo et al., 2009), and 42% in Australia (Malczewski et al., 
2005).  The reason for the association between diabetes and risk of developing 
melioidosis are unclear. It was recently demonstrated that polymorphonuclear 
neutrophil from diabetic subjects displayed impaired phagocytic function, migration and 
apoptosis when compared to those of healthy subjects (Chanchamroen et al.,  2009). 
 
2.2.6  Clinical manifestations of melioidosis patients 
The clinical presentation of melioidosis is difficult as the broad spectrum of its clinical 
symptoms can range from benign skin and soft tissue infection to a rapidly fulminant 
and septicaemia (Puthucheary, 2009).  Due to this wide array of clinical signs and 
symptoms, B. pseudomallei is dubbed as “the great mimicker” (Wiersinga et al., 2006).   
 
The incubation period of melioidosis may range from 1 day (Currie et al., 2000b) to 62 
years, thus indicating the remarkable capability of the bacterium to remain latent in the 
host (Ngauy et al, 2005).  Recently, a very short incubation period of melioidosis for a 
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high inoculum in near-drowning event in Phang Nga, a region in southern Thailand was 
documented by Chierakul and co-workers (2005).   
 
In general, the broad clinical spectrum of melioidosis can be divided into to: acute, 
subacute, chronic and latent melioidosis (Limmathurotsakul et al., 2012).  Acute and 
subacute melioidosis are characterized by the presence of symptoms for less than 2 
weeks, and 2 weeks to 2 months, respectively, prior to presentation.  The most common 
acute clinical presentation of melioidosis is pneumonia.  Chronic melioidosis is often 
localized, with an incubation period longer than 2 months that may mimic cancer or 
tuberculosis.  Latent melioidosis is an asymptomatic infection that the organism can 
remain dormant for years, but which may become active at some indefinite point in 
future (Limmathurotsakul et al., 2012).   
 
However, there exists a clinical continuum as the less acute or localized forms may 
rapidly progress to the septicaemia form, so Puthucheary and Vadivelu (2002) 
suggested another more functional and useful clinical classification into septicemia and 
non-septicemia (localized) melioidosis.  The presentation of septicemia melioidosis 
include simple to disseminated bacteremia while localized melioidosis include: 
pneumonia, acute suppurative lesions, chronic granulomatous, superficial abscess, 
cellulitis, sepsis following trauma, cervical lymphadenophy, septic arthritis, 
osteomyelitis, parotitis, chronic otitis media, prostatitis, peritonitis and mycotic 
aneurysms (Puthucheary and Vadivelu, 2002). 
 
The type of clinical presentation can vary largely based on geographical location, 
inoculating dose, strain virulence, route of exposure, risk factors in the host, and the 
host immune response (Wiersinga et al., 2012).  For instance, there is a high incidence 
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of genitourinary infection with prostatic abscesses in Australia, but these cases rare in 
Thailand (White, 2003).  On the contrary, suppurative parotitis is a common 
presentation in Thai children with melioidosis, but it is uncommon in Australia (Dance 
et al., 1989). 
 
2.3  Burkholderia pseudomallei and host interaction 
2.3.1  Intracellular lifecycle 
B. pseudomallei is a facultative intracellular pathogen that can efficiently invade and 
replicate inside non-phagocytic cells including HeLa, CHO, A549 and VERO (Harley et 
al., 1998a; Jones et al., 1996; Kespichayawattana et al., 2000), phagocytic cells such as 
polymorphonuclear leukocytes, macrophages and human monocyte-derived dendritic 
cells (Charoensap et al., 2009; Jones et al., 1996; Utaisincharoen et al., 2001), and 
Acanthamoeba astronyxis (Inglis et al., 2000b; Inglis et al., 2003).  
 
Figure 2.3 is a simple overview of the bacterium utilizing diverse survival strategies to 
persist in the intracellular environment.  It is likely that there is no single cause but 
rather a combination of a complicated and multifactorial interaction of various virulence 
factors.  The attachment of B. pseudomallei to host cells represents an essential early 
step in the pathogenesis.  In particular, it was reported that adhesion of B. pseudomallei 
to lung carcinoma A549 cell line appeared to be temperature dependent, as the bacteria 
grown at 30°C were more adherent than bacteria grown at 37°C (Brown et al., 2002).  
The GM1-GM2 glycosphingolipid ganglioside had been identified as host receptors for 
B. pseudomallei based on attachment inhibition studies (Gori et al., 1999; Kanai et al., 
1997).   Other candidate virulence factors include capsule, flagellum fliC, pilus, two 
adhensins, BoaA and BoaB have been reported to mediate attachment of the bacterium 
to epithelial cells (Figure 2.3). 
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A two-component response regulator, irlRS which is involved in regulating resistance to 
heavy-metals was reported to regulate the invasion of B. pseudomallei to epithelial cells, 
but not macrophages (Jones et al., 1997).  B. pseudomallei contains 3 Type 3 Secretion 
Systems (T3SSs); however, only Burkholderia secretion apparatus (Bsa) which is 
homologous to the inv/spa/prg of Salmonella typhimurium and the ipa/mxi/spa of 
Shigella flexneri (Attree and Attree, 2001), are important for pathogenesis 
(Muangsombut et al., 2008; Stevens et al., 2003).  Several Bsa proteins including BpoE 
(Stevens et al., 2003), BipD (Stevens et al., 2003) and BsaQ (Muangsombut et al., 2008) 
have been reported to facilitate bacterial invasion in non-phagocytic cells.  The effector 
protein BpoE resembles Salmonella enterica SopE/SopE2, which promotes invasion by 
acting as a guanine nucleotide exchange factor for RhoGTPases that induces 
cytoskeletal rearrangements (Stevens et al., 2003). 
 
Following internalization of the bacterium into cells, B. pseudomallei have been shown 
to reside inside plasma-membrane derived phagosomes (Puthucheary and Nathan, 2006).  
Using transmission electron microscopy, the authors demonstrated that phagolysosome 
fusion occurred slowly in B. pseudomallei-infected macrophages in patients with 
melioidosis compared to normal subjects with a concomitant increase in the intracellular 
bacteria (Puthucheary and Nathan, 2006).   
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           Figure 2.3.  Intracellular lifestyle of B. pseudomallei.   (Allwood et al., 2011) 
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The ability of B. pseudomallei to survive intracellularly is crucial for its pathogenesis.  
It can inhibit the inducible nitric oxide synthase (iNOS), an antimicrobial molecule 
needed to generate reactive nitrogen intermediate to control the intracellular growth of 
this bacterium in macrophage (Utaisincharoen et al., 2001).  Inhibition of inducible 
iNOS expression was reported to be associated with the defective production of 
interferon (IFN)-β, leading to reduced interferon regulatory factor 1 and subsequently 
iNOS expression (Utaisincharoen et al., 2003).   Besides, low level expression of iNOS 
also might be partly modulated by the O-antigenic polysaccharide moiety of B. 
pseudomallei (Arjcharoen et al., 2007; Utaisincharoen et al., 2000).  On the other hand, 
the expression of two negative regulators, a suppressor of cytokine signaling 3 and 
cytokine-inducible Src homology 2-containing protein that demonstrated interference of 
cytokine production via a STAT-1 pathway, could result in depression of iNOS 
expression, thus facilitating its intracellular survival (Utaisincharoen et al., 2005). 
 
As early as 15 minutes of internalization, the bacteria can escape from endocytic 
vesicles into the cytoplasm by destroying phagosome membrane (Harley et al., 1998b).  
Defects in bsa T3SSs in mutants lacking BopA (Cullinane et al., 2008; Gong et al., 
2011), BipD (Gong et al., 2011), BsaZ (Stevens et al., 2002) and BsaQ (Muangsombut 
et al., 2008) resulted in delayed or no escape from phagosome.  Furthermore, B. 
pseudomallei mutants lacking either BipD or BsaZ demonstrated unable to escape into 
cytoplasm at 6 h after infection in J774.2 cells (Stevens et al., 2002) while they also 
displayed decreased bacteria escape in RAW 264.7 cells (Burtnick et al., 2008; Gong et 
al., 2011).   
 
B. pseudomallei actively evades autophagy and enhances its survival by the secretion of 
Bsa T3SS effector protein, BopA (Cullinane et al., 2008; Gong et al., 2011).  Once in 
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the cytoplasm, it is able to form actin-based membrane protrusions into neighboring 
cells, which allows the organism to spread directly from cell-to-cell without exposure to 
host innate and adaptive immune responses (Kespichayawattana et al., 2000; Stevens et 
al., 2006).  The actin polymerization of B. pseudomallei is mediated by BimA, a 
bacterial protein with an actin-binding domain which is essential for binding to host 
actin, located at the site of actin nucleation (Stevens et al., 2005a).  This notion is 
supported by subsequent studies by Stevens et al. (2005b) and Sitthidet et al. (2011), 
who showed that bimA mutant loses ability to form membrane protrusions in J774.2 
cells and did not form plaques in A549 monolayers. 
 
The spread of bacteria from cell-to-cell appears to cause cell fusion and this result in the 
formation of multinucleated giant cells (MNGC) (Kespichayawattana et al., 2000). 
Inactivation of BipB (bsa T3SS), rpoS or hcp genes showed impaired ability of B. 
pseudomallei to induce MNGC formation in J774A.1 macrophage-like cells at 6 hours 
post infection (Suparak et al., 2005) and RAW 264.7 cell monolayers (Burtnick et al., 
2011; Utaisincharoen et al., 2006).  These findings indicate that by the stimulation of 
cell fusion, MNGC support the growth of B. pseudomallei within its hosts while 
protecting the bacterium from host immune responses.  In addition, the detection of 
giant cells in lung of humans had also been reported under histopathological study of 5 
autopsy cases (Wong et al., 1995). 
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2.3.2  Virulence factors  
Discovery of virulence factors is very important for the understanding of host-pathogen 
interactions in melioidosis, which may also serve as novel targets in drug and vaccine 
development in combating bacterial disease.  The virulence factors in this context are 
referred as proteins or other molecules that are involved in the infection, which enable a 
pathogen to enter, survive, replicate within host cells and maintain the disease state.   
 
Several approaches, including subtractive hybridization (SH) (Puthucheary et al., 2012a; 
Reckseidler et al., 2001), comparative genomics (Yu et al., 2006), signature-tagged 
mutagenesis (STM) (Cuccui et al., 2007), transposon mutagenesis (Rholl et al., 2008), 
in vivo expression technology (IVET) (Shalom et al., 2007), and microarray (Chieng et 
al., 2012) have accelerated the virulence factor discovery over the past decades.  The 
availability of the genomic sequences of several B. pseudomallei strains (Section 2.2.2) 
has rapidly add candidate virulence genes to databases. 
 
With the recent development in the construction of gene-targeted knock-out mutants 
using transposons, integrative vectors, allelic exchange vectors, and broad-host-range 
plasmids (Choi et al., 2008; Galyov et al., 2010; Kang et al., 2011), these tools can 
assess the importance of candidate virulence factors at the molecular level.  The 
methods used to generate B. pseudomallei mutants involved random insertional 
mutagenesis using transposon Tn5-OT182 (DeShazeret al., 1997; Reckseidler et al., 
2001) and Himar 1-based elements (Rholl et al., 2008).  Site-specific mutagenesis 
requires integration of a suicide plasmid carrying resistance cassetets into the 
chromosome by a single crossover recombination (Burtnick et al., 2008; Sarkar-Tyson 
et al., 2007; Song et al., 2005).   
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Gene replacement is a way to create mutants by replacing the relevant gene with an 
antibiotic resistance marker such as kanamycin from pUT-Km (Chua et al., 2003),  tet 
cassette from pFRTT1 or zeocin cassette from pCLOXZ1 (Tan et al., 2010), allowing 
easy selection of mutant.  Another method is unmarked deletion involving allelic 
exchange and the use of counter-selectable markers such as sacB (Yuen et al.,  2012), I-
SceI (Kvitko et al., 2012) and pheS (Norris et al., 2011). 
 
After obtaining mutant strains, their role can be studied using available models for 
investigating the disease and virulence as shown in Table 2.1.  However, no single 
animal and/or cultured cell monolayer model can answer all biological questions, thus 
various different in vivo infection models such as mice, diabetic rat, hamsters, 
Caenorhabditis elegans as well as in vitro cell lines including A549, BEAS-2B, RPMI-
2650, Hep2, A549, NHBE, J774A.1, HeLa, CHO, and RAW 264.7 have been 
extensively used in B. pseudomallei research (Allwood et al.,  2011).   
 
As shown in Table 2.1, previous efforts to identify potential virulence factors in B. 
pseudomallei, have been met with varied results using in vivo and/or in vitro models.  
The most notable candidates for virulence factors were Type IV pili (pilA), bpscN, Bsa 
T3SS and T6SS (hcp1, virAG, bprC, tssAB).  Studies by Essex-Lopresti et al. (2005) 
showed that unmarked in-frame deletion mutant of pilA of B. pseudomallei reduced 
bacterial adherence to human respiratory cell lines as well as significantly attenuated 
virulence in C. elegans and BALB/c mice.  This result was further supported by Boddey 
and colleagues (2006) who reported the pilA gene, putatively encoding a type IV pilin, 
enhanced association with eukaryotic cells by mediating microcolony formation.   
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Table 2.2. Examination of mutants of virulence determinants in different infection models. 
Virulent  determinant(s) Mutant phenotype References 
Product Gene Vertebrate/ invertebrate models Eukaryotic cell culture models 
Quorum sensing luxI and luxR Decreased virulence in mice (i.n)  and hamster  
(i.p); Less lung colonization in mice (i.n) 
ND Ulrich et al., 2004 
PmII-PmIR Full virulence in mouse model ND Valade et al., 2004 
Type IV pili (TFP) pilA  Slightly decreased virulence in  mice (i.n but 
not i.p )  
Reduced adherence to A549, BEAS-2B and 
RPMI-2650  
Boddey et al., (2006);  Essex-
Lopresti et al., (2005) 
Adhesin boaA/ boaB ND Reduced adherence to Hep2, A549 and NHBE 
and decreased growth in J774A.1. 
Balder et al., 2010 
Flagelum fliC Reduced virulence in mice (i.n and i.p), but no 
in C. elegans, diabetic rats and hamsters (i.p) 
Same as wild type Chua et al., 2003; Chuaygud et al., 
2008; DeShazer et al., 1997 
Two-component 
response regulator 
irlR No virulence in diabetic rats and hamsters  Less invasion in A549, HeLa and CHO, but 
not in macrophages 
Jones et al., 1997 
TTSS1 bpscN Reduced virulence in mice (i.n) Diminished survival and replication in 
RAW264.7 
D’Cruze et al., 2011 
Bsa T3SS bpoE Same as wild type in mice (i.p and i.n) Reduced invasion in HeLa, but same as wild 
type in J774A.1 
Steven et al., 2002; Steven et al., 
2003; Steven et al., 2004 
bipD Reduced virulence in mice (i.p and i.n) Reduced invasion in J774A.1 and RAW264.7, 
but no HeLa. 
Gong et al., 2011; Steven et al., 
2002; Steven et al., 2003; Steven et 
al., 2004 
bsaQ ND Reduced invasion in A549. Muangsombut et al., 2008; Sun et 
al., 2005 
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Table 2.1. (Continued) 
Virulent  determinant(s) Mutant phenotype References 
Product Gene Vertebrate/ invertebrate models Eukaryotic cell culture models 
Bsa T3SS bsaZ Reduced virulence in mice (i.n) and hamster 
(i.p) 
Reduced invasion in J774A.1 and can survive 
in RAW264.7. 
Burtnick et al., 2008; Stevens et al., 
2002; Stevens et al., 2004; Warawa 
and Woods, 2005;  
sctU1/sctU2/bsaZ Reduced virulence in hamster (i.p) Same as wild type in RAW264.7. Burtnick et al., 2008; Warawa and 
Woods, 2005 
bsaU Reduced virulence in mice (i.n) Same as wild type in HeLa and RAW264.7. Pilatz et al., 2006 
bopA Same as wild type in mice (i.p) and hamster 
(i.p) 
Impaired survival in RAW264.7. Cullinane et al., 2008; Gong et al., 
2011; Stevens et al., 2004; Warawa 
and Woods et al., 2005 
bipB Reduced virulence in mice (i.p) Reduced invasion in HeLa Suparak et al., 2005 
bpoC ND Reduced invasion in A549. Muangman et al., 2011 
T6SS tssH-5, bhuT ND Same as wild type in RAW264.7. Shalom et al., 2007 
hcp1 Reduced virulence in hamster (i.p) Impaired growth in RAW264.7. Burtnick et al., 2011 
virAG, bprC, 
tssAB 
Reduced virulence in mice (i.n) Impaired growth in RAW264.7. Chen et al., 2011 
BcaA, BcaB Same as wild type in mice (i.n) Same as wild type in A549. Campos et al., 2013 
Phosphoribosyl-
formyl-
glycinamidine 
purM Reduced virulence in mice (i.n) and hamster 
(i.n) 
Same as wild type in HeLa. Pilatz et al., 2006; Propst et al., 
2010 
Phosphoribosyl-
glycinamide 
purN Reduced virulence in mice (i.n) Same as wild type in HeLa. Pilatz et al., 2006 
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Table 2.2. (Continued) 
Virulent  determinant(s) Mutant phenotype References 
Product Gene Vertebrate/ invertebrate models Eukaryotic cell culture models 
Imidazole glycerol 
phosphate 
hisF Reduced virulence in mice (i.n) Same as wild type in HeLa. Pilatz et al., 2006 
Para-
aminobenzoate 
synthetase  
pabB Reduced virulence in mice (i.n) Same as wild type in HeLa. Pilatz et al., 2006 
Putative exported 
protein 
Bpsl1528 ND Same as wild type in HeLa. Pilatz et al., 2006 
Autosecreted 
Protein 
bimA ND Abolished actin-based motility in J774.2. Stevens et al., 2005a 
Lactonase family 
protein A 
lfpA ND Same as wild type in RAW264.7 Boddey et al., 2007 
Phospholipase C plc-1, plc-2 ND Reduced plaque formation Korbsrisate et al., 2007 
plc-3 Reduced virulence in hamster (i.p) ND Tuanyok et al., 2006 
Capsule wcb Reduced virulence in hamster (i.p) Increased deposition of C3b Reckseidler-Zenteno et al., 2005 
Oxidative 
regulatory factor 
rpoS ND Reduced invasion in Raw264.7  Utaisincharoen et al., 2006 
oxyR ND Hypersensitive to H2O2 Loprasert et al., 2002 
Siderophores mbaJ, mbaF, 
mbaL, fmtA, 
mbaA 
ND Defect growth in iron-limiting conditions 
(Chelax-treated M9) 
Alice et al., 2006 
Superoxide 
dismutases 
sodC Reduced virulence in mice (i.p) Impaired survival in J774A.1 Vanaporn et al., 2011 
ND – Not done;  i.n – intranasal;   i.p - intraperitoneal 
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The Type 3 Secretion System Cluster 1 (TSS1) gene bpscN contains 63.5% amino acid 
that is identical to a HrcN in R. solanacearum, which is a predicted TTSS-associated 
ATPase.  Mutants lacking gene bpscN demonstrated less virulence than wild type in 
BALB/c mice and diminished survival and replicative capacity in RAW264.7 cells 
(D'Cruze et al., 2011).  The Bsa T3SS is important for virulence as demonstrated by 
numerous studies (Burtnick et al., 2008; Cullinane et al., 2008; Gong et al., 2011;  Jones 
et al., 1997; Muangman et al., 2011; Muangsombut et al., 2008; Pilatz et al., 2006; 
Stevens et al., 2002; Stevens et al., 2003;  Stevens et al., 2004; Suparak et al., 2005; 
Warawa and Woods, 2005).  Warawa and co-workers (2005) have shown that 
Bsa/TTSS3 was required for optimal virulence via intraperitoneal (i.p) route in Syrian 
Golden hamsters. 
 
B. pseudomallei possess 6 clusters of genes associated with Type Six Secretion System 
(T6SS) and T6SS-1 cluster was first identified in the B. pseudomallei infected 
macrophages through IVET (Shalom et al., 2007).  The mutation in the T6SS-1 cluster, 
hcp1 gene significantly attenuated virulence in the hamster model.  The mutant showed 
impaired growth in RAW264.7 cells and it also failed to stimulate MNGC formation 
(Burtnick et al., 2011).   The expression of T6SS-1 cluster is dependent on BprC and 
VirAG inside the host cells (Chen et al., 2011). 
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2.3.3  in vivo and in vitro models to study pathogenesis 
The use of animal models in the study of B. pseudomallei infection provides valuable 
insights into the host and bacterial factors involved in melioidosis as it reflects the 
natural infection process in humans.  Thus far, a wide spectrum of, models, ranging 
from non-mammalian C. elegans to mammalian, i.e., small animal such as mice and 
Syrian hamster to large animals models such as goats, pigs and non-human primates are 
available (Sivalingam et al., 2012).  It is not yet clear which animal model of 
melioidosis best reflects the disease pattern in humans. 
 
The mouse model system is probably the most adaptable and popular for studying the 
pathogenesis of melioidosis.  For instance, BALB/c and C57BL/6 mouse models 
exhibited the acute and chronic forms of human melioidosis, respectively (Sivalingam 
et al., 2012).  However, long reproductive cycles, the difficulties and cost associated 
with obtaining and maintaining sufficient number of animals for experiments is 
discouraging.  Hence, one of the simplest inverterbrate model, the nematode worm, C. 
elegans has gained significant attention as a model organism since Sidney Brenner first 
promoted its use in the study of neurobiology in 1960s (Brenner, 1974) while Tan and 
colleagues first reported its use in the study of Pseudomonas aeruginosa pathogenesis.  
It has since been used extensively to study host-pathogen interaction for various 
pathogens such as B. cenocepacia (Kothe et al., 2003), Staphylococcus aureus (Sifri et 
al., 2003) as well as Drechmeria coniospora fungus (Jansson et al., 1994) by simply 
replacing its food, E. coli OP50 with pathogens and measuring the survival of worms. 
 
In the context of B. pseudomallei, previous investigators have supported the use of C. 
elegans as a surrogate host for infection study although they have conflicting opinion- 
whether nematode killing by B. pseudomallei is due to toxin (Gan et al., 2002; Ooi et 
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al., 2012) or direct prolonged contact with organism (Gan et al., 2002; Lee et al., 2011; 
O'Quinn et al., 2001).  Overall, the C elegans model offers several advantages as a host 
model including simple growth conditions, short generation time and being cost-
effective.  Therefore, in this study, C elegans has been chosen as an infection model and 
details of this system will be further elaborated in Section 2.3.3.1. 
 
2.3.3.1  Features of Caenorhabditis elegans system 
C. elegans is a small body sized, non-parasitic free-living nematode (roundworm) that 
lives in soil, where it feeds on microorganisms.  The standard C. elegans laboratory 
strain is Bristol N2 and it is typically propagated on agar plates containing a lawn of 
slow-growing uracil auxotrophic Escherichia coli strain of OP50.   
 
The life cycle of C. elegans is simple and fast: approximately two to three days at room-
temperature (from fertilized egg to an adult).  As illustrated in Figure 2.4, it has four 
larval stages (L1 to L4) and the larva will go into dauer stage under unfavorable life 
conditions for up to four months.  Once food becomes available, dauer larva feed and 
continue development to the adult stage.  After worms have reached adulthood, they 
survive for about 2 to 3 weeks (Altun and Hall, 2005). 
 
C. elegans population consists of two sexes, hermaphrodites and males.  
Hermaphrodites produce both oocytes and sperm and are capable of self-fertilization, 
where a single hermaphrodite will produce approximately 300 eggs.  Males occur 
spontaneously non-disjunction in the hermaphrodite germline at low frequency (0.1%).  
It produces only sperm and must mate with a hermaphrodite in order to reproduce 
(Altun and Hall, 2005).   
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Importantly, it is the first multicellular organism to have its whole genome sequenced to 
enable the study of an array of molecular genetics and signaling pathways (The C. elegans 
Sequencing Consortium, 1998).  The body of C. elegans is transparent and its entire cell 
lineage from egg to adult is visible under the light microscope.  The transparency also 
permits the direct observation of host-pathogen interactions at the cellular level when 
bacterial pathogens are tagged with fluorescent proteins (Luhachack et al., 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4. Life cycle of C. elegans. (Altun and Hall, 2005) 
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2.4  Host defense against Burkholderia pseudomallei 
Similar to other bacterial infections, the innate and adaptive immune systems are 
important in controlling infection by B. pseudomallei.  Toll-like receptors (TLR) play a 
vital role in initiating innate immune cells via pattern recognition receptors, which 
recognize pathogen-associated-molecular patterns (PAMPs) of B. pseudomallei and 
subsequently signal the production of inflammatory cytokines and chemokines.  
Supporting this, an upregulation of multiple TLRs, i.e., TLR1, TLR2 and TLR4 are seen 
in melioidosis patients with septic shock (Wiersinga et al., 2007).  It is worthwhile to 
note that TLR2 knockout mice demonstrated significantly improved host defenses as 
reflected by an improvement in survival with decreased bacterial loads and distant organ 
injury as well as reduced lung inflammation.  A recent study by West et al. (2012) also 
demonstrated a significant association between TLR polymorphisms and melioidosis 
patients.  
 
The production of proinflammatory cytokines IFN-γ, tumor necrosis factor (TNF)-α, 
interleukin (IL)-6, IL-8 and IL-12 are elevated in severe melioidosis patients (Lauw et 
al., 1999).  A study using mouse model demonstrated direct inhibition of IFN-γ with the 
neutralizing monoclonal antibody increased the bacterial burden in organs greater than 
4,000-fold and reduced the median lethal dose from > 5 x 10
5
 to ca 2 CFU (Santanirand 
et al., 1999).  Besides, the use of CpG oligodeoxynucleotides to enhance innate immune 
response in mice prior to challenge with B. pseudomallei, has been reported 
(Wongratanacheewin et al., 2004).   
 
Apart from cell-mediated immune response, the humoral immune response also plays a 
role in limiting disease progression (Chenthamarakshan et al., 2001a; 
Chenthamarakshan et al., 2001b).  Not surprisingly, melioidosis patients have detectable 
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antibody titers, with the dominant isotype IgG and consisting of subclasses IgG1 and 
IgG2 (Chenthamarakshan et al., 2001a ; Ho et al., 1997).  These 2 subisotypes are 
thought to activate the classical complement pathway and IgG1, has high opsonic 
potential, binds to mononuclear cells (Chenthamarakshan et al., 2001a).  Another 2 
immunoglobulins, IgM and IgA were elevated in melioidosis patients with localised, 
soft tissue infections (Chenthamarakshan et al., 2001a ; Ho et al., 1997).  This may 
reflect continuous B cell priming due to sequestration of intracellular bacterial antigens, 
perhaps necessitating continued antimicrobial therapy (Vasu et al., 2003). 
 
2.5  Laboratory diagnosis and detection 
Melioidosis is difficult to diagnose clinically due to the wide range of presenting and 
associated symptoms (Section 2.2.6).  The mortality is high among patients with 
underlying diseases especially diabetes and immunosuppression (Section 2.2.5).  
Definitive diagnosis of melioidosis has historically been based on the isolation of the 
bacterium from specimens such as blood, urine, sputum or pus using culture techniques. 
Bacterial culture may take up to 4 days and reportedly can have associated problems 
such as inter-strain and medium dependent variability in colony morphology.  Apart 
from this “gold standard”, various serological assays, molecular techniques and 
commercial identification system are also being developed, aiming to enhance 
diagnostic performance.  Besides, appropriate imaging techniques are utilized to assist 
in detecting infection sites.  With this brief background, details of each diagnostic 
method will be further described in Sections 2.5.1 to 2.5.5. 
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2.5.1  Culture-based methods 
Ashdown’s agar (ASA) is currently the favored selective medium for the isolation of B. 
pseudomallei, which contains neutral red (differentiation of this organism from others), 
glycerol (enhances the formation of wrinkled colonies), crystal violet and gentamicin 
(inhibition of other organisms) (Ashdown, 1979).  The presumptive identification of B. 
pseudomallei can be identified on the basis of colonial color, i.e., purple color with dry 
and wrinkled appearance when grown on this selective media after 24 to 48 h of 
incubation  (Figure 2.1).   
 
A second medium, B. pseudomallei selective agar (BPSA) improves recovery of the 
mucoid colonies and provides large wrinkled colonies faster than ASA (Howard et al., 
2003).   A third medium, B. cepacia medium, is widely available and offers a suitable 
alternative in non-endemic areas for the isolation of B. pseudomallei from patients with 
suspected melioidosis.  These 3 media have been evaluated for their ability to grow B. 
pseudomallei.  The sensitivity of each medium was comparable, but the BPSA showed 
the lowest selectivity (Peacock et al., 2005). 
 
2.5.2  Serodiagnosis 
A major drawback of using the culture method is time-consuming.  Therefore, attempts 
to identify the organism more rapidly than culture method such as, immunological 
assays have been developed for either detection of antigens (Ags) or antibodies (Abs) 
against the organism in clinical specimens.  
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2.5.2.1  Antigen detection 
Antigen detection assays are based on the use of specific antibody that reacts with B. 
pseudomallei in clinical specimens through different types of tests as shown in Table 
2.2.  This approach was first undertaken by Ismail et al. (1987) when they developed a 
monoclonal antibody-based ELISA assay for quantitation of exotoxin (> 16 ng/mL) of 
B. pseudomallei in culture supernatant fluid.  Monoclonal antibodies (MAbs) for cell 
wall components, including lipopolysaccharide (LPS) (Dharakul et al., 1999; Sirisinha 
et al., 2000), 200-kDA protein (Anuntagool et al., 2000; Rudgech et al., 1995; 
Samosornsuk et al., 1999; Sirisinha et al., 2000), exopolysaccharide (EPS) (Steinmetz et 
al., 1999) and  30-kDA protein (Ekpo et al., 2007; Pongsunk et al., 1999), were 
developed for the detection of B. pseudomallei antigen present in blood, sputum, pus 
and urine, however, none are yet commercially available.   
 
Of these assays, Dharakul et al. (1999) described a highly satisfactory test based on the 
use of a monoclonal antibody latex agglutination (MAb-LA) against LPS (Bsp1-L1) in 
88 blood cultures, which gave both sensitivity and specificity of 100% (Dharakul et al., 
1999).  Another 2 MAb-LA tests specific to 30 and 200-kDa proteins had a high 
sensitivity and specificity overall after evaluation in 11 and 12 hospitals in north eastern 
part of Thailand, respectively.  It was shown that MAb specific to the 30-kDA protein 
could directly agglutinate with all 243 clinical isolates of B. pseudomallei but not with 
other Gram-negative bacteria, except for one strain of B. mallei; however, the cross-
reaction with some gram-positive bacteria was observed (Ekpo et al., 2007; Pongsunk et 
al., 1999).   
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Table 2.3. Various antigen detection tests for the diagnosis of melioidosis. 
Methods Antibody used References Sensitivity (%) Specificity (%) 
Indirect ELISA Monoclonal anti-exotoxin Ismail et al., 1987 NR NR 
MAb 5F8 (MAb anti 200-kDA protein) Rudgech et al., 1995 NR NR 
Anuntagool et al., 1996 75 98 
Sirisinha et al., 2000 59 56 
Direct agglutination 5F8 Rudgech et al., 1995 NR NR 
anti 30-kDA protein Pongsunk et al., 1999 94.1 98.3 
MAb-LA Bsp1-L1(anti-LPS) Dharakul et al., 1999 100 100 
anti-EPS Steinmetz et al, 1999 NR NR 
Bsp L2 (anti-LPS) Sirisinha et al., 2000 23 100 
5F8,4B11,6G9-LA  (anti 200-kDA protein) Samosornsuk et al., 1999 95 100 
Anuntagool et al., 2000 95.1 99.7 
anti 30-kDA protein Pongsunk et al., 1999 100 
a
 
100 
b
 
96.5 
a
 
85.9 
b
 
Ekpo et al., 2007 96.8 99.6 
Direct IF Whole-cell specific antibodies of B. 
pseudomallei conjugated FITC 
Walsh et al., 1994 73 99 
Wuthiekanun et al., 2005 66 99.5 
 
NR- Not reported; a-Blood culture;  b-Brain Heart Infusion Broth specimens
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The other investigators used a MAb mixture consisting of 5FB, 4B11 and 6G9 reactive 
with a 200-kDa protein antigen highlighting that the serodiagnostic potential of this 
assay was due to its ability to distinguish B. pseudomallei from B. thailandensis and the 
ability to react with B. pseudomallei strains with atypical LPS patterns (Anuntagool et 
al., 2000; Samosornsuk et al., 1999). 
 
Immunofluorescence (IF) can be used to detect B. pseudomallei directly from sputum, 
urine and pus, using whole-cell specific antibodies conjugated to fluorescein 
isothiocyanate (FITC).  Standard IF is relatively labor intensive and takes more than 2 
hours to complete (Walsh et al., 1994) whereas a modified rapid IF can be completed in 
10 minutes (Wuthiekanun et al., 2005).  A standard and rapid IF had sensitivities of 
73% and 66%, and specificities of 99% and 99.5%, respectively.  However, the use of 
this test may be limited due to the requirement of specialized microscopy facilities. 
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2.5.2.2  Antibody detection 
An antibody detection test measures the presence of humoral antibodies against 
immunodominant antigens of B. pseudomallei.  Efforts to develop antibody detection 
tests for the diagnosis of melioidosis have been under way for decades, and the 
performance of these tests has been well described in Table 2.3.   Basically, these tests 
are developed into formats depending on (a) antigen source either native or recombinant 
protein (b) class of immunoglobulin detection, e.g., IgG, IgM or total antibodies (c) on 
the test design.  Overall, the most common types of tests included indirect 
hemagglutination assay (IHA), indirect immunofluorescent test (IFAT), enzyme-linked 
immunosorbent assay (ELISA) and immunochromatographic test (ICT).   
 
The IHA is used to detect serum antibodies of patients, based on agglutination of sheep 
red cells sensitized with B. pseudomallei antigens (Cheng et al., 2006; Gilmore et al., 
2007; Vadivelu et al., 1995).  The antibody titer is recorded as the highest dilution that 
shows agglutination.  However, IHA assay is poorly standardized, with variation in B. 
pseudomallei strains, antigen preparation protocol and difference of detection threshold.  
The diagnostic cut-off for IHA in Thailand is > 1:160 (Wuthiekanun et al., 2006a) while 
in Australia, it is > 1:40 to 1:160 (Cheng et al., 2006).  Strikingly, high background 
titers in healthy individuals were reported and led to difficulty in interpretation 
(Chantratita et al., 2007; Wuthiekanun et al., 2006a; Wuthiekanun et al., 2006b).  For an 
example, 53 out of 200 healthy blood donors in Malaysia demonstrated positive 
antibody titer (> 1:40) against B. pseudomallei (Norazah et al., 1996).  
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Table 2.4.  Antibody detection tests for diagnosis of melioidosis. 
Methods Antigen References Sensitivity 
(%) 
Specificity 
(%) 
IHA Meliodin 
 
Kunakorn et al., 1990 88 97.4 
Petkanjanapong  et al.,1992 80.9 91.4 
Vadivelu et al., 1995 45 100 
Dharukul et al., 1997 71 74.7 
Sermswan et al., 2000 61.9 79.8 
O’Brien et al., 2004 80 NR 
Wuthiekanun et al., 2004 72 68 
Chuah et al., 2005 76 99 
IFAT Whole cell Ag of B. 
pseudomallei 
Vadivelu et al., 1995 91 100 
Vadivelu et al., 2000 100 72 
Mathai et al., 2003 36 99 
Whole cell Ag of B. 
thailandensis 
Puthucheary et al., 2010 98.5 92.3 
Western blot 16-kDa recombinant 
Bps antigen 
Sirisinha et al., 2000 70 91 
Dot 
immunoassay 
CF 40-kDa Sirisinha et al., 2000 72 64 
Sermswan et al., 2000 85.7 85.3 
Gold blot Whole cell Ag Kunakorn et al., 1990 (IgM) 87.5 88 
Kunakorn et al., 1990 (Protein 
A) 
100 91 
Immunoblot 
assay 
19.5-kDa Anuntagool et al., 1993 92 91 
39-kDa Anuntagool et al., 1993 92 80 
Crude cell extract Anuntagool et al., 1993 92 79 
Veronal extract Anuntagool et al., 1993 87 79 
ELISA Whole cell Ag of B. 
pseudomallei 
Kunakorn et al., 1990 88 92.2 
Vadivelu et al., 1995 91 96 (IgM) 
Affinity purified 
antigen 
Dharukul et al., 1997 85.7 82.5 (IgG) 
Dharukul et al., 1997 63.5 81.8 (IgM) 
Immunoaffinity 
purified antigen 
Sermswan et al., 2000 71.4 86.2 (IgG) 
Culture filtrate 
antigen 
Chenthamarakshan et al., 2001 96 94 (IgG) 
Chenthamarakshan et al., 2001 74 99 (IgM) 
 
 
 
 
 
 
 
 Chapter 2 
36 
 
Table 2.4. (Continued) 
 
Methods Antigen References Sensitivity Specificity 
ELISA Recombinant 
truncated flagellin 
Chen et al., 2003 93.8 96.3 (IgG) 
Crude LPS Thepthai et al., 2005 96 100 
Affinity purified Ag Chantratita et al., 2007 82 70 
Crude extract Chantratita et al., 2007 81 70 
EPS Chantratita et al., 2007 64 74 
LPS Chantratita et al., 2007 66 81 
EPS + LPS Chantratita et al., 2007 77 74 
BipB Duar et al., 2008 68 61 
BipD Duar et al., 2008 63 61 
BPSL0972 Allwood et al., 2008 95 98 
BipD Allwood et al., 2008 42 100 
OmpA Allwood et al., 2008 51 100 
EPS Splettstoesser et al., 2008 83.3 98 (IgG) 
Recombinant 
flagellin from B. 
thailandensis 
Wajanarogana et al., 2012 82.7 94.6 
TssD-5 Hara et al., 2013 71 96 
Omp3 Hara et al., 2013 59 90 
smBpF4 Hara et al., 2013 41 89 
Omp85 Hara et al., 2013 19 96 
Cocktails  Hara et al., 2013 65 99 
Multiple antigens Hara et al., 2013 88.2 96 
ICT  Culture filtrate 
antigen 
 
Cuzzubbo et al., 2000 (IgG) 100 95 
Cuzzubbo et al., 2000 (IgM) 93 95 
O’Brien et al., 2004 (IgG) 77 90 
O’Brien et al., 2004 (IgM) 88 69 
Chuah et al., 2005 (IgG) 50.6 97.4 
Chuah et al., 2005(IgM) 72 71.5 
Cheng et al., 2006 (IgG) 86 47 
Cheng et al., 2006 (IgM) 83 47 
Splettstoesser et al., 2008 (IgG) 90 98.5 
Splettstoesser et al., 2008 (IgM) 84 99.5 
 
NR- Not reported 
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IFAT uses whole-cell antigen labeled with fluorescent dye for the detection of total 
antibodies to B. pseudomallei and view under fluorescent microscope.  Each test serum 
is serially diluted at various dilutions in PBS and cut-off values differ between 
laboratories.  The diagnostic cut-off for Malaysia has been set at titer > 1:10 for IgG 
and >1:40 for IgM (Vadivelu et al., 1995) while the threshold cut-off in India is > 1:32 
for both IgG and IgM antibodies (Mathai et al., 2003).  As shown in Table 2.3, the 
reported sensitivities varied between 36% and 100% but specificities remained high at 
between 72% and 100% (Mathai et al., 2003; Vadivelu et al., 1995; Vadivelu et al.,  
2000).  Interestingly, a modified IFAT using B. thailandensis as antigen was developed 
and this resulted in good sensitivity of 98.5% and satisfactory specificity of 92.3% 
(Puthucheary et al., 2010).  However, the major drawback of both IFAT assays using 
either B. pseudomallei or B. thailandensis is subjective scoring test which is based on 
the judge decision of laboratory personnel.  
 
An ELISA utilizing either native or recombinant antigens to capture antibodies 
(IgG/IgM or both) specific to B. pseudomallei, have included an affinity purified 
antigen, recombinant truncated flagellin, crude lipopolysaccharide (LPS), 
exopolysaccharide (EPS), BipB, BipD, BPSL0972, OmpA, TssD-5, Omp3, smBpF4 
and Omp85 (Allwood et al., 2008;  Chantratita et al., 2007; Chen et al., 2003; 
Chenthamarakshan et al., 2001; Duar et al., 2008; ; Hara et al., 2013; Sermswan et al., 
2000; Splettstoesser et al., 2008; Thepthai et al., 2005; Wajanarogana et al., 2012).  
However sensitivities and specificities of these assays were highly variable as shown in 
Table 2.3.   Thus far, an ICT (PanBio Ltd, Australia) is the only test that has been 
marketed (Cuzzubbo et al., 2000).  The strip test used pre-coated culture filtrate antigen 
for the detection of IgG and IgM antibodies, and the results could be obtained in 10 
minutes (Chuah et al., 2005; Cuzzubbo et al., 2000; Wuthiekanun et al., 2004).  The test 
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showed varied performance of sensitivity (range 50.6% to 100%) and specificity (range 
47% to 99.5%).  Given the unsatisfactory performance, it was not further developed and 
the kit is not currently commercially available. 
 
2.5.3  Molecular identification techniques 
With the advances in molecular technology, various molecular detection platforms for 
B. pseudomallei have been developed, but few have been evaluated in the field.  PCR-
based diagnostic assays  targeting 16S rRNA gene (Dharakul et al., 1996), 23S rRNA 
gene (Lew and Desmarchelier, 1994), 16S-23S rRNA intergenic region (Kunakorn et al., 
1995), LPS (Rattanathongkom et al., 1997), and flagellin C (fliC) and ribosomal protein 
subunit S21 rpsU (Tomaso et al., 2005) have been evaluated for detecting B. 
pseudomallei DNA.  Generally, these PCR assays demonstrated satisfactory sensitivities 
and specificities when tested on bacterial cultures however direct testing on blood 
specimens remain problematic. 
 
Despite of the conventional end-point detection platform, a quantitative real-time PCR 
targeting various region such as fliC (Tomaso et al., 2005); TTS1-orf1 (Meumann et al., 
2006; Supaprom et al., 2007), TTSS1-orf 2 (Kaestli et al, 2012), TTSS3-orf2 (Novak et 
al., 2006) also had been developed for specific and rapid identification of the bacterium.  
A high sensitivity with low limit of detection but also high specificity was documented 
from these reports.  For instance, Supaprom and co-workers (2007) reported that their 
qPCR was able to detect the presence of B. pseudomallei at a low threshold of 50 
femtogram of DNA and a specificity of 100%.  Recently, another new method of real 
time PCR, BurkDiff was introduced by Bowers and co-workers (2010) and this test is 
targeted on single nucleotide polymorphisms that differentiate B. pseudomallei and B. 
mallei.  
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Generally, the high sensitivity of both conventional and real time PCR-based assays is 
due to the ability to utilize minute bacterial DNA to produce a high yield of the 
amplified targeted  DNA and high specificity is based on the unique DNA sequence of 
the marker used.  However, these methods are relatively expensive and not easily 
available in regions where melioidosis is endemic.  Therefore, an inexpensive and easy 
system, loop-mediated isothermal DNA (LAMP) was developed wherein the gene 
amplification could be completed in 90 minutes under isothermal conditions employing 
a set of four specially designed primers, by incubating all the reagents in a single tube.  
The detection limit of LAMP was 38 genomic copies per reaction.  Further work to 
improve the sensitivity of the test is required as the overall sensitivity of 30.2% was too 
low for detection of B. pseudomallei (Chantratita et al., 2008). 
 
2.5.4  Commercial identification system 
Many commercial systems are available for the identification of B. pseudomallei, which 
can be divided into two groups, manual and automated system.  The manual systems 
include  test panels of API 20E, API 20NE, API 50CH (bioMérieux, France), Microbact 
24E (MetVet, Australia) and RapID NF Plus (Remel, USA).  Lowe and colleagues 
(2002) reported that both API 20E and 20NE correctly identified 99% and 98% of 103 
clinical isolates of B. pseudomallei, respectively.  On the contrary, Inglis et al. (2005) 
demonstrated the poor perfomance of API 20NE which only identified 37%  of 71 B. 
pseudomallei siolates obtained from a diverse range of sources.  The reasons for the 
inconsistency in the results are not clear but API 20NE is still commonly used in 
diagnostic laboratories (Amornchai et al., 2007; Glass and Popovic, 2005; Inglis et al., 
1998; Inglis et al., 2005; Lowe et al., 2002).    
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Comparison of clinical and soil isolates of B. pseudomallei was performed by 
Wuthiekanun et al. (1996) by using API 50CH.  The most significant differences were 
that soil isolates (Ara+ isolates) assimilate L-arabinose (100%), adonitol (100%), 5-
keto-gluconate (90%) and D-xylose (84%), but do not assimilate dulcitol (0%), 
erythritol (0%) and trehalose (10%).  Another test, Microbact 24E was considered to be 
reliable for the identification of B. pseudomallei as it correctly identified 46 of 50 
isolates, but the system has not yet been definitively evaluated.  RapID NF plus system 
was found  not suitable for the identification of B. pseudomallei as a preliminary report 
showed that it did not correctly identify any of the 58 B. pseudomallei isolates from 
diverse geographically areas (Glass and Popovic, 2005). 
 
Various automated systems such as VITEK (bioMériuex), BD phoenix system (Becton 
Dickinson) and MicroScan WalkAway-96 (Dade Behring) have been used in 
microbiology laboratories to ensure that patient management is more cost effective.  
Lowe et al. (2002) reported a good result with the use of Vitek 1, which demonstrating 
99% accuracy for 103 clinical isolates.  However, the performance of Vitek 2, BD 
phoenix, and MicroScan WalkAway-96 systems have been shown to misidentify B. 
pseudomallei as B. cepacia (Kiratisin et al., 2007; Koh et al., 2003; Lowe et al., 2002; 
Weissert et al., 2009; Zong et al., 2012).    
 
2.5.5  Medical imaging 
As described in Section 2.2.6, melioidosis can involve any organ system and may 
present with varying clinical manifestations.  Hence, medical imaging including X-ray, 
computerized axial tomography, ultrasound and magnetic resonance imaging  are very 
helpful in confirming sites of infection and supporting decision  making for 
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management, medical imaging is also important in assessing patients whose clinical 
condition deteriorates or  do not respond to treatment (Ramsay, 2012). 
 
2.6  Treatment and vaccine development 
B. pseudomallei is characteristically resistant to a wide range of antimicrobial  agents 
including penicillin, amino-penicillins, first-, second- and third-generation 
cephalosporins, most amino-glycosides, most macrolides and rifampicin whilst sensitive 
to newer β-lactam antibiotics, such as ceftazidime,  imipenem, meropenem, piperacillin, 
amoxicillin-clavulanate, ceftriaxone, and cefotaxime (Cheng and Currie, 2005).  
Recently, however, response to ceftazidime treatment is slow due to the extensive 
pathology of melioidosis and the immunocomprised state of the host (Puthucheary and 
Sam, 2012b).  Hence, imipenem or meropenem is considered as an alternative to 
ceftazidime. 
 
The disease therefore can be treated with the use of appropriate medication.  An initial 
intravenous therapy with ceftazidime or meropenem is given for 10-14 days followed 
by oral maintenance therapy for 12 to 20 weeks.  Oral treatment is with three drug 
combination of doxycycline and trimethoprime-sulfamethoxazole (co-trimoxazole) 
(Peacock et al., 2008; Wiersinga et al., 2012).   The maintenance therapy is important to 
prevent relapse or recurrence.  For instance, Puthucheary and Vadivelu (2002) reported 
that the rate of relapse or recurrence in Malaysia was found to be approximately 13% 
over a period of 5 years, however, this is an underestimate due to cases being lost to 
follow-up.   
 
Currently, there is no effective vaccine to protect against melioidosis but efforts to 
develop vaccine have been underway for many years.  Mouse monoclonal antibodies 
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specific to the capsular polysaccharide, lipopolysaccharide, or proteins of B. 
pseudomallei were developed and have been shown able to passively protect against B. 
pseudomallei infection using a mouse model (Jones et al., 2002).  Another DNA-based 
vaccine encoding the flagellin gene fliC has been tested with promising results (Chen et 
al., 2006).  However, BipD has also been evaluated as a protein subunit vaccine but 
conferred no protection in a mouse model (Stevens et al., 2004).  The development of 
mouse scFv antibodies against B. pseudomallei exotoxin (Nathan et al., 2002) and 
protease (Chan et al., 2004) had been published, but these antibodies have not been 
tested in animal models.    
 
2.7  Shotgun expression library 
A shotgun expression library is a genomic library that represents the entire genome of 
an organism.  It is useful for analysis since whole genome of an organism is too large to 
be analysed directly.  Basically, the genomic DNA of an organism is randomly digested 
into small pieces and then cloned into a suitable expression vector, for example 
pSCREEN-T in this study.  The clones express a small peptide or protein and mapping 
can be performed by using an antibody of interest as the probe.  Positive clones can be 
further analyzed by DNA sequencing to identify the amino acid sequence of interest 
(Novatope System, USA).   
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  Chapter 3   
General materials and methods 
 
 
3.1  Introduction 
All materials and methods used in this study are described in detail in Chapters 4 and 5; 
only those general methods and preparations are described below. 
 
3.2  Materials 
3.2.1  Bacterial strains and plasmids  
Several local clinical isolates of B. pseudomallei were obtained from Department of 
Medical Microbiology, Faculty of Medicine, University of Malaya (UM), Kuala Lumpur.  
The details of strains and plasmids used in study are described in Chapters 4 and 5.   
 
3.2.2  Biochemicals and other materials 
All chemicals and reagents used were of Analar
®
 grade or the highest grade available 
commercially, and obtained from various companies (Appendix I). 
 
3.2.3  Buffers and other solutions 
Buffers and solutions used were made as described in methods (Appendix II-VII) and 
obtained from Sambrook and Russell (2001), and Stiernagle (2006).  
 
3.3  General methods 
All methods used were referred or modified from the protocols as described by 
Sambrook and Russell (2001). 
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3.3.1  Sterilization 
3.3.1.1  Steam sterilization 
Media, solutions, buffers, universal bottles, and other apparatus were steam sterilized at 
121ºC (15 psi) for 15 min in an autoclave (HVE-50, Hirayama, Japan).  Micropipette 
tips, microcentrifuge tubes, canisters containing pipettes, bottles, and other apparatus 
were sterilized in the same manner and dried in an oven (Memmert, Germany) at 65ºC. 
 
3.3.1.2  Membrane sterilization 
Thermo-labile solutions were filter-sterilized via disposable sterile membrane filters 
with 0.22 µM (Millipore, USA). 
 
3.3.2     Bacterial culture and maintenance conditions 
In general, B. pseudomallei or E. coli cultures were grown overnight in LB broth at 
37ºC.  An appropriate antibiotic solution consisting of ampicillin (50 µg/mL), 
carbenicillin (50 µg/mL), chloramphenicol (100 µg/mL), gentamicin (100 µg/mL), 
streptomycin (50 µg/mL), and tetracycline (15 µg/mL) was added to LB broths when 
required.  Sterile glycerol was added to the overnight culture to a final concentration of 
20% (v/v) for storage at -80ºC for future work.  
 
3.3.3    Polymerase chain reaction (PCR) amplification 
All PCRs were carried out using appropriate primers, on a Mastercycler (ABI, USA).  
Generally, a master mix consisting of 10X LA PCR buffer II, 25 mM MgCl2, 2.5 mM 
dNTPs mixtures, 5 U/µL LA Taq DNA polymerase (Takara, Japan), 20 pmol/µL 
upstream and downstream primers, were usually prepared and dispensed into individual 
0.2 mL thin-walled tubes (Axygen, USA) which contained DNA templates and 
nucleases-free water, respectively.  A negative control (using sdH2O) was included in 
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every PCR assay to ensure there was no DNA contamination during reaction mixture 
preparation.  The mixtures were subjected to PCR using an appropriate thermal cycling 
program for the different reactions.  The common PCR program used was  96°C – 3 min 
(1 cycle); 96°C – 30 sec, 52°C – 15 sec, 72°C – 1 min (30 cycles);  72°C – 10 min (1 
cycle).  As a general rule, extension time of 1 min per 1 kb was used in the extension 
step.   
 
3.3.4     PCR from a bacterial colony 
Amplification of the target genes was carried out using the same protocol as described 
in Section 3.2.3 but using a crude DNA instead of purified DNA and different PCR 
reagents.  Firstly, a colony from an agar plate was picked using a sterile 200 µL pipette 
tip and transferred to a 1.5 mL tube containing 100 µL LB broth with an appropriate 
antibiotic.  The culture was then incubated for 3 h at 37°C with shaking at 150 rpm.   
 
Next, 3 µL of culture was transferred to a 0.2 mL PCR tube and boiled in a heat block at 
95°C for 5 min to lyse the cells and denature DNases.  Colony PCR was then carried out 
in a volume of 20 µL containing 1X ThermoPol buffer (New England Biolabs, UK), 
0.10 mM of each dNTPs, 1.00 mM MgCl2, 20 pmol of each primers, 0.07 U of Taq 
DNA polymerase (New England Biolabs, UK), and 3 µL of crude DNA. 
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3.4  Concentration measurement 
The concentration of extracted DNA or protein was determined by using a 
spectrophotometer (Implen, Germany).   
 
3.4.1  Quantitation of genomic DNA 
The LabelGuard
TM
 Microliter cell (Implen, Germany) was inserted into the cell holder 
with the cell windows facing the light beam.  Three microliter of DNA sample was 
pipetted onto the centre of the measuring window.  
 
An optical density (OD) ratio of 1 corresponds to approximately 50 µg of double-
stranded DNA/mL.  The DNA concentration was calculated with this following formula 
- A260 x 50 µg/mL x Dilution factor. The A260/A280 ratio provides an estimate for the 
purity of the nucleic acid.  While pure DNA preparation demonstrated A260/A280 of 1.8, 
a range of  1.8 to 2 was  acceptable. 
 
3.4.2  Quantitation of protein sample 
The estimation of protein concentration was performed by using quick Start
TM
 Bradford 
Protein Assay (Bio-Rad, USA) according to the manufacturer’s protocol.  Twenty 
microliter of sample was mixed with 1 mL of 1X dye reagent and incubated at room 
temperature for 5 min.  Later, the mixture was transferred to a disposable polystyrene 
microcuvette and the OD was measured at 595 nm.  The concentrations of unknown 
samples were assayed in duplicate and determined by comparison with the standard 
curve, working range of 0.125 to 2 mg/mL. 
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3.5  Electrophoresis 
3.5.1  Agarose gel electrophoresis (AGE) 
Based on the percentage of the gel needed, an appropriate amount of agarose powder 
(Promega, USA) was mixed with 1X TBE [90 mM Tris-borate, 1 mM EDTA (pH 8.0)] 
in a Schott bottle and dissolved by melting the agarose in a microwave oven (Sanyo, 
Japan) for at least 1 min.  Ethidium bromide (0.5mg/mL) was then incorporated into the 
gel solution.  The homogenous molten agarose was cooled down to about 60ºC before it 
was poured onto a gel tray.  A comb was inserted at one side of the tray and the gel was 
allowed to be solidified.  After that, the gel surface was flooded with 1X TBE and the 
comb was removed.   
 
The PCR products, each mixed with an appropriate amount of 6X loading dye [0.25% 
(w/v) Bromophenol blue, 0.25% (w/v) Xylene cyanol, 50% (v/v) Glycerol, 1 mM Tris 
(pH 8.0)] mixture, were loaded into the sample wells of the gel.  AGE was then carried 
out at room temperature at a constant voltage of 130 using a power pack PAC 300 
(BioRad, U.S.A.).   Upon completion of the AGE, the gel was viewed and photographed 
by using a MS Compact 2 Megapixel CCD Image System (Major Science, Taiwan). 
 
3.5.2  SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
The glass plates were assembled vertically according to the instructions of the 
manufacturer (Bio-Rad, USA). 
 
The glass plates were then cleaned thoroughly with deionized water and wiped with 
ethanol to ensure that the glass plates were free of grease spots in order to prevent air 
bubbles from forming in the gel.  The recipes of 12% PAGE were as below:  
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Table 3.1. Recipes for separating and stacking gels. 
Stock solution Separating gel Stacking gel 
30% acrylamide:bisacrylamide (29:1) 
ready-mix gel solution 
6 mL           650 µL 
4X Tris.Cl/SDS 3 mL 750 µL (pH 8.8) 1 mL 250 µL (pH 6.8) 
10% APS 5 mL 250 µL 3 mL   50 µL 
TEMED             50 µL             25 µL 
Distilled water             10 µL               5  µL 
 
During preparation of the gel solution, APS and TEMED were added at the last steps 
and the mixture stirred gently to avoid the formation of air bubbles.  APS is used as a 
catalyst for the copolymerization of acrylamide and bisacrylamide gels while TEMED, 
acts as a free-radical catalyst.   
 
In order to prepare the gel, separating gel solution was dispersed quickly into the 
assembled gel cassette before the acrylamide polymerized.  Even flow was maintained 
so that the solution was filled from the bottom without trapping air bubbles.  After the 
gel solution reached the height around 6 cm of the plates, H2O-saturated isobutyl 
alcohol was added slowly to cover the top of the gel.  The gel was then allowed to 
polymerize for at least 45 min at room temperature. 
 
Upon completion of polymerization, H2O-saturated isobutyl alcohol was poured off and 
rinsed with 1X Tris.Cl/SDS buffer.  Later, stacking gel solution (Table 3.1) was 
prepared and dispensed till it reached the top of the plates, and a clean comb was 
immediately inserted into the gel.  The stacking gel was then allowed to polymerize for 
at least 45 min at room temperature.  After that, the comb was gently removed.  The gel 
cassette assemblies were removed from the casting stand and placed into the 
electrophoresis apparatus with the shorter plates facing inwards. 
 Chapter 3 
49 
The inner chamber was filled with 1X SDS running buffer [25 mM Tris, 192 mM 
Tricine, 0.1% (w/v) SDS] until the level reached halfway between the tops of the taller 
and shorter glass plates of the gel cassettes.  The Mini tank was also filled using the 
same buffer.   After the samples were loaded into the respective wells, the SDS-PAGE 
was conducted using a constant voltage of 150.  The power supply PAC 300 (BioRad, 
USA) was switched off when bromophenol blue dye migrated to the bottom of the gels.  
The gel was then stained with coomassie blue or used for western blot analysis. 
  
3.5.3  Bio-Safe Coomassie Blue Staining 
After separating protein samples by SDS-PAGE, the mini gels were rinsed 3 times with 
distilled water and stained with Bio-Safe Coomassie Blue (Bio-Rad, USA) for 30 min. 
Destaining of gels using distilled water was then performed until the stained protein 
bands could be clearly seen. 
 
3.6  Purification methods 
3.6.1  Isolation and purification of genomic DNA from bacterial culture 
The bacterial genomic DNA was prepared by using Bacterial Genomic DNA Isolation 
Kit (Norgen Biotek, Canada) according to the manufacturer’s protocol.  One milliliter of  
overnight bacterial culture was transferred into a microcentrifuge tube and centrifuged 
at 14,000 x g for 30 sec.  The supernatant was carefully removed and discarded as not to 
disturb the cell pellet. The pellet was then resuspended in 250 µL of Resuspension 
Solution by gently vortexing.   To the content, 250 µL of the Lysis Solution and 12 µL 
of Proteinase K were added, mixed well and incubated at 55ºC for 30 min.  Following 
that, 50 µL of Binding Solution was added to the lysate and mixed thoroughly to obtain 
a homogenous mixture.  The mixture was passed through a column and centrifuged for 
4 min at 5,200 x g.  After that, 500 µL of Wash Solution I was added to the column to 
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remove impurities and centrifuged at 14,000 x g for 1 min.  After the flow-through was 
discarded, 500 µL of Wash Solution II was added and the column was re-centrifuged at 
14,000 x g for 2 min.  An additional centrifugation at 14,000 x g for 1 min was 
performed in order to completely dry the column.  In order to elute the DNA, the waste 
collection tube was replaced with an elution tube and 100 µL of Elution Buffer was 
added to the column.  Centrifugation at 3,000 x g for 1 min was applied to allow for 
hydration of the DNA to occur.  Finally, centrifugation at 14,000 x g for an additional 2 
min was done and the eluted DNA was collected.  The extracted DNA was subjected to 
spectrophotometric measurement and stored at -20ºC for further use. 
 
3.6.2  Isolation and purification of plasmids 
The HiYield
TM
 Plasmid Mini Kit (RBC, Taiwan) was used for plasmid isolation 
according to the manufacturer’s protocol.  The bacteria that carry the desired clone was 
inoculated into 3 mL of LB medium containing appropriate antibiotic and incubated 
overnight at 37ºC with vigorous shaking.  The bacterial culture was harvested using 
centrifugation at 14,000 x g for 1 min.  The supernatant was discarded and the pellet 
was resuspended in 200 µL of PD1 buffer containing RNase A by vortexing.  Next, 200 
µL of PD2 buffer was added to the suspension, gently mixed by inverting the tube 10 
times and incubated at room temperature for 2 min until the lysate was clear.  After that, 
300 µL of PD3 buffer was added to the mixture and mixed immediately by inverting the 
tube 10 times, and centrifuged at 14,000 x g for 3 min.  After centrifugation, the 
supernatant was transferred to a PD column in a collection tube.  The flow-through was 
discarded after centrifugation at 6,000 x g for 30 sec.  The column was washed by 
adding 400 µL of W1 Buffer and centrifuged at 6,000 x g for 30 sec.  After that, the 
flow-through was removed and 600 µL of Wash Buffer was added, and the column was 
re-centrifuged at 6,000 x g for 30 sec.  An additional centrifugation step at 14,000 x g 
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for 2 min was performed in order to dry the column completely.  The column was 
placed in a clean microcentrifuge tube and 50 µL of water was added onto the center of 
the column, left for 2 min to allow hydration of the plasmid to occur.  Finally, 
centrifugation at 14,000 x g for 2 min was done and the eluted plasmid was collected.  
 
3.6.3  Isolation and purification of DNA bands from agarose gel   
The QIAEX II Gel Extraction Kit (QIAGEN, Germany) was used for DNA fragment 
recovery according to the manufacturer’s protocol.  The expected DNA band was 
excised from the agarose gel and transferred to a microcentrifuge tube.  Three volumes 
of Buffer QX1 were added to 1 volume of the gel (100 mg of gel ~ 300 µL of Buffer 
QX1), 10 µL of QIAEX II was then added to the mixture and incubated at 50ºC for 10 
min.  The mixture was mixed by vortexing every 2 min to keep QIAEX II in suspension.  
The sample was centrifuged at 14,000 x g for 30 sec and supernatant were carefully 
removed by using a micropipette.  After that, 500 µL of Buffer QX1 was added to the 
pellet in order to remove agarose residuals and centrifuged at 14,000 x g for 30 sec.  
The pellet was then washed twice with 500 µL of Buffer PE to remove salt residuals 
and centrifuged at 14,000 x g for 30 sec.  Next, the pellet was air-dried for 15 min and 
resuspended in 20 µL of H2O.  The suspension was incubated at room temperature for 5 
min followed by centrifugation at 14,000 x g for 30 sec.  The supernatant containing the 
purified DNA was transferred to a new microcentrifuge tube and stored at -20ºC for 
further use. 
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3.6.4  Isolation and purification of dsDNA products   
The QIAquick PCR purification kit (QIAGEN, Germany) was used for recovery of 
dsDNA from enzymatic reaction according to the manufacturer’s protocol.  To 1 
volume of sample, 5 volumes of Buffer PB was added and mixed by inverting the 
microcentrifuge tube.  The mixture was transferred to a QIAquick spin column and 
centrifuged at 10,000 x g for 30 sec and the flow-through was carefully discarded.  
After that, 750 µL of Buffer PE was added to the spin column for washing purpose and 
centrifuged at 10,000 x g for 30 sec.  After the flow-through was discarded, the spin 
column was re-centrifuged for 1 min to remove the wash buffer residual.  The column 
was placed in a new microcentrifuge tube and 50 µL of water was added into the center 
of the column and left for 1 min.  Finally, centrifugation at 10,000 x g for 1 min was 
carried out and elution was collected. 
 
3.7  Cloning 
3.7.1  Restriction enzyme digestion 
Digestion of the amplified products was  carried out in a final volume of 100 µL with 
each containing 20 to 40 U of appropriate restriction endonuclease (New England 
Biolabs, UK) and corresponding 1X of restriction buffer and then incubated at 37°C for 
3 h.  The digested products obtained were then purified using QIAEX II Gel Extraction 
Kit (QIAGEN, Germany) before continuing with next experiment. 
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3.7.2  Calf intestinal alkaline phosphatase (CIP) treatment  
One microgram  of the restricted digested vector was treated with 10 U of calf intestinal 
alkaline phosphatase (CIP) (New England Biolabs, UK) and 1X NEB buffer 3 [100 mM 
NaCl, 50 mM Tris-HCl, 10 mM MgCl2, 1 mM DTT] at 37°C for 1 h.  The treated 
products were then purified using QIAquick PCR Purification Kit (Section 3.6.4) prior 
to the ligation process. 
 
3.7.3  DNA ligation 
A ligation reaction consisted of purified DNA to be cloned into purified restriction 
enzyme digested plasmid vector using a 3:1 or 5:1 molar ratio, 1 µL of T4 DNA ligase 
(New England Biolabs, UK), 1X ligation buffer [50 mM KCl, 10 mM Tris-HCl pH 7.4, 
0.1 mM EDTA, 1 mM DTT and 50% (v/v) glycerol] and appropriate amount of distilled 
water to a final volume of 20 µL.  The mixture was incubated overnight at 16°C 
followed by transformation into chemically-treated competent cells.  
 
3.7.4  Preparation of chemically competent cells 
A single bacterial colony was used to inoculate 3 mL of LB broth and incubated 
overnight at 37ºC with agitation at 200 rpm.  On the following day, 200 µL of overnight 
culture was added to 20 mL prewarmed LB broth.  This was incubated at 37ºC with 
agitation until an absorbance reading of 0.5 was reached.  The bacterial culture was 
centrifuged at 3,850 x g for 10 min at 4ºC.  The supernatant was then carefully removed 
and discarded into a container of Clorox bleach.  Later, 8 mL of ice-cold CaCl2 was 
added to the cell pellet, followed by incubation on ice for 1 h.  Centrifugation was 
performed once again, and pellets were resuspended in 1 mL ice-cold CaCl2 and 10% 
glycerol.  The mixture was aliquoted (100 µL each) into labeled 1.5 mL microcentrifuge 
tubes and kept at -80ºC. 
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3.7.5  Heat shock transformation 
Two microliter of ligation reaction was added to 50 µL competent cells and mixed by 
gentle stirring with the pipette tip.  Following that, the reaction was incubated on ice for 
30 min, then heat-shocked at 42ºC for 1 min followed by 2 min on ice.  To each 
transformation, 1 mL of prewarmed LB broth (with no antibiotic added) was added and 
incubated at 37ºC for 1 h to allow the recovery of the bacteria and the expression of the 
antibiotic resistance genes.  Transformed cells were then collected by centrifugation at 
13,000 x g for 1 min and resuspended in 200 µL LB broth.  One hundred microliter of 
the bacterial suspension was plated onto LB agar plates supplemented with appropriate 
antibiotic and grown at 37ºC overnight. 
 
3.8  Sequencing 
All the samples to be sequenced in this study were sent to 1
st
 Base Laboratories 
(Malaysia) and ABI 3730xl automated sequencer was used for DNA sequencing.   
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Chapter 4   
Characterization of putative virulence determinants in 
B. pseudomallei 
 
 
4.1  Introduction 
B. pseudomallei has been considered as a potential bioweapon and virulence factors 
which associated with the bacterial pathogenesis are being intensively studied at an 
increasing rate.  The availability of a complete genome sequence database of the 
organism further allows researchers to discover many molecules and mechanisms that 
may be involved in the virulence of the organism (Holden et al., 2004; Tuanyok et al., 
2008) via comparative analysis approach either between species or within isolates. 
 
Past studies have focused on genomic differences between species, i.e., the virulent B. 
pseudomallei and a closely related but avirulent family member B. thailandensis 
(Reckseidler et al., 2001; Yu et al., 2006).  On the contrary, PCR-based subtractive 
hybridization was recently undertaken in our laboratory using a virulent clinical isolate 
B. pseudomallei (v) and an attenuated strain of the same B. pseudomallei isolate (av) 
(Puthucheary et al., 2012a). 
 
The virulent strain of B. pseudomallei (v) was isolated from the blood culture of a 44 
year old male diabetic patient in 1994, who subsequently died after developing the 
infection.  This virulent strain was used for antigen preparation for the purpose of in-
house serological tests.  However, in 2003, the freshly prepared antigen failed to give a 
positive reaction and the organism also did not agglutinate with our in-house polyvalent 
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antiserum.  The loss of virulence in this strain was further confirmed by challenge 
experiment using Balb/C mice.  The survival rate of mice, in days, was twice longer 
compared to a virulent strain.  Henceforth this strain is referred to as the “attenuated” B. 
pseudomallei (av) strain.  PCR-based subtractive hybridization demonstrated 6 
subtracted DNA fragments that were unique to the virulent strain of B. pseudomallei (v), 
whereas these DNA fragments were not seen in its “attenuated” strain (av) as illustrated 
in Figure 4.1 (Puthucheary et al., 2012a).  Subtracted DNA fragments were sequenced 
and revealed 6 unique genes with unknown functions as stated in Table 4.1.   However 
much is still unknown regarding the bacterial factors contributing to the virulence.   
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Figure 4.1. Subtractive hybridization of virulent (v) and attenuated (av) B. 
pseudomallei strains 
  Lane (s) 1 – 100bp DNA ladder (Fermentas, USA) 
                           2 – virulent  B. pseudomallei (v) hybridized with attenuated B.  
           pseudomallei (av) 
     3 – B. pseudomallei (av) hybridized with virulent B.  
           pseudomallei (v) 
     4 – control (unsubstracted genomic DNA from virulent B.  
           pseudomallei (v) 
 
(Puthucheary et al., 2012a) 
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Table 4.1. Characterization of 7 candidate genes for their roles in B. pseudomallei infection. 
No Locus tag Nucleotide 
sequence 
Amino 
acid 
Location Annotation 
(RefSeq: NCBI) 
Orthologs/ 
comparative genomics 
References 
1 Fragment 2: 
BPSL2033 
1287 428 Chr I:  
2428723..2430009 
YP_108630.1 BG003741  
 
 
 
Current study 
2 Fragment 3: 
BP1026B_I2784 
927 308 Chr I: complement 
3091068..3091994 
NC_017831.1 - 
3 Fragment 4: 
BP1026B_I2780 
870 289 Chr I: 
3085731..3086600 
NC_017831.1 BG015169 
4 Fragment 5: 
BURPS1106A_A0094 
636 211 Chr II: complement  
82340..82975 
YP_001074137.1 BG005228 
5 Fragment 6: 
BURPS1106A_1131 
342 113 Chr I: complement 
(1112960..1113301) 
YP_001065411.1 BG011052 
6 Fragment 1: 
BURPS1710A_1419 
225 74 Chr I:  
1354038-1354262 
NZ_CM000832.1 BG013631 
7 BPSL3147 1011 336 Chr I: complement 
3746560..3747570 
YP_109740.1 BG000325 Cuccui et al., 2007 
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Besides, another candidate BPSL3147 encoding a putative lipoprotein was identified by 
signature-tagged mutagenesis (STM) (Cuccui et al., 2007).  Interestingly, this putative 
lipoprotein contains 39.16% amino acid sequence that is identical to a VacJ lipoprotein 
in Shigella flexneri.  The Tn10 mutant of S. flexneri YSH6000T VacJ lipoprotein was 
found unable to spread from cell to cell, suggesting VacJ is important for intercellular 
spread of the organism (Suzuki et al., 1994).   There remains much opportunity for 
further investigation of BPSL3147 contributing to the pathogenesis of B. pseudomallei 
infection. 
 
Hence, the aim of this study was to characterize the 7 putative virulence determinants 
using a gene knockout approach, in vitro and in vivo assays.  Six of these genes were 
absent in the “attenuated” strain (av) that is believed to have reduced virulence after 
several subcultures and long-term storage in the laboratory; and an additional candidate, 
BPSL3147, was chosen as it might be important for cell to cell spreading of the 
bacterium.   
 
The specific objectives for the work in this chapter are: 
1. to construct 7 insertion mutant strains of B. pseudomallei.  
2. to construct complemented strains for the 7 insertion mutants.   
3. to examine the survival of these mutants as well as complemented strains in 
murine RAW246.7 macrophage cell line. 
4. to investigate the possible virulence of these mutants as well as complemented 
strains using C. elegans model. 
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4.2  Materials and methods 
4.2.1  Bacterial strains, plasmids and culture conditions 
The virulent B. pseudomallei strain was isolated from patient CMS, at the University 
Hospital, University of Malaya (UM), who died from melioidosis (Puthucheary et al., 
2012a) and this strain was used throughout the study (henceforth referred to as Bp-
CMS).  The Escherichia coli strains DH10B, CC118λpir, S17-1λpir and vector pUT-
Km were kind gifts from Prof. Dr. Wang Jin-Town (National Taiwan University, 
Taiwan).   
 
The E. coli DH10B was mainly used for propagation of CC118λpir plasmid and 
maintaining the delivery plasmids; S17-1λpir which was used as the donor strain in 
conjugation experiments to allow mobilization of the λpir-dependent plasmid pUT-Km 
into B. pseudomallei CMS (Table 4.1).   All strains were grown in LB broth at 37°C 
overnight with 150 rpm agitation.  Antibiotics were used at the following final 
concentrations: ampicillin 100 µg/mL; kanamycin 50 µg/mL; chloramphenicol 100 
µg/mL and streptomycin 100 µg/mL. 
 
4.2.2  Cell lines and culture conditions  
RAW264.7, the mouse leukaemic monocyte macrophage cell line was obtained from 
American Type Culture Collection (USA).  It was cultured and maintained in 25 or 75 
cm
2
 flask (Corning, USA) with DMEM (Gifco, USA) supplemented with 10% (v/v) 
fetal bovine serum (Gifco, USA), 4 mM L-glutamine and an antibiotic mixture 
containing  100 U/mL penicillin and 0.1 mg/mL streptomycin at 37°C in 5% CO2 
atmosphere.   
 
 
 Chapter 4 
61 
4.2.3  Nematode strain and culture conditions 
The wild type C. elegans N2 was obtained from Carolina Biological Supply Company 
(USA).  The nematode was propagated on nematode growth medium (NGM) plate and 
fed on the normal food source E. coli OP50-1, which was a kind gift from Prof. Dr. 
Sheila Nathan (National University of Malaysia, Malaysia). 
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Table 4.2.  Bacterial strains and plasmids used in this study. 
No Strains/plasmids Relevant characteristic(s) Reference 
B. pseudomallei strains 
1 Bp-CMS Clinical isolate from blood; Wild type parental strain for generation of  insertion mutants  
 
 
 
 
 
 
 
Current study 
2 BPSL2033::Km  BPSL2033::Km derivative of CMS; Kan
R
 
3 BPSL2033::Km (pC-BPSL2033) BPSL2033::Km complemented in trans with pC-BPSL2033; Kan
R 
Cm
R
 
4 BP1026B_I2784::Km BP1026B_I2784::Km derivative of CMS; Kan
R
 
5 BP1026B_I2784::Km (pC-P1026B_I2784) BP1026B_I2784::Km complemented in trans with pC-BP1026B_I2784; Kan
R 
Cm
R
 
6 BP1026B_I2780::Km BP1026B_I2780::Km derivative of CMS; Kan
R
 
7 BP1026B_I2780::Km (pC-BP1026B_I2780) BP1026B_I2780::Km complemented in trans with pC-BP1026B_I2780; Kan
R 
Cm
R
 
8 BURPS1106A_A0094::Km BURPS1106A_A0094:: Km derivative of CMS; KanR 
9 BURPS1106A_A0094::Km 
(pC-BURPS1106A_A0094) 
BURPS1106A_A0094::Km complemented in trans with pC-BURPS1106A_A0094; Kan
R 
Cm
R
 
10 BURPS1106A_1131::Km BURPS 1106A_1131::Km derivative of CMS; Kan
R
 
11 BURPS1106A_1131::Km  
(pC-BURPS1106A_1131) 
BURPS 1106A_1131::Km complemented in trans with pC- BURPS1710A_1419; Kan
R 
Cm
R
 
12 BURPS1710A_1419::Km BURPS1710A_1419::Km derivative of CMS; Kan
R
 
13 BURPS1710A_1419::Km  
(pC-BURPS1710A_1419) 
BURPS1710A_1419::Km complemented in trans with pC-BURPS1710A_1419; Kan
R 
Cm
R
 
15 BPSL3147::Km BPSL3147::Km derivative of CMS; Kan
R
 
16 BPSL3147::Km (pC-BPSL3147) BPSL3147::Km complemented in trans with pC-BPSL3147; Kan
R 
Cm
R
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Table 4.2.  (Continued) 
No Strains/plasmids Relevant characteristic(s) Reference 
E. coli strains 
1 DH10B A general cloning strain;  
F_ mcrA D(mrr-hsdRMS-mcrBC) f80lacZDM15 DlacX74 recA1 endA1 araD139 
D(ara, leu)7697 galU galK l_ rpsL nupG 
Gifts from Prof. 
Dr. Wang Jin-
Town, National 
Taiwan 
University, 
Taiwan. 
2 CC118λpir Strain used for maintenance of suicide plasmid;  
D(ara-leu) araD DlacX74 galE galK phoA20 thi-1 rpsE rpoB argE(Am) recA1 lpir 
phage lysogen 
3 S17-1λpir Strain used for conjugational transfer of suicide plasmid from E.coli to B. 
pseudomallei; 
hsdR recA pro RP4-2 (Tc::Mu; Km::Tn7)(lλpir) 
4 OP50-1 A streptomycin-resistant derivative of E.coli OP50 used as food source in C. elegans 
cultivation and uninfected control 
 
Gift from Prof. 
Dr. Sheila 
Nathan, National 
University 
Malaysia, 
Malaysia. 
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Table 4.2.  (Continued) 
No Strains/plasmids Relevant characteristic(s) Reference 
Plasmid 
1 pUT-Km Source of kanamycin resistance cassette;  oriR6K mobRP4 Kan
R
 Amp
R
 
 
(Chuang et al., 
2006) 
2 pGEM-T easy Cloning vector for PCR cloning; Amp
R
 Promega, USA 
3 pUT-BURPS1710A_1419 pUT-Km carrying 196 bp amplified BURPS1710A_1419 DNA fragment from Bp-
CMS 
Current study 
4 pUT-BPSL2033 pUT-Km carrying 500 bp amplified BPSL2033 DNA fragment from Bp-CMS Current study 
5 pUT-BP1026B_I2784 pUT-Km carrying 346 bp amplified BP1026B_I2784 DNA fragment from Bp-CMS Current study 
6 pUT-BP1026B_I2780 pUT-Km carrying 323 bp amplified BP1026B_I2780 DNA fragment from Bp-CMS Current study 
7 pUT-BURPS1106A_A0094 pUT-Km carrying 205 bp amplified BURPS1106A_A0094 DNA fragment from Bp-
CMS 
Current study 
8 pUT-BURPS1106A_1131 pUT-Km carrying 247 bp amplified BURPS1106A_1131 DNA fragment from Bp-
CMS 
Current study 
9 pUT-BPSL3147 pUT-Km carrying 492 bp amplified BPSL3147 DNA fragment from Bp-CMS Current study 
10 pC-BPSL2033 A modified pGEM-T carrying 1703 bp BPSL2033 PCR product containing 
BPSL2033 promoter, Cm
R
 
Current study 
11 pC-BP1026B_I2784 A modified  pGEM-T carrying 1213 bp BP1026B_I2784 PCR product containing 
BP1026B_I2784 promoter, Cm
R
 
Current study 
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Table 4.2.  (Continued) 
No Strains/plasmids Relevant characteristic(s) Reference 
Plasmid 
12 pC-BP1026B_I2780 A modified  pGEM-T carrying 1395 bp BP1026B_I2780 PCR product containing 
BP1026B_I2780 promoter, Cm
R
 
Current study 
13 pC-BURPS1106A_A0094 A modified  pGEM-T carrying 1119 bp BURPS1106A_A0094 PCR product 
containing BURPS1106A_A0094 promoter, Cm
R
 
Current study 
14 pC-BURPS1106A_1131 A modified  pGEM-T carrying 861 bp BURPS1106A_1131 PCR product containing 
BURPS1106A_1131 promoter, Cm
R
 
Current study 
15 pC-BPSL3147 A modified  pGEM-T carrying 1705 bp BPSL3147 PCR product containing 
BPSL3147 promoter, Cm
R
 
Current study 
16 pC-BURPS1710A_1419 A modified  pGEM-T carrying 699 bp BURPS1710A_1419 PCR product containing 
BURPS1710A_1419 promoter, Cm
R
 
Current study 
 
Kan – kanamycin; Amp - ampicillin; Cm - chloramphenicol; R - resistant 
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4.2.4  Insertion mutagenesis  
4.2.4.1  Primers designation 
Primer pairs designed to amplify particular regions of target genes are shown below: 
 
Table 4.3 Primers used for PCR and construction of mutants and 
complemented plasmids in this study. 
 
Name  Primer sequence (5’         3’) Fragment size (bp) 
P1 (pUT-R)  TTTGAGTGACACAGGAACAC - 
P2 (KmF)  ATGAGCCATATTCAACGGGA - 
P3 
P4 
 AGAACTTCGAGCAATTGCTG 
 GAGAGATGACGTTCGGTCTT 
500 
P5 
P6 
 GTCGAGAGTACGGTGTGTTC 
 CCTGCGAAATCCTTATCAC 
346 
P7 
P8 
 AAACCAGAAGGGCGATTTC 
 GCGTTCTTTTAAGAATTGGGTAG 
323 
P9 
P10 
 AAGGAGTTGGGTACGTCG 
 CCCTTGTGCCATTGATAG 
247 
P11 
P12 
 GCGATAGCGATTGGAAAACT 
 GAATCCAGACCCATTCCGT 
196 
P13 
P14 
 GACCAGTACGCGCTCAAG 
 GAACGAATACTTGTCGATCG 
492 
P15 
P16 
 GTGAACTGGTACAAAGAAATATCG 
 CACGTTTCTCGGATAGAGC 
6256 
P17 
P18 
 CTGTTTTCTAAGCGTCAGAAG 
 AAATATGCAGGAAATAGCCCG 
5771 
P19 
P20 
 CAGGTACGATTCATGGAACG 
 GGTATTCCGTGACCTGAATGT 
5648 
P21 ACGCATGCTCAAGAAATG - 
P22 
P23 
GTGAATGTCGATCTTGCG 
TCAATCTCCAGCGAGCTT 
5541 
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Table 4.3  (Continued) 
 
Name  Primer sequence (5’         3’) Fragment size (bp) 
P24 
P25 
GATGTACACGTTCAACGACAAG 
CTCTTCCGGCATCTCGTA 
5751 
P26 
P27 
CTAGAGCGCGGCCTCGCG 
CATCACTCGGCGCAATGAGACTG 
1703 
P28 
P29 
CCTTCGCGCTGATTTGGT 
CTACTTCGTAGCTTGATGCGCC 
1213 
P30 
P31 
AGGCTCGGAGTAGTAACACTT 
CTACTGCCTATGCTGGGGTAT 
1395 
P32 
P33 
TTCTACCAGCGACTTGGC 
TCAATCTCCAGCGAGCTT 
1119 
P34 
P35 
GTGGTTCAGCCAGGCACG 
GTATGTGTCGTCCGCATTTG 
861 
P36 
P37 
TGCACAAGCTGTTCAAATG 
TTAAGGCTTGGGTGCAAG 
695 
P38 
P39 
TTCAGGGTTACGAAGCGAAG 
TCAGTGCAGCCGGATGCTCG 
1705 
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4.2.4.2  Construction of suicide plasmids for conjugation 
The strategy to construct all 7 plasmids targeting genes BPSL2033, BP1026B_I2784, 
BP1026B_I2780, BURPS1106A_A0094, BURPS1106A_1131, BURPS1710A_1419 and 
BPSL3147 for conjugation purpose is outlined in Figure 4.2.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. Construction of plasmids for conjugation. 
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A partial region of the gene to be inactivated (serving as a significant site of gene 
exchange through conjugation and recombinant events) was amplified by PCR (Section 
3.3.3) using primer pairs as listed in Table 4.3.  Two microliter of the amplicon was 
subcloned into pGEM-T Easy (Promega, USA) and then transformed into 100 µL of 
competent E. coli DH10B cells (Section 3.7.4).  Selection of transformants by plating 
onto LB agar containing 50 µg/mL ampicillin/X-Gal/IPTG and rapid screening for 
desired inserts by colony PCR was performed (Section 3.3.4).     
 
The transformed E. coli carrying the desired insert (positive clone) was inoculated into 3 
mL of LB broth with 100 µg/mL of ampicillin and incubated overnight at 37ºC with 
agitation at 150 rpm.  The next day, DNA plasmid was isolated as described previously 
(Section 3.6.2) and subjected to EcoRI digestion (Section 3.7.1).  The digested products 
were then gel purified and ligated into EcoRI–restricted, calf intestinal phosphatase 
treated pUT-Km vector (Section 3.7.2).  The pUT-Km is a suicide vector having the 
R6K origin of replication and can be maintained only in host strains producing 
particular protein, i.e., CC118λpir.  Therefore, 2 µL of ligation products were 
transformed into 100 µL chemically competent E. coli CC118λpir and followed by 
transformant selection by plating the bacteria onto LB agar plates containing 50 µg/mL 
kanamycin.  Positive clones with correct orientation were confirmed by colony PCR 
(Section 3.3.4). 
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4.2.4.3  Filter conjugation 
The resulting pUT-Km plasmids containing the flanking regions of gene of interest of B. 
pseudomallei are suicide vectors and they cannot replicate in the recipient cells which 
do not have the π protein.  Hence, 2 µL of each recombinant plasmid was transformed 
into 100 µL of E. coli S17-1λpir and used for chromosomal integration into the wild 
type B. pseudomallei (Bp-CMS) by conjugation.  
 
A single colony of donor (E. coli S17-1λpir harboring suicide plasmid) and recipient 
(wild type Bp-CMS) were separately grown in 3 mL of LB broth with 50 µg/mL 
kanamycin and without antibiotic, respectively.  The culture was then incubated 
overnight at 37°C with agitation at 150 rpm.  The next day, to the 3 mL of LB broth, 30 
µL of the overnight culture was inoculated and incubated for 4 h at 37°C with shaking 
at 150 rpm until the OD600 reached  0.6 - 0.8.  An equal amount of donor and recipient 
were mixed together into 2 mL of 10 mM MgSO4.  The mixture was spotted on 0.2 µM 
sterile mixed cellulose ester membrane (Fioroni, France).  The filter paper was 
transferred onto LB agar without antibiotic and incubated overnight for mating purpose 
at 37°C. 
 
After that, filter paper was transferred into a sterile 50 mL falcon tube containing 5 mL 
of 10 mM MgSO4.  The bacterial lawn on each filter was then harvested after 3 min of 
vigorous vortexing.  Serial dilutions of the culture were plated on minimal medium 
supplemented with 50 µg/mL kanamycin to counter select donors and untransformed 
recipient cells and these plates were incubated overnight at 37°C.   
 
As illustrated in Figure 4.3, transconjugants with pUT-Km vector carrying a partial 
homology DNA sequence integrated into the target gene on wild type B. pseudomallei 
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chromosome via single cross recombination were confirmed for their insertion by PCR 
using alignment specific primers and sequencing.  The primers pUT-R and KmF are 
located in pUT-Km plasmid that annealed only to the mutated sequences when paired 
with corresponding chromosomal primers.  In other words, primers pUT-R and KmF 
were used to detect the presence or absence of the pUT-Km vector sequence in the B. 
pseudomallei choromosome.  This suggests that integration of pUT-Km plasmid has 
taken place in the intended location on the B. pseudomallei chromosome.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Construction of the insertion mutants in Bp-CMS. 
 
 
 
 
1.3kb   
Suicide plasmid 
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4.2.5  Construction of complemented plasmids for mutant strains  
Kanamycin was used to select for an insertion mutant as described in the previous 
section (Section 4.2.4.3).  To construct a complemented plasmid, a second antibiotic 
resistance marker such as chloramphenicol was chosen.  A chloramphenicol 
acetyltransferase (CAT) cassette with approximately size of 900 bp (a gift from Prof. Dr. 
Wang Jin-Town, National Taiwan University, Taiwan) was inserted into a pGEM-T 
Easy at NcoI site.   
 
Next, the intact BURPS1710A_1419, BPSL2033, BP1026B_I2784, BP1026B_I2780, 
BURPS1106A_A0094, BURPS1106A_1131, and BPSL3147 genes and their promoter 
were amplified from the genomic DNA of Bp-CMS by using primer pairs as shown in 
Table 4.3.  Their promoters were identified using Softberry (BPROM) software.  Two 
microliter of amplicon was cloned into a modified pGEM-T easy vector, which contains 
CAT, followed by transforming into 100 µL of E. coli DH10B.  Positive transformants 
were selected by plating onto LB agar containing 100 µg/mL of chloramphenicol.   
 
The confirmation of the positive clones and their insert orientation was then performed 
by colony PCR using each forward primer paired with a T7 primer (Section 3.3.4).   A 
simplified diagram to describe the location of CAT and PCR fragment at pGEM-T easy 
is shown in Figure 4.4.   
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Figure 4.4. Construction of a complemented plasmid. 
 
 
 
 
 
 
 
 
 
 
Modified pGEM-T 
easy vector 
CAT 
Amp
R
 
F1 ori 
T7 primer 
Forward primer 
Full-length of candidate gene  
and its promoter 
lacZ 
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4.2.6  Bacterial growth curves  
A single bacterial colony was inoculated into 3 mL of LB broth with or without 
antibiotic and incubated overnight at 37°C with agitation at 150 rpm.  The next day, 200 
µL of an overnight culture was added into 20 mL of prewarmed LB broth containing the 
appropriate antibiotics and incubated 37°C with agitation at 150 rpm.  The growth was 
monitored over 8 h and 1 mL of culture broth was taken every hour to perform OD600 
readings.  B. pseudomallei wild type Bp-CMS was used as a positive control. 
 
4.2.7  Replication of bacteria in macrophage cells 
Mouse leukaemic monocyte macrophage cells (RAW264.7) were cultured in DMEM 
containing antibiotic to confluence, scraped from cell culture flasks, and transferred into 
24 well culture plates (Corning, USA) at a density of 1 X 10
5
 cells/well and incubated 
overnight at 37°C with 5% CO2.  A single colony of wild-type, insertion mutant and 
complemented strains were incubated overnight in 3 mL LB with or without antibiotics 
at 37°C.  
 
On the following day, an overnight culture was diluted 1:100 and inoculated into a fresh 
LB followed by incubation at 37°C for 3 h with shaking at 250 rpm until the OD600 
reached 0.4 to 0.6.  The bacterial culture was transferred to a microcentrifuge tube and 
was spun briefly at 13,000 x g for 5 min.  The pellet was washed once with pre-warmed 
DMEM without antibiotic and resuspended in 1 mL of DMEM without antibiotic.  The 
bacterial suspension was adjusted to 1 X 10
7
 cfu/mL in DMEM without antibiotic by 
measuring the OD600 using a spectrophotometer (Implen, Germany).  Cell monolayers 
were washed twice with PBS and incubated in fresh DMEM without antibiotic for 1 h 
prior to infection with bacteria.   
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Twenty five microliter of bacterial suspension was added at a MOI of 100:1 and the co-
culture was immediately centrifuged at room temperature with 170 x g for 5 min to 
bring the bacteria in direct contact with the host cells.  Tissue culture plates were 
incubated at 37°C for 1 h to allow for the uptake of the bacteria by the cell.  After that, 
cells were washed twice with PBS and then incubated in fresh DMEM containing 300 
µg/mL of tetracycline to suppress the growth of residual extracellular bacteria.  This 
point was taken as time zero, and cells were further incubated for 2, 4 and 8 h.   
 
At each time point, infected monolayers were washed twice with PBS and lysed with 
150 µL of 0.1% (v/v) Triton X-100 for 15 min.  Serial dilutions of the released bacteria 
(expressed as colony forming unit, CFU) were plated on Tryptic Soy Agar (TSA) plates 
to enumerate bacterial loads by direct colony counts.  The number of internalized 
bacteria obtained at 2 h post infection represented the initial entry of bacteria whereas 4 
and 8 h post infection represented intracellular bacterial replication.  Bacterial survival 
was normalized to counts obtained at 2 h post infection and the data presented as 
relative survival in percentage.  The assays were performed in triplicate for each (2, 4, 
and 8 h) post infection and this process was repeated 3 times on different days. 
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4.2.8  Caenorhabditis elegans killing assay 
4.2.8.1  Worm synchronization 
All nematodes were age synchronized by bleaching procedure prior to the killing assay 
(Powell and Ausubel, 2008; Stiernagle, 1999).  Gravid hermaphrodites were harvested 
from a Nematode Growth Medium (NGM) plate by washing with 1 mL M9 buffer 
across the plate several times to loosen worms and eggs that were stuck in the E. coli 
OP50-1 lawn.  The suspension was aseptically collected into a 15 mL falcon tube and 
M9 buffer was added to total 3.5 mL.  To the suspension, 0.5 mL of 5N NaOH and 1 
mL of 5% bleach were added.  The mixture was mixed by shaking the tubes for about 5 
to 10 min until the mixture became clear and no worms visible, and then spun for 30 sec 
at 1,500 x g to collect the released eggs.  The supernatant was carefully removed and 5 
mL M9 buffer was added to wash the eggs.  This washing step was repeated twice to 
remove all bleach solution in order to make sure the eggs would survive.  After 2 
washes, the eggs were resuspended in 5 mL of M9 buffer and allowed to hatch 
overnight at room temperature. 
  
Next day, the hatched L1 larvae in the falcon tube were collected by centrifugation for 
30 sec at 1,500 x g.   The supernatant was discarded leaving behind the pellet in the 
remaining 100 µL of liquid and transferred to NGM plates seeded with an E. coli OP50-
1 lawn.  The plates were incubated for 2 days at room temperature until maturation.  
The killing assay was begun with L4 or young adult stage nematodes. 
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4.2.8.2  Slow killing assay 
A single colony of B. pseudomallei derived-strains (wild type Bp-CMS, 7 insertion 
mutants and 7 complemented strains) and E. coli OP50-1 were inoculated into 3 mL of 
LB broth with or without antibiotic and incubated at 37°C overnight with agitation at 
150 rpm.  The overnight culture was then standardized to an OD600 of 2.0 and 40 µL of 
culture was plated on a modified NGM containing 50 µg/mL 5-fluorodeoxyuridine 
(FUDR) (Merck, USA) to inhibit the eggs from hatching.  Plates were incubated at 
37°C for 24 h and then allowed to equilibrate to room temperature for 24 h before co-
culturing with the host worms.   
 
The worms were washed with M9 buffer and pelleted by centrifugation for 30 sec at 
1,500 x g.  The same procedure was repeated 3 times to get rid of contaminating E. coli 
OP50-1 bacteria, and the worms were then transferred to killing agar plates.  In each 
assay, a total of 30 age-matched hermaphrodites were individually transferred to freshly 
lawned plates by using the flattened tip of a worm pick (platinum wire).  The plates 
were incubated at room temperature and virulence was tracked by counting the number 
of live and dead worms every 24 h for 3 days.  A worm was considered dead on failure 
to respond to gentle touch by worm pick and any worms that died as a result of getting 
stuck to the wall of the plate were censored from the analysis.  E. coli OP50-1 was used 
as a negative control.  Three independent experiments were carried out for each strain, 
and each test was performed in triplicates (with a total of 270 worms) to yield consistent 
results. 
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4.2.9  Statistical analysis 
For macrophage infection assay, percentage of survival was calculated using the 
formula as shown below and a graph was plotted using an excel database.   Student’s  t-
test was used to determine if there was  statistical  significance  (P<0.05) of the mean 
value. 
             Relative survival =  number of intracellular bacteria post infection  
                               number of initial entry of  bacteria  
 
 
For killing assay, worm survival was analyzed using GraphPad Prism 5 software 
(GraphPad Software Inc, la Jolla, CA) and a Kaplan-Meier survival plot was 
constructed.  The differences of the curves were compared using a log rank test, which 
generates a P value testing the null hypothesis that the survival curves are identical. 
Survival curves are considered significantly different from the control when P< 0.05. 
  
 The flow chart for the entire experimental procedures in this study is shown in Figure 
4.5.  
 
X 100 
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Figure 4.5. Summary of the experiments carried out in this study. 
Construction of insertion mutants Construction of complemented strains  
Cloned into a modified pGEM-T Easy containing 
CAT cassette 
Amplification of full-length and its promoter 
of target gene 
Transformed into the  
corresponding  
mutant strains 
Growth curve 
RAW264.7 survival and replication assay 
Wild type Bp-CMS 
Insertion mutants 
BPSL2033::Km 
BP1026B_I2784::Km 
BP1026B_I2780::Km 
BURPS1106A_A0094::Km 
BURPS1106A_1131::Km 
BURPS1710A_1419::Km 
BPSL3147::Km 
 
 
 
Complemented strains 
BPSL2033::Km (pC-BPSL2033) 
BP1026B_I2784::Km (pC-BP1026B_I2784) 
BP1026B_I2780::Km (pC-BP1026B_I2780) 
BURPS1106A_A0094::Km (pC-BURPS1106A_A0094) 
BURPS1106A_1131::Km (pC-BURPS1106A_1131) 
BURPS1710A_1419::Km (pC-BURPS1710A_1419) 
BPSL3147::Km (pC-BPSL3147) 
 
 
 C. elegans slow killing assay 
Statistical analysis 
Amplification of partial DNA 
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4.3  Results 
4.3.1  Construction of BPSL2033::Km mutant 
The putative 1287 bp BPSL2033 gene encodes the predicted transport-related membrane 
protein of 428 amino acids.  Primers P3 & pUT-R and P4 & KmF yielded amplicons of 
599 bp and 1700 bp in the mutant but not in the wild type as shown in Figure 4.6.  Later, 
the integration of pUT-BPSL2033 (Table 4.2) into the BPSL2033 gene on the B. 
pseudomallei chromosome was confirmed by using 2 chromosomal primers (P15 & P16) 
flanking the homologous region.  The insertion mutant gave approximately the expected 
6256 bp PCR product after amplification while wild type showed a band about 1056 bp.  
One of the resulting strains designated as BPSL2033::Km was used for further study.  
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Figure 4.6. Verification of the construction of BSL2033::Km mutant by PCR 
using specific alignment primers.  M and W represent mutant and wild 
type strains respectively, while L indicates 1 kb DNA ladder from 
Fermentas (USA). 
 
 
 
 
 
 
 
1.3kb   
 
Mu
tan
t  ~599 bp   
 ~1056 bp   
 ~6256 bp   
 ~1700 bp Homologous 
region 
6000 
2000  
1000  
500  
  bp          L       M      W      M      W      M      W      
 599 bp                  1700 bp 
Wild type  
 
 
 
 
 
6256 bp 
Mutant  
 
 
 
 
 
 1056 bp 
P15   P3 P4   P16 
  P15 P3    pUT-R              KmF          P4              P16                     
P18 
 
 Chapter 4 
82 
4.3.2  Construction of BP1026B_I2784::Km mutant 
The putative 927 bp BP1026B_I2784 gene encodes for the hypothetical protein of 308 
amino acids.  PCR using primers P5 & pUT-R and KmF & P6 yielded DNA fragments 
of 497 bp and 1743 bp, respectively in the mutant but not in the wild type, suggesting 
the presence pUT-BP1026B_I2784 in the intended location on the B. pseudomallei 
chromosome, which was verified by sequencing.  Next, both upstream and downstream 
of flanking sequences of this homologous region were PCR amplified using primers 
P17 and P18 to confirm the integration of the entire pUT-BP1026B_I2784 into the 
bacterial chromosome.  PCR results demonstrated a band of 725 bp in the wild type and 
5771 bp in the mutant (Figure 4.7).  One mutant designated BP1026B_I2784::Km was 
then chosen for further study.   
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Figure 4.7. Verification of the construction of BP1026B_I2784::Km mutant by 
PCR using specific alignment primers.  M and W represent mutant and 
wild type strains respectively, while L indicates 1 kb DNA ladder from 
Fermentas (USA). 
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4.3.3  Construction of BP1026B_I2780::Km mutant 
The putative 870 bp BP1026B_I2780 gene encodes for the hypothetical protein of 289 
amino acids.  The 422 bp and 1683 bp fragments were amplified by primers P7 & pUT-
R and KmF & P8, respectively, in the mutant but not in the wild type.  The amplicons 
were clearly visible on a 1% (w/v) agarose gel (Figure 4.8).  On the contrary, no 
amplification product was observed in the wild type tested.  Next, PCR analysis using 
chromosomal primers (P19 & P20) amplified 5648 bp and 625 bp in the mutant and 
wild type strains, respectively.  The mutant designated as BP1026B_I2780::Km was 
used for further study. 
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Figure 4.8. Verification of the construction of BP1026B_I2780::Km mutant by 
PCR using specific alignment primers.  M and W represent mutant and 
wild type strains respectively, while L indicates 1 kb DNA ladder from 
Fermentas (USA). 
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4.3.4  Construction of BURPS1106A_A0094::Km mutant 
The putative 636 bp BURPS1106A_A0094 gene encodes for the regulatory protein of 
211 amino acids.  As shown in Figure 4.9, PCR using primers P21 & pUT-R and KmF 
& P23 amplified products of 540 bp and 1710 bp that were observed in the mutant but 
not in the wild type, suggesting the presence of pUT-Km vector sequence on B. 
pesudomallei chromosome as previously described (Section 4.2.4.3).  Next, the mutant 
was confirmed by using chromosomal primers P22 & P23 to amplify full-length of the 
target gene and this  generated a  longer PCR fragment 5541 bp compared to the wild 
type, 636 bp.  The mutant was designated as BURPS1106A_A0094::Km and used for 
further study. 
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Figure 4.9. Verification of the construction of BURPS1106A_A0094::Km mutant 
by PCR using specific alignment primers.  M and W represent mutant 
and wild type strains respectively, while L indicates 1 kb DNA ladder 
from Fermentas (USA). 
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4.3.5  Construction of BURPS1106A_1131::Km mutant 
The putative 342 bp BURPS1106A_1131 gene encodes the hypothetical protein of 113 
amino acids.  Figure 4.10 shows that the mutant yielded a DNA fragment of 346 bp, 
using P9 & pUT-R and 1347 bp fragment using KmF & P10.  No amplification product 
was observed in the wild type by using primers containing plasmid backbone.  Both 
results confirmed the presence of the pUT vector sequence.  Furthermore, the mutant 
should be appeared to be legitimate single-crossover recombinant based on the principle 
of homologous recombination-mediated integration (Section 4.2.4.3).  It was  expected 
to give rise to 2 PCR products, small (247 bp) and large (4947 bp) fragments using 
primers P9 & P10 whereas wild type only amplified a small fragment (247 bp).  One of 
the mutants was designated BURPS1106A_1131::Km and used for further study. 
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Figure 4.10. Verification of the construction of BURPS1106A_1131::Km mutant 
by PCR using specific alignment primers.  M and W represent mutant 
and wild type strains respectively, while L indicates 1 kb DNA ladder 
from Fermentas (USA). 
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4.3.6  Construction of BURPS1710A_1419::Km mutant 
The 225 bp BURPS1710A_1419 gene encodes the putative lipoprotein of 74 amino 
acids.  As illustrated in Figure 4.11, Primers P11 & pUT-R and KmF & P12 amplified 
214 bp and 1296 bp, respectively in the mutant, but not in the wild type.  Based on the 
principle of homologous recombination-mediated integration (Section 4.2.4.3), the 
mutant should be appeared to be legitimate single-crossover recombinant, the 
confirmation was then performed using primers P11 & P12. As expected, the mutant 
yielded 2 PCR products, small (196 bp) and large (5092 bp) fragments whereas the wild 
type only amplified a small fragment (196 bp).  One of the mutants was designated 
BURPS1710A_1419::Km and used for further study. 
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Figure 4.11. Verification of the construction of BURPS1710A_1419::Km mutant 
by PCR using specific alignment primers.  M and W represent mutant 
and wild type strains respectively, while L indicates 1 kb DNA ladder 
from Fermentas (USA). 
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4.3.7  Construction of BPSL3147::Km mutant 
The putative 1011 bp BPSL3147 gene encodes the lipoprotein of 336 amino acids.  As 
illustrated in Figure 4.12, amplicons of 591 bp and 1592 bp were seen in the mutant, but 
not in the wild type when using primer pairs, pUT-R and KmF, respectively.  The 
insertion mutant was confirmed using PCR with primers flanking the expected site of 
mutagenesis (P24 & P25).  The mutant yielded a longer expected PCR product, i.e., 
5751 bp compared to the wild type with 637 bp.  Both PCR results showed that the 
mutation of BPSL3147 gene on B. pseudomallei chromosome was constructed and one 
strain named BPSL3147::Km was selected for further study.   
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Figure 4.12. Verification of the construction of BPSL3147::Km mutant by PCR 
using specific alignment primers.  M and W represent mutant and wild 
type strains respectively, while L indicates 1 kb DNA ladder from 
Fermentas (USA). 
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4.3.8  Growth curve 
The growth rate of the parental B. pseudomallei (Bp-CMS) and the insertion derivatives 
were measured (OD reading) in liquid media over 8 h.  All 7 mutant strains 
demonstrated similar growth rate to the parental strain (Figure 4.13).  Hence, all 7 
mutants were used for construction of complemented strains and further characterized 
for virulence in vitro and in vivo. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13. Growth of wild type and mutant strains of B. pseudomallei in liquid 
media at 37°C monitored by absorbance at 600 nm over 8 hours. 
(Mean from 2 independent experiments). 
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4.3.9  Construction of complemented strains 
A complemented strain was constructed in following methods: a) a complemented 
plasmid was constructed by cloning an intact copy of the native gene containing its own 
promoter into the modified pGEM-T vector (Figure 4.4) b) reintroducing a 
complemented plasmid into the corresponding insertion mutant by transformation.  
 
Figure 4.14 shows the expected fragments demonstrated by complemented plasmids. 
All PCR products from lane 2 were found to posses a longer DNA fragments compared 
to that in lane 1 due to the presence of CAT cassette.  All of these complemented 
plasmids were transformed into each corespsonding mutant and the resulting 
complemented strains were designated as: BPSL2033::Km (pC-BPSL2033), 
BP1026B_I2784::Km (pC-BP1026B_I2784), BP1026B_I2780::Km (pC-
BP1026B_I2780), BURPS1106A_A0094::Km (pC-BURPS1106A_A0094), 
BURPS1106A_1131::Km (pC-BURPS1106A_1131), BURPS1710A_1419::Km (pC-
BURPS1710A_1419) and BPSL3147::Km (pC-BPSL3147) (Table 4.2).   
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Figure 4.14. Verification of construction of complemented plasmids by PCR.    Lanes 1 and 2 represent DNA fragments amplified from plasmids 
with and without CAT cassette by using specific primers for each gene.  Lane L indicates 1 kb DNA ladder from Fermentas (USA).
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4.3.10  Bacterial replication and survival in macrophage assay 
The murine macrophages were infected with B. pseudomallei Bp-CMS and the mutants, 
and their intracellular survival ability was determined for up to 8 h post infection.  
Bacterial survival was presented as relative survival (%) after normalizing to CFU 
counts that were recovered at 2 h post infection.   
 
As can be seen in Figures 4.15 (A) to (G), wild-type bacteria were able to survive and 
replicate in macrophage cells over the course of the experiment.  In contrast, the 5 
mutant strains BPSL2033::Km, BP1026B_I2780::Km, BURPS1106A_A0094::Km, 
BURPS1710A_1419::Km and BPSL3147::Km showed reduced intracellular survival 
inside RAW264.7 cells at 4 and 8 h post infection.  However, only the differences of 
survival rate of BPSL2033::Km reached statistical significance (p=0.049) at 8 h post 
infection when compared to the wild type.  On the other hand, the differences of 
survival rate in macrophages of another 2 mutant strains BP1026B_I2784::Km and 
BURPS1106A_1131::Km were not significant at 4 and 8 h post infection.   
 
Importantly, most of these plasmid-complemented strains partially restored intracellular 
survival and replication except for BP1026B_I2780::Km, BURPS1106A_A0094::Km 
and BURPS1106A_1131::Km at 8 h post infection.  The results postulated that 3 genes, 
BPSL2033::Km (p value=0.049), BURPS1710A_1419::Km (p value=0.165) and 
BPSL3147::Km (p value=0.076) individually had little effect on the survival of B. 
pseudomallei growing intracellularly in phagocytic cells.  
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(D)    
BURPS1106A_A0094::Km 
& complemented strain. 
 
 
 
(F)    
BURPS1710A_1419::Km  
& complemented strain. 
 
 
(E)    
BURPS1106A_1131::Km & 
complemented strain. 
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Figure 4.15.  Bacterial survival and replication within RAW264.7 macrophage-
like cells infected at MOI of 100 using wild type strain and the 7 
insertion mutants as well as their complemented strains.  Data 
represents means and standard errors of 3 separate experiments; each 
experiment was carried out in 3 technical replicates for each time 
point.  Asterisk indicates significant differences (p<0.05) relative to 
the wild type strain Bp-CMS at each time point. 
 
 
(G)    
BPSL3147::Km  
& complemented strain. 
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4.3.11  Caenorhabditis elegans killing assay 
To further investigate the virulence of these mutants in C. elegans, Bristol N2 wild-type 
strains were infected on NGM plates containing FUDR.  The results of survival 
proportions of C. elegans are shown in Table 4.4, while the comparison of survival 
curve for each mutant and its complemented strain against wild type are illustrated in 
Figure 4.16.  The negative control was E. coli OP50-1. 
 
Table 4.4.  Survival proportion of C.elegans challenged with bacterial strains. 
Strains Survival proportions (%) in 
hours 
0 24 48 72 
E. coli OP50-1 100 100 100 100 
Wild type Bp-CMs 100 58 40 26 
BPSL2033::Km 100 73 59 47 
Complemented strain of BPSL2033::Km 100 65 45 30 
BP1026B_I2784::Km 100 73 60 44 
Complemented strain of BP1026B_I2784::Km 100 66 54 30 
BP1026B_I2780::Km 100 74 64 45 
Complemented strain of BP1026B_I2780::Km 100 73 64 36 
BURPS1106A_A0094::Km 100 77 65 39 
Complemented strain n of BURPS1106A_A0094::Km 100 73 54 32 
BURPS1106A_1131::Km 100 70 62 50 
Complemented strain of BURPS1106A_1131::Km 100 63 61 42 
BURPS1710A_1419::Km 100 71 60 51 
Complemented strain of BURPS1710A_1419::Km 100 60 49 28 
BPSL3147::Km 100 79 67 44 
Complemented strain of BPSL3147::Km 100 70 58 36 
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A) BPSL2033::Km & its complemented strain 
B) BP1026B_I2784::Km & its complemented strain 
C) BP1026B_I2780::Km & its complemented strain 
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D) BURPS1106A_A0094::Km & its complemented strain 
E) BURPS1106A_1131::Km & its complemented strain 
F) BURPS1710A_1419::Km & its complemented strain 
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Figure 4.16. Kaplan-Meier survival curves for C. elegans infected with different 
strains of B. pseudomallei.  Values are the pooled data from triplicate of 
3 separate experiments (N=270) (E. coli OP50-1 was the negative 
control). 
 
 
 
 
 
 
 
 
 
 
 
G) BPSL3147::Km & its complemented strain 
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The virulence of the wild type Bp-CMS is reflected in reduced survival as the strain 
killed approximately 42% and 74% of the worms after 1 and 3 days, respectively.  No 
killing of C. elegans was observed under slow-killing conditions when they were fed E. 
coli OP50-1.  By comparing all the graphs, the 6 mutants (BPSL2033::Km, 
BP1026B_I2784::Km, BP1026B_I2780::Km, BURPS1106A_1131::Km, 
BURPS1710A_1419::Km and BPSL3147::Km) exhibited low level of virulence 
attenuation in C. elegans, where survival rates of the worms were only twice higher 
than that of the wild type.  Likewise, the complemented strains of mutants demonstrated   
approximately partial restoration of virulence for BPSL2033::Km, BP1026B_I2784::Km 
and BURPS1710A_1419::Km.  
 
Among them, BURPS1710A_1419::Km was highly attenuated as 51% worms able to 
survive and followed by BPSL2033::Km (47%) than the wild-type parental strain (23%) 
after 3 days.  From the results, both genes BURPS1710A_1419::Km and 
BPSL2033::Km seem to contribute a minor role to virulence in nematode infection 
model. 
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4.4  Discussion 
4.4.1  Natural competence of Bp-CMS 
The targeted mutagenesis procedure described here (Section 4.2.4) is based on natural 
transformation, i.e., naturally competent B. pseudomallei strains are able to acquire 
DNA and integrate this genetic material into their genomes.  However, not all B. 
pseudomallei strains are naturally transformable, i.e., unable to facilitate mutant strain 
construction (Thongdee et al., 2008). 
 
The parental wild type B. pseudomallei strain, named Bp-CMS that used to construct 
mutants was the virulent strain used earlier in mice challenge studies using male and 
female mice.  This strain (Bp-CMS) was found to be virulent in a mouse model for both 
groups, male (p value = 6.9x10
-8
) and female (p value = 3 x10
-7
) at 3 different doses, i.e., 
10, 100 and 1000 cfu/mL (Puthucheary et al., 2012a).  Therefore, natural transformation 
competence in Bp-CMS strain would allow the construction of all 7 insertion mutants 
(Sections 4.3.1 to 4.3.7).  Positive chromosomal integration mutants were successfully 
constructed for the 7 candidate genes, on the first or second attempt. 
 
4.4.2  Growth curve 
The growth of the all 7 mutants, assayed in rich media showed no difference in growth 
rates compared to that of the wild type, ruling out the possibility that these genes are not 
affect the growth but involved in other aspects such as pathogenicity.   
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4.4.3  Insertion mutagenesis as a genetic tool for investigating gene 
function 
Reverse genetic analysis offers a logical approach that enables investigation of the 
function of unknown genes, where a specific gene is disrupted to study the resulting 
phenotypic characteristic(s) of the microorganism (Reyrat et al., 1998).  As mentioned 
in Section 2.3.2, a number of methods can be used to inactivate bacterial chromosomal 
genes and a site-specific insertion mutagenesis was chosen for this study, because this 
technique had been used successfully to generate mutants in B. pseudomallei 
(Lumjiaktase et al., 2006; Song et al., 2005; Stevens et al., 2002; Stevens et al., 2004; 
Tuanyok et al., 2006) as well as it has become a common procedure in knockout studies 
(Ortiz-Martin et al., 2006).   
 
Thus far, only a few approved antibiotic selection markers for B. pseudomallei such as 
genes encoding resistance to kanamycin, zeocin and gentamicin have been described 
(Galyov et al., 2010; Schweizer and Peacock, 2008).  A suicide vector pUT-Km that 
contains kanamycin resistance genes was chosen in this study.  This vector is a valuable 
tool for constructing mutants by insertion mutagenesis.  It is a straight-forward method 
as the mutants grow directly on agar plates containing appropriate antibiotics and can be 
confirmed by simple PCR assay (Chuang et al., 2006; Lin et al., 2008).  Moreover, its 
utility to generate insertion mutant of quorum sensing genes in B. pseudomallei has 
already been successfully demonstrated by Song et al. (2005).   
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4.4.4   Assessment of virulence of the candidate genes 
 The infection assay on macrophage cells showed that without gene BPSL2033 (putative 
transport-related membrane protein), the mutant demonstrated reduced ability to 
replicate and survive over 8 h.  The result was supported by a plasmid-encoded 
complemented strain, which demonstrated partial restoration for intracellular survival 
when compared to wild type Bp-CMS.  Similar outcomes have been noted with 
BURPS1710A_1419 (putative lipoprotein) and BPSL3147 (lipoprotein).   
 
At 8 h post infection, loss of gene BPSL2033 showed a survival reduction of 5-times in 
RAW264.7 cells while both BURPS1710A_1419 and BPSL3147 resulted in 3-times 
reduction.  Our observations indicate that these genes may be involved in intracellular 
survival.  There was a weak but still significant difference (p=0.049) of intracellular 
survival exhibited by BPSL2033::Km compared to the Bp-CMS.  Thus, this suggests 
that BPSL2033 may act in concert with other genes to play an essential role in virulence.   
 
Subtractive hybridization as illustrated in Figure 4.1 revealed that Bp-CMS contained 6 
DNA sequences that were not found in the attenuated strain, indicated evidence that  
maximal virulence probably requires multiple genes (Puthucheary et al ., 2012a).  This 
hypothesis is further supported by the present study in which B. pseudomallei virulence 
in the phagocytic cell line model was not critically dependent on any single putative 
gene tested.   
 
Several studies have suggested that a double mutant but not a single mutant of B. 
pseudomallei contribute significantly to the growth inside murine macrophage (Balder 
et al., 2010; Muller et al., 2012).  Future experiment involved in the use of double 
mutant (i.e., BPSL2033 and BURPS1710A_1419) will probably assess this possibility.  
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In the context of BPSL3147, there may be other unidentified gene(s) acting together for 
full virulence in B. pseudomallei infections. 
 
It is unclear why these genes, i.e., BPSL2033, BURPS1710A_1419 and BPSL3147 with 
their corresponding complemented plasmids, only restored intracellular survival and 
replication to approximately 50% of wild-type levels.  One possible explanation for this 
might be due to the gene being present on multiple copies of the plasmid.  It is also 
possible that other genes present on adjacent loci may be contributing to the virulence.  
Another possibility is that a polar effect on the expression of downstream genes, co-
transcribed with the target gene, may be responsible for the observed phenotype.  This 
phenomenon has been reported by Muangsombut et al. (2008) in which a mutant 
lacking bsaQ of the type III secretion system, showed defects in secretion of BopE and 
BipD proteins due to the polar effect on the downstream genes (bsaR/S/T) expression.   
 
C. elegans has been used as a simple surrogate host for modeling bacterial disease 
(Gravato-Nobre & Hodgkin, 2005).  It has previously been shown that on a low nutrient, 
nematode growth medium (NGM), the B. pseudomallei kills C. elegans strain N2 within 
3 days and this type of killing is referred to as “slow killing” (Chua et al., 2003; Gan et 
al., 2002; Song et al., 2005).   
 
In this study, wild-type strain Bp-CMS killed 74% of the nematode population at 72 h 
time point.  Our results are in agreement with previous studies reporting that differences 
in killing efficiency of C. elegans between wild type of B. pseudomallei (Gan et al., 
2002; Lee et al., 2011; O'Quinn et al., 2001).  As an example, the percentage of killing 
of worms by various B. pseudomallei strains, i.e., ATCC23343, EY4, #40 and KHW 
were approximately 50, 60, 75 and 90% at 72 h time point (Gan et al., 2002).  The 
 Chapter 4 
110 
virulence of B. pseudomallei into nematode is diverse and it is likely due to the different 
genetic determinants in the strains. 
 
In the present study, all the constructed mutants were less effective in killing C. elegans 
under slow-killing conditions, i.e., twice as many worms survived when fed on mutant 
strains compared to those worms fed on wild type Bp-CMS after 72 h of co-culture.  
However, there was no significant difference of C. elegans-killing between the mutants 
and wild type. Two complemented strains of BPSL2033::Km and 
BURPS1710A_1419::Km achieved at least partial restoration of virulence at 72 h co-
culture, thus suggesting that both genes are most probably involved in bacterial 
virulence. 
 
The low level of attenuation in the mutants, may possibly due to;   
(i)  a single gene was insufficient to mediate full killing in the animal model.  Probably 
at least 2 genes are required to act together in controlling virulence in B. pseudomallei.   
A double mutant ∆relA∆spoT was reported to exhibit significant and severe attenuation 
in larva of the wax moth Galleria mellonella and C57BL/6 mice models, which were 
not seen in the single mutant (Muller et al., 2012).  
 
(ii) C. elegans may not be sensitive enough to reveal phenotypes for all factors that 
contribute to the virulence in B. pseudomallei.  A flagella mutant of B. pseudomallei, 
KHW∆fliCKm was found to be equally lethal to C. elegans when compared to wild type 
but it had low virulence in Balb/c mice via intranasal infection (Chua et al., 2003).  
Another example was demonstrated by the isolate of B. pseudomallei, Sheep 4523, 
which showed high killing rate when exposed to C. elegans but had a low virulence in 
Balb/c mice while the reverse situation was observed for the isolate Ostrich 9166 (Lee 
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at al., 2011).  Collectively, previous studies suggested that pathogenicity in nematodes 
may not correlate to mammals directly (Chua et al., 2003; O'Quinn et al., 2001).   
 
(iii) C. elegans possess mechanisms to avoid or move away from pathogenic bacteria 
like B. pseudomallei.  It has a simple nervous system that consists of 302 neurons that 
facilitate the identification of molecules, neurons and circuits involved in their behavior 
(White et al., 1986).  It uses chemotaxis to find food on the plate and able to 
discriminate food both physically, based on size, and chemically, based on taste and 
olfaction (Kiyama et al., 2012).  Interestingly, worms can modify their olfactory 
perference via neurotransmitter serotonin to avoid odours from pathogen and this 
learning occurs with exposures as short as 4 h (Zhang et al., 2005).   
 
Zhang et al (2005) demonstrated that in the 4 choice maze assay, C. elegans were given 
a choice between non-pathogenic bacteria (E. coli OP50) and pathogenic bacteria 
(Pseusomonas aeruginosa PA14) that the worms had experienced earlier, and 2 novel 
bacterial strains that worms not experienced previously, i.e., non-pathogenic bacteria 
(Pseudomonas fluorescens) and pathogenic bacteria (Serratia marcesces ATCC13880).  
Their results showed that worms strongly preferred the known healthy bacteria E. coli 
OP50 and Pseudomonas fluorescens while attraction to the known pathogenic bacteria 
decreased compared to naïve worms. 
 
So, olfactory learning enables worms to differentiate among natural food sources on the 
basis of experience.  In our study, C. elegans was cultivated on E. coli OP50-1 that best 
supports growth, so the worms have already experienced good food, which might have 
increased their exploratory bahaviour when the switch to very bad food such as B. 
pseudomallei, especially in appetitive and leaving bahaviours.  It is impossible to raise 
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worms on B. pseudomallei alone because of the virulence.  Consequently, worm 
starvation over several hours before being transffered into a plate containing pathogen, 
could be considered in future experiments because hungry worms tend to accept any 
food they first encounter.  
  
Working with C. elegans possesses 2 challenges.  First is proper staging of L4 larval 
stage worms (Figure 2.4) is important in order to obtain reproducible data.  The L4 or 
young adult stage of C. elegans is commonly used in most virulence experiments with 
bacteria, because the worms have maximum number of germ line nuclei (Tan et al.,  
1999).  It is therefore important to start the experiment with synchronized culture with 
eggs as described in Section 4.2.8.1.    
 
Second, it is difficult to detect and enumerate surviving worms because of phenotype 
“bagging of worms” in which the progeny has hatched internally.  This was observed in 
nearly all of our preliminary experiments. C. elegans continued laying eggs and 
producing larva as the killing assay extended over its generation time and this 
phenomenon has been reported from elsewhere (O'Quinn, et al., 2001; Tan, et al., 1999).   
Addition of this drug FUDR will prevent growth of progeny subsequently prevent 
interference when conducting the killing assay (Irazoqui et al., 2008; Shivers et al., 
2010).  An alternative method had been suggested is the use of sterile germ line 
proliferation-deficient animals generated by cdc-25.1 gene knock-down (Ashcroft and 
Golden, 2002). 
 
 
 Chapter 4 
113 
4.4.5  Structural basis of 2 novel virulence determinants 
To better understand the function of the two novel virulence determinants that had not 
been described previously, i.e., BPSL 2033 and BURPS1710A_1419, the prediction of 
protein structures and functions from their amino acid sequence was performed by using 
bioinformatics database. 
 
4.4.5.1   BPSL2033  
BPSL2033 is a 428 amino acid protein with molecular mass of 46 kDa as a transport-
related membrane protein.   As seen in Figure 4.17, the predicted amino acid sequences 
of BPSL2033 from strain K96243 were identical to other species in genus level with 
percentage of similarity as: B. pseudomallei strains 1710 (99.8%), MSHR305 (99.8%), 
BURPS1106A (99.5%), MSHR346 (99.5%), 1026b (99.5%) and 668 (99.3%); B. 
thailandensis strains E264 (93.2%) and  MSMB121 (93.2%) as well as B. mallei NCTC 
1022 (99.7%), indicating a high level of conservation.   
 
Further bioinformatics analysis suggests that amino acids 23-324 of BPSL2033 encode a 
domain belonging to major facilitator superfamily (MFS).  MFS transporters are 
ubiquitous in all classes of organisms and several pathogens such as Francisella 
tularensis (Marohn et al., 2012) and Legionella pneumophila (Sauer et al., 2005).   
Chatfiled and colleagues (2011) have shown MFS protein play a role in virulence in 
promoting bacterial iron-siderophore import. 
 
BPSL2033 is a member of the MFS of transporters but has no assigned function yet.  
Subsequently, homology modeling analysis was carried out by Phyre 2 server to obtain 
its structural information.  The Phyre 2 is used for the alignment of combination hidden  
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Figure 4.17.  ClustalW alignments of amino acid sequences of BPSL2033.  Species 
abbreviations: bps, B. pseudomallei K96243 (YP_333187.1); bpm, B. 
pseudomallei 1710b (YP_108630.1); bpse, B. pseudomallei MSHR305 
(YP_008340740.1); bpl, B. pseudomallei BURPS1106A_1625 
(YP_001065896.1); bpq, B. pseudomallei BPC006 (YP_006652457.1); 
bpr, B. pseudomallei MSHR346 (YP_002896364.1); bpd, B. 
pseudomallei 668 (YP_001058645.1); bte, B. thailandensis E264 
(YP_443199.1); btd, B. thailandensis MSMB121 (YP_007918904.1); 
bml, B. mallei NCTC 10229 (YP_001026485.1).  Dot indicates sequence 
identical to a standard Bps.  
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Markov models and ab initio folding simulation that could create the accurate model at 
very low sequence identity (15-25%) (Kelley and Sternberg, 2009).   
 
BPSL2033 is a member of the MFS of transporters but has no assigned function yet.  
Subsequently, homology modeling analysis was carried out by Phyre 2 server to obtain 
its structural information.  The Phyre 2 is used for the alignment of combination hidden 
Markov models and ab initio folding simulation that could create the accurate model at 
very low sequence identity (15-25%) (Kelley and Sternberg, 2009).  The first step in the 
Phyre analysis was to do a secondary structure led to the template 1pw4A (the structure 
of the E. coli glycerol-3-phosphate transporter protein) even though it has 16% identity 
in terms of sequence alignment.  The results imply that BPSL2033 might exhibit new 
structural and/or functional characteristicsand further X-ray crystallography analysis 
may provide intense investigation.  At present, it is postulated that BPSL2033 transports 
nutrients (probably glycerol-3-phosphate) that are essential for the replication of B. 
pseudomallei. 
 
4.4.5.2  BURPS1710A_1419 
BURPS1710A_1419 is a 74 amino acid protein with a calculated molecular mass of 8 
kDa is a putative lipoprotein.  Database searches with the NCBI blastp tool identified 
this putative lipoprotein within genus level is diverged from 37 to 82%.  As illustrated 
in Figure 4.18, the putative lipoprotein exhibited 82, 73, 70, 50, 47, 38 and 37%  
sequence identity to B. glumae BGR1, B. gladioli BSP3, B. phymatum STM815, B. 
oklahomensis, B. lata, B. phytofirmans PsJN and B. ambifaria MC40-6, respectively.  
No conserved domain was identified as well as a lack of three-dimensional structural 
information, possibly suggesting that BURPS1710A_1419 gene product has new or 
different functional characteristics.   
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Figure 4.18. ClustalW alignments of BURPS_1710A_1419 gene products (putative 
lipoprotein). Species abbreviations: bpa, B. pseudomallei 
BURPS_1710a (WP_004526362.1); bgl, B. glumae BGR1 
(YP_002909360); bgd, B. gladioli BSP3 (YP_004358893);  bph, B. 
phymatum STM815 (YP_001860254.1); bko, B. oklahomensis 
(WP_010111058.1); bla, B. lata (YP_372144.1); bpy, B. phytofirmans 
PsJN  (YP_0018888760); bac, B. ambifaria MC40-6 (YP_001811047.1).  
Dot indicates sequence identical to a standard bpa. 
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4.5  Concluding discussion and future prospects 
In this study, the insertional inactivation of 7 putative virulence determinants and their 
virulence assessment in 2 different infection models - murine macrophages and a 
nematode model has facilitated the identification of novel virulence determinants in B. 
pseudomallei.   
 
BPSL2033::Km and BURPS1710A_1419::Km showed a reduced survival inside 
macrophage cell lines. Both complemented strains partial restored the defect in the 
macrophage cell lines as well as in C. elegans model.  It is thus hypothesized that both 
gene, BPSL2033 and BURPS1710A_1419 are individually likely to contribute a minor 
role in virulence and provide a basis for further characterization of their role in 
pathogenesis. 
 
It is speculated that the combination effect of both genes can provide a clear virulence 
role in B. pseudomallei.  However, a major drawback of insertion mutagenesis is 
inability to construct a double mutant due to the limitation of the difficulty of drug 
selection.  It is suggested that construction of a markerless double-gene deletion mutant 
in Bp-CMS via an unmarked deletion method warrants further investigation.   
 
For the infection model, mammalian host such as Balb/c mouse is proposed for future 
experiment.  Quantitation of bacterial burden in different organs such as liver, lung and 
spleen should be examined for tissue pathology in order to obtain additional information 
related to severity and bacterial load.   
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4.6  Limitations of the study 
A drawback of the method is that no further manipulation of the mutant strains can be 
performed due to restriction of drug selection, also the same vector cannot be used, and 
consequently construction of multiple gene knockout mutants is not possible. 
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Chapter 5   
Identification of potential immunogenic polypeptides 
of B. pseudomallei and evaluation of their efficacy for 
serodiagnosis of melioidosis 
 
 
5.1  Introduction 
B. pseudomallei has emerged as an important human pathogen causing a fatal infectious 
disease, called melioidosis.  It is a gram-negative bacterium found as a saprophyte in 
soil and commonly present in melioidosis-endemic areas, i.e., northeast Thailand, 
Malaysia and Northern Australia and increasingly being recognized around the world in 
recent decades (Wiersinga et al., 2012).  In addition to being a public health hazard it is 
also a potential Class B biological warfare agent (Rotz et al.,  2002).   
 
The clinical signs and symptoms of melioidosis are very varied and often seem to 
mimic other diseases (Section 2.2.6).   In addition, it exhibits resistance to diverse 
groups of antimicrobials including third-generation cephalosporins (Wiersinga et al., 
2012).  These factors make it difficult to establish a diagnosis and the reported mortality 
is high among patients with underlying risk factors especially diabetes and 
immunosuppression (Puthucheary and Vadivelu, 2002).   
 
Definitive identification of B. pseudomallei relies exclusively on the gold standard   
culture of a specimen.  Isolation of the organism requires several days (may take up to 4 
days) to produce colonies and reportedly can have associated problems such as inter-
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strain and medium dependent variability in colony morphology (Puthucheary et al., 
2010).  
 
Most recently, quantitative real time PCR targeting various specific regions such as 
Type Three Secretion 1 (TTS1)-open reading frame 1 (Supaprom et al., 2007), TTS1-
opening reading frame  2 (Kaestli et al., 2012) and asparty/asparaginly beta-hydroxylase 
(lpxO) (Kaestli et al., 2012), and loop-mediated isothermal DNA amplification 
(Chantratita et al., 2008) have been developed for identification of B. pseudomallei. 
However, these assays demonstrated only moderate sensitivities and direct testing on 
blood specimens remain problematic.   
 
Thus serological assays appear to be a useful tool for the presumptive diagnosis of the 
melioidosis.  In a broader context, serodiagnostic tests can have multiple uses, 
including: screening for febrile illness (in any patient who had visited endemic areas); 
patient management (when infections are deep-seated and no specimens are available); 
monitoring disease activity (investigating the persistence of antibody levels) (Vadivelu 
and Puthucheary, 2000).   
 
The development of serological diagnostic tests for the detection of antibodies and 
antigens has been attempted for decades (Sections 2.5.2.1 and 2.5.2.2), but have yielded 
disappointing results due to lack of specific immunogenic antigen.  The most common 
of these tests has focused on measuring the presence of antibodies against antigens of B. 
pseudomallei including IHA, ICT, IFAT and ELISA.   
 
Among these assays, IHA is most commonly used in disease-endemic countries (Cheng 
et al., 2006; Chuah et al., 2005; O'Brien et al., 2004), but high background titers raise 
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problems in differentiating past and current infections (Vadivelu et al., 1995; 
Wuthiekanun et al., 2006).  In addition, the IHA has been reported to have low 
sensitivity in sera from patients with acute septicemia (Appassakij et al. 1990; Dharakul 
et al., 1997). 
 
In Malaysia, Vadivelu and coworkers have previously developed an IFAT using a 
whole cell antigen derived from B. pseudomallei for detection of total antibodies (IgG 
and IgM) in patients with possible melioidosis (Vadivelu et al., 1995).  This IFAT test 
performed better than IHA and had satisfactory sensitivity and specificity compared to 
culture approach (Vadivelu et al., 1995). However, the drawback is preparation of B. 
pseudomallei as antigen will require biosafety laboratory level 3 (BSL-3) facilities, 
which are not commonly available in developing countries.  A modification of the test 
by using B. thailandensis as antigen was developed and yielded satisfactory results in 
term of sensitivity (98.8%) and specificity (92.3%) (Puthucheary et al., 2010).  However, 
both IFAT assays using either B. pseudomallei or B. thailandensis may be influenced by 
the subjective judgment and they are not readily adaptable to large scale investigations.   
 
ELISA studies using either crude or purified antigen preparations for the detection of 
antibodies to B. pseudomallei demonstrated varying results of sensitivities and 
specificities (Allwood et al., 2008; Chenthamarakshan et al., 2001b; Druar et al., 2008; 
Sirisinha et al., 2000).  However, this test offer advantages that enable many serum 
samples to be tested in parallel and the workflow can be completely automated to 
generate quantitative results.    
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In summary, a serological test detecting antibody response to recombinant antigen of B. 
pseudomallei would be less complex and less expensive than molecular detection 
techniques, and  more rapid than traditional bacterial culture.   
 
Hence, the general aim of this work was to identify immunogen(s) for the serological 
diagnosis of infections due to B. pseudomallei.    
 
The specific objectives are: 
1. to construct shotgun expression library from clinically confirmed local virulent 
isolates of B. pseudomallei. 
2. to identify immunogenic polypeptides of B. pseudomallei recognized by the sera 
of patients with IFAT (serologically) proven melioidosis. 
3. to evaluate these immunogens for potential use in the serological diagnosis of 
melioidosis. 
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5.2  Materials and methods 
5.2.1  Bacterial strains and plasmids  
Four clinical strains of B. pseudomallei were obtained from the University Hospital, 
University of Malaya (UM), Kuala Lumpur (details are shown in Table 5.1.).  These 
strains had been isolated and identified by standard biochemical tests and the API 20NE 
system (bioMérieux, France).  All 4 strains were then subjected to genomic DNA 
extraction as previously described (Section 3.6.1). 
 
Table 5.1.  Bacterial strains and plasmids used in this study. 
Strains/plasmids Relevant characteristic(s) Sources of 
reference 
Strains 
B. pseudomallei 
Bp C1 
Bp C2 
Bp C3 
Bp C4 
 
E.coli 
NovaBlue (DE3) 
 
 
Clinical isolate from blood 
Clinical isolate from swab 
Clinical isolate from sputum 
Clinical isolate from splenic biopsy 
 
 
endA1 hsdR17(rK12
-
mK12
+
) supE44 thi-1 recA1 
gyrA96 relA1 lac (DE3) F’[proA+B+lacIqZ 
ΔM15::Tn10] (TetR) 
 
 
Current study 
 
 
 
 
 
Novagen, USA 
Plasmid 
pSCREEN T 
 
Cloning vector 
 
Novagen, USA 
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5.2.2  Construction of genomic expression library 
The NovaTope System (Novagen, USA) was used for genome expression library 
construction according to the manufacturer’s protocol.  Ten microgram of pooled DNA 
of the 4 clinical strains were randomly cleaved with 1 µL of DNaseI.   Each was diluted 
1:133, 1:200, 1:300 and 1:450, and incubated for 10 min at room temperature in the 
presence of 10 mM Mn
2+
.  The digested DNA fragments of 50 to 300 bp were recovered 
from a 2% (w/v) agarose gel with QIAEX II Gel Extraction Kit (Qiagen, Germany).   
 
One microgram of purified DNA fragments were flush ended with T4 DNA polymerase 
together with 1X Flush buffer [0.5 M Tris-HCl pH 8.0, 50 mM MgCl2, 1 mg/mL BSA], 
1X dNTP mix [1 mM each dCTP, dGTP, dTTP, 10 mM dATP], 5 mM DTT for 20 min 
at 11ºC, and the reaction was stopped by heating for 10 min at 75ºC.  The entire 
flushing reaction was then added with a single deoxyribosylalanine (dA) residue at 3’ 
end using Tth polymerase in the presence of  1X dA Tailing buffer [100 mM Tris-HCl 
pH 9.0, 0.5 M KCl, 0.1% gelatin, 1% Triton X-100] for 15 min at 70ºC.  
 
The A-tailed DNA fragments were then ligated into a linearized and T-tailed pSCREEN 
T-vector, designed for the expression of small peptides as a carboxy-terminal fusion to 
the T7 bacteriophage gene 10 capsid protein.  One microliter of the ligation mixture was 
transformed into 20 µL NovaBlue (DE3) competent cells followed by selection of 
transformants by plating onto LB agar containing 50 µg/mL carbenicillin (CB) and 15 
µg/mL tetracycline (Tet). 
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5.2.3  Colony immunoscreening 
Transformed colonies were picked by sterilized toothpicks and re-streaked on fresh LB-
agar containing CB and Tet and incubated overnight at 37ºC.  Next day, bacterial 
colonies were transferred onto nitrocellulose filters (colony side up) and induced with 
250 µM IPTG for 4 h at 37ºC on LB-agar plates containing CB and Tet.  After 
induction, the filters were incubated sequentially in the petri dishes at room temperature 
as follows: 10% (w/v) SDS for 10 min to disrupt cell membranes; denaturing solution 
for 5 min; neutralization solution for 10 min and lastly 2X saline-sodium citrate (SSC) 
for 15 min for colony lysis and binding of protein to the filters.  
 
The filters were then washed with 1X Tris-buffered saline (TBS) [10 mM Tris-HCl pH 
8.0, 150 mM NaCl] for 10 min and blocked with 1% (v/v) fish gelatin (Amresco, USA) 
in 1X TBST [10 mM Tris-l pH 8.0, 150 mM NaCl, 0.05% (v/v) Tween-20] for 1 h with 
gentle agitation at room temperature.  Filters were again washed twice in 1X TBST for 
10 min to remove bacterial debris and incubated with 2 different pools of sera, i.e., 
pooled melioidosis positive and melioidosis negative (1:1000 in blocking buffer) for 1 h 
at room temperature.   
 
Next, filters were washed with 1X TBST and incubated for 1 h with AP-conjugated 
Immunopure® Protein A/G (1:10000 in blocking buffer) (Pierce, USA).  The filters 
were washed with 1X TBST as described above, immunoreactive clones were then 
detected and visualized with BCIP/NBT phosphatase substrate (Pierce, USA).  
Reactions were stopped by immersing the filters in distilled water.  Finally, mean signal 
intensity and background measurements were obtained for each clone on each filter 
using Image Scanner III (GE Healthcare, USA).   
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The dataset were analyzed using ImageQuant software (GE Healthcare, USA) and each 
filter was normalized using the signals of pSCREEN T-vector without insert.  
Calculation of the ratio of signal of intensities produced by melioidosis positive and 
negative groups was performed.  Reactive clones were then recovered from the master 
plates and cryopreserved in 20% (v/v) glycerol at -80 ºC. 
 
5.2.4  Plasmid preparation and sequencing 
The HiYield
TM
 Plasmid Mini Kit (RBC, Taiwan) was used for plasmid isolation from 
immunoreactive clones (Section 3.6.2).  The plasmids were sent for sequencing (1
st
 
Base Laboratories, Malaysia) using the T7 gene 10 primer (5’ 
TGAGGTTGTAGAAGTTCCG 3’) and T7 terminator primer (5’ 
GCTAGTTATTGCTCAGCGG 3’).  Later, homology searches against known protein 
databases were performed using BlastX program at NCBI based on NCBI non-
redundant protein database (B. pseudomallei strains K96243, 1710, 1106, MSHR668, 
and MSHR305). 
 
5.2.5  Preparation of purified recombinant polypeptides  
The selected colonies were cultured overnight at 37ºC in 10 mL of 2X YT broth 
containing both CB and Tet.  The broth culture was diluted 1:20 with 100 mL fresh 
medium and incubated at 37ºC with shaking at 200rpm until the OD600 had reached the 
range from 0.5 to 0.7.  The culture was induced by adding 250 µM IPTG and incubated 
for an additional of 4 h at 37ºC. The bacterial cells were collected by centrifugation and 
resuspended in 500 µL ice-cold 1X TES buffer [0.2 M Tris-HCl, 0.5 mM EDTA, 0.5 M 
sucrose].  A volume of 750 µL of 1/5X TES was added and the mixture incubated on 
ice for 30 min with agitation.  The supernatant containing the soluble recombinant 
polypeptides was pelleted by centrifugation and stored at -20ºC for further use.  The 
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concentration of recombinant polypeptides was determined by the Bradford assay 
(Section 3.4.2). 
 
5.2.6  SDS-PAGE and Western blot analysis  
The recombinant polypeptide samples were mixed with 2X Laemmli buffer (1:1) 
(Sigma-Aldrich, USA) and heated in boiling water for 5 min.  The denatured samples 
were separated by electrophoresis on 12% SDS-PAGE at 170V for 1 h.  The gel was 
transferred to a nitrocellulose membrane using TE 70 Semi-Dry Transfer Unit (GE, 
USA).  Blocking, incubating and washing steps were performed as described in the 
section 5.2.3.  Two pools of sera, i.e., melioidosis-positive and melioidosis-negative 
were used to confirm the presence of the recombinant polypeptides specific to B. 
pseudomallei. A negative control, pSCREEN T with no insert was included in the 
experiment. 
  
5.2.7  Serum samples 
The collected sera were serologically-confirmed melioidosis by the in-house IFAT test 
(Vadivelu, et al., 1995), at the University Malaya Medical Centre, Kuala Lumpur, from 
2010 to 2012 (Ethical approval MEC: 260.1).  Of 60 melioidosis-positive and 123 non-
melioidosis sera i.e., IFAT-negative, 8 groups were identified as follows: Group A, sera 
from patients clinically and serologically (IFAT +ve) confirmed as melioidosis (n=60); 
Group B, sera from individuals negative (IFAT –ve) for melioidosis (n=60); Group C, 
healthy blood donors (n=10); Groups D to H, sera from patients who were diagnosed 
with  Legionella pneumoniae (n=11); Leptospirosis  (n=13); Chlamydophila 
pneumoniae (n=10); Mycoplasma pneumoniae (n=12) and Rickettsiosis (typhus group) 
(n=7). 
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5.2.8  Evaluation of purified recombinant polypeptides 
An indirect ELISA was carried out to test the large number of samples in order to 
confirm the immunoreactivity of clones detected in the colony immunoblot assay.  
Optimization was performed using antigens (i.e., recombinant polypeptides) with the 
dilution ranging from 100 ng/µL to 20 µg/mL.  The IFAT-confirmed melioidosis 
positive and negative sera were optimized using dilution ranging from 1:100 to 1:3,000. 
Antigen concentration of 20 µg/mL and dilution of sera of 1:500 were optimized by 
checkerboard titration.   
 
ELISAs were performed in duplicate using Costar 96 well microliter plates (Corning, 
USA).  Wells were coated and incubated overnight at 4ºC, with each antigen in 1X PBS 
(pH 8.4) in a final volume of 100 µL/well.  Following the coating step, wells were 
washed 3 times with PBS containing 0.05% Tween 20 (1X PBST) to remove unbound 
antigen.  Blocking step was then carried out by adding 100 µL of 1% fish gelatin 
(Amresco, USA) in PBST for 2 h at 37ºC.  The plates were again washed using 1X 
PBST and the wells were incubated with 100 µL of sera at 37ºC for 2 h.   
 
Following incubation, wells were washed 3 times with 1X PBST and adding of AP-
conjugated Immunopure
®
 Protein A/G ( 1:5,000 in blocking buffer) (Pierce, USA) at 
37ºC for 2 h.  Wells were washed 3 times with 1X PBST and the enzyme reaction was 
detected by the addition of 100 µL of p-Nitrophenyl Phosphate for 30 min at 37ºC in the 
dark.  A solution of 100 µL of 2N H2SO4 was then added to stop the reaction.  The 
optical density (OD) 415nm values were determined using an iMark reader (Biorad, 
USA).   
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5.2.9  Statistical analysis 
The cutoff values for ELISA were determined by using the mean OD for the IFAT-
confirmed melioidosis negative group (Group B) plus 3 standard deviations (M + 3SD).  
The sensitivity, specificity, positive and negative predictive values were calculated 
using the formula as below (Zhou et al., 2011):   
 
   Infection with B. pseudomallei 
 
Positive result   
Negative result 
                         
a: True positives (TP), number of diseased person with a positive test result 
b: False positives (FP), number of non-diseased persons with a positive test result 
c: False negatives (FN), number of diseased persons with a negative test result 
d: True negatives (TN), numbered of non-diseased persons with a negative test result 
 
i) Sensitivity =        a     
                          a  +  c 
 
(proportion of people with the target disorder who have a positive test result) 
 
 
ii) Specificity =        d     
                          b  +  d 
 
(proportion of  people without the target disorder who have a negative test result) 
 
iii) Positive predictive value (PPV) =        a     
                                                                    a  +  b 
 
 (the probability of disease among all persons with a positive test result) 
 
 
iv) Negative predictive value (NPV) =       d     
                                                                      c  +  d 
Present Absent 
A b 
C d 
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 (the probability of non-disease among all persons with a negative test result) 
 
v) Positive likelihood ratio  =       sensitivity    
                                                           1 - specificity 
 
vi) Negative likelihood ratio  =    1- sensitivity    
                                                              Specificity 
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5.3  Results 
5.3.1  DNase  I shotgun cleavage 
The starting genomic DNA was successfully cleaved into small fragments averaging 50 
to 300 bp in size at random location by using different dilutions of DNase I.  As 
illustrated in Figure 5.1, 2 dilutions of DNase I (1:133 to 1:200) demonstrated good 
digestion results.  So, the same procedure (Section 5.2.2) was repeated and a pool of 
cleavage reactions containing fragments in the 50 to 300 bp size range was subjected to 
DNA recovery. 
 
 
 
  
 
 
 
 
 
 
 
Figure 5.1. EtBr-stained 2% (w/v) agarose gel of digested genomic DNA  
of  B.  pseudomallei. 
Lane (s) M  – 100 bp DNA ladder (Fermentas, USA)  
                1  – 1:133 dilution of DNase I 
       2  – 1:200 dilution of DNase I 
       3  – 1:300 dilution of DNase I 
       4  – 1:450 dilution of DNase I 
     bp                 M             1            2              3              4 
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5.3.2  Construction of genomic library and selection of immunogenic  
  polypeptides 
A small diversely sized genomic expression library was successfully constructed using 
local clinical strains of B. pseudomallei carrying random fragmented inserts of 50-300 
bp.  From the resulting library, 480 transformants were chosen at random and subjected 
to colony blot detection assay using pooled positive (P: IFAT-confirmed positive) and 
pooled negative sera (N: IFAT-confirmed negative).   
 
A total of 4 sets of pooled sera were prepared for screening purpose, i.e., Pos1, Neg1, 
Pos2 and Neg2 and each pool containing 10 samples.  In initial screening step using 
sera Pos1 and Neg1, 79 clones with signal intensity ratios (P/N) of two-fold and above 
were observed.  Subsequently, another set of pooled sera (Pos2 and Neg2) was used to 
retest for their reactivity and finally 20 clones with signal ratio intensities (P/N) of at 
least 3-fold and above were obtained. 
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Figure 5.2. Representative clones (1-8) of colony blot assay in 2 different  
 pooled sera.  
A- melioidosis positive pooled sera 
B- melioidosis negative pooled sera 
C- control strain, E. coli NovaBlue (DE3) containing the   
     pSCREEN T-vector with no insert  
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5.3.3  Confirmation of the identity of clones by sequencing 
Twenty of the clones were subjected to confirmatory sequencing.  As demonstrated in 
Table 5.2, a search performed using BlastX to identify homologous sequence showed 
that these clones represented 6 distinct polypeptides.  These polypeptides including, 
BPSS1904, BPSL3130, BURPS1710b_0454, BPSS1856, BPSS0897, BPSS1757 
encoded putative proteins corresponding to benzoate 1,2-dioxygenase beta subunit, a 
putative 200 kDa antigen p200, phosphotransferase enzyme family protein, short chain 
dehydrogenase and 2  hypothetical proteins as summarized in Table 5.3. 
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Table 5.2.  BlastX results of the 6 recombinant polypeptides of B. pseudomallei.           
Locus tag Sequence alignment Accession Amino acid sequence 
  no. Identity 
(%) 
Coverage 
(%) 
E-value 
(%) 
BPSS1904 
 
Query 3        KYVVLKNDYINQLIDIYHI     59 
                     KYVVLKNDYINQLIDIYHI 
Sbjct   145    KYVVLKNDYINQLIDIYHI     163 
YP 111910 100 39.7 8.0E-5 
BPSL3130 Query 43      MPESPNFPPSYOS     2 
                     MPESPNFPPSYOS 
Sbjct   1        MPESPNFPPSYOS    14 
 
YP_109723 100 33.9 0.00 
BURPS1710b_0454 
 
Query 2        ARFDACGGERRGQRDVQPLEALAVRLAV     84 
                     ARFDACGGERRGQRDVQPLEALAVRLAV 
Sbjct   189    ARFDACGGERRGQRDVQPLEALAVRLAV     217 
 
           85      PAAQHADEIDGCLRARDETGELAHVEGG       168 
                     PAAQHADEIDG   LRARDETGELAHVEGG 
Sbjct   217    PAAQHADEIDGCLRARDETGELAHVEGG       245 
 
           169    QLDDVD    187 
                     QLDDVD 
            245   QLDDVD     250 
 
YP_331868 98 98 8E-31 
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Table 5.2 continued. 
Locus tag Sequence alignment Accession Amino acid sequence 
  No. Identity 
(%) 
Coverage 
(%) 
E-value 
(%) 
BPSS1856 
 
Query 114    IHNDFRFDNVVLDPADPLSIVGVLDWEM     31 
                     IHNDFRFDNVVLDPADPLSIVGVLDWEM 
Sbjct   214    IHNDFRFDNVVLDPADPLSIVGVLDWEM     241 
                         
Query  30     ATLGDPLMDL     1 
                     ATLGDPLMDL 
Sbjct   242    ATLGDPLMDL      251 
 
YP 111860 100 99 3E-17 
BPSS0897 Query 1        DYYLQGRALPRAQVPADVTGPVLFLLSD     84 
                     DYYLQGRALPRAQVPADVTGPVLFLLSD 
Sbjct   206    DYYLQGRALPRAQVPADVTGPVLFLLSD     233 
 
Query 85      AARFVTGQLLPVNGGF     132 
                     AARFVTGQLLPVNGGF 
Sbjct   234    AARFVTGQLLPVNGGF     249 
 
YP 110906 98 98 3E-21 
BPSS1757 Query 206   MKAAMRAKESEr  l  a t I r l l l  a aIKQREVD     121 
                     MKAAMRAKESERLATIRLLLAAIKQREVD 
Sbjct  11      MKAAMRAKESERLATIRLLLAAIKQREVD     40   
                
Query 120   ERVTLDDAGCTACCDKMIKQRKDSISQFE      33 
                     ERVTLDDAGCTACCDKMIKQRKDSISQFE 
Sbjct 41        ERVTLDDAGCTACCDKMIKQRKDSISQFE     68 
 
Query 32      AAGRTDLVEK     3 
                     AAGRTDLVEK 
Sbjct 69        AAGRTDLVEK     78 
YP 105144 100 98 3E-27 
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Table 5.3.  Characteristics of the 6 recombinant polypeptides of B. pseudomallei.                 
Locus tag Chromosome Putative identity Predicted function Cellular  location 
a
 
BPSS1904 2 benzoate 1,2-dioxygenase beta 
subunit 
Secondary metabolites biosynthesis, 
transport, and catabolism 
C 
BPSL3130 1 hypothetical protein Function unknown CM 
BURPS1710b_0454 1 200 kDa antigen p200,  
putative 
Cell envelope biogenesis, outer 
membrane / carbohydrate transport and 
metabolism 
 
C 
BPSS1856 2 phosphotransferase enzyme family 
protein 
Function unknown C 
BPSS0897 2 short chain dehydrogenase Secondary metabolites biosynthesis, 
transport, and catabolism 
 
C 
BPSS1757 2 hypothetical protein Function unknown C 
  
a
 As predicted by PSORTb V3.0 .Cytoplasm (C), cytoplasmic membrane (CM). 
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5.3.4  SDS-PAGE and Western blot analysis of the 6 recombinant 
polypeptides 
Those selected 6 clones were induced to express a small peptide derived from the 
protein under study and the expressed polypeptides were separated under denaturing 
conditions on a 12% SDS-PAGE gel.  Figure 5.3 shows a band of approximately 46 to 
48 kDa (predicted calculated molecular weight).  The band was clearly detected for all 
purified recombinant polypeptides indicating that protein under study was successfully 
expressed in the prokaryotic system. 
 
 
 
 
 
 
 
 
 
 
 
            
           
            Figure 5.3. SDS-PAGE showing purified recombinant polypeptides. 
The protein samples (~20µg) were fractionated and stained with 
Bio-Safe Coomassie Blue. 
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Subsequently, the expressed recombinant polypeptides were confirmed through western 
blotting using patients’ sera.  As shown in Figure 5.4, all 6 recombinant polypeptides 
demonstrated strong reactivity towards pooled melioidosis-positive sera (n=10) when 
compared to the pooled negative sera (n=10).  No reactivity with either melioidosis-
positive or negative sera was observed for the negative control, pSCREEN T vector 
with no insert. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4. Western blot analysis of candidate polypeptide antigens. 
Western blot with two different pool of sera obtained from  melioidosis- 
positive and negative patients that were confirmed serologically by in- 
house IFAT assay.  Each pooled sera was a mixture of 10 serum samples.  
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5.3.5  Investigation on the serodiagnostic potential of the 6 recombinant 
polypeptides 
Based on our in-house IFAT as a reference test (sensitivity and specificity equal to 
100%), the cutoff point was defined as the mean A415 + 3SD of the IFAT-confirmed 
melioidosis-negative sera. The cutoff values were 0.123, 0.133, 0.145, 0.136, 0.198 and 
0.122 for BPSS1904, BPSL3130, BURPS1710b_0454, BPSS1856, BPSS0897 and 
BPSS1757, respectively.  These values enabled us to identify positive and negative sera 
and the percentages of positive sera were calculated as demonstrated in Table 5.4.  
Furthermore, an estimation of the ELISA performance was also calculated and is 
presented in Table 5.5.   
 
Overall, the 6 recombinant polypeptides showed widely variable performance in ELISA 
test, with sensitivities and specificities ranging from 33.3 to 97.6%.  Two recombinant 
polypeptides, BPSS1904 and BPSL3130 recognized a large proportion of the 
melioidosis positive sera (54/60) and (45/60); however cross-reactions with some of the 
disease control sera were also observed (Table 5.4).  Overall, both BPSS1904 and 
BPSL3130 demonstrated satisfactory performance, sensitivities of 75.0% and 90.0%, 
specificities of 90.2% and 88.6%, positive predictive value of 79.0% and 79.4%, 
negative predictive value of 88.1% and 94.8%, positive likelihood ratio of 7.79 and 7.91 
and negative likelihood of 0.28 and 0.11, respectively (Table 5.5). 
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Table 5.4.  ELISA screening for melioidosis and disease control sera using the 6 recombinant polypeptides. 
        
 
Disease group Percentage  positivity         
  BPSS1904 BPSL3130 BURPS1710b_0454 BPSS1856 BPSS0897 BPSS1757 
A   Melioidosis-positive  (n=60) 75.0 (45/60) 90.0 (54/60) 66.7 (40/60) 66.7 (40/60) 60.0 (36/60) 33.3 (20/60) 
B   Melioidosis-negative (n=60)   1.7 (1/60)   1.7 (1/60)     0/60   1.7 (1/60)     0/60   3.3 (2/60) 
C   Healthy control (n=10)       0/60        0/60      0/60     0/60     0/60     0/60 
D   Legionella pneumoniae (n=11) 36.4 (4/11) 36.4 (4/11) 27.3 (3/11) 36.4 (4/11) 27.3 (3/11)    0/11 
E   Leptospirosis (n=13) 15.4 (2/13)   7.7 (1/13)   7.7 (1/13) 15.4 (2/13)   7.7 (1/13)    0/13 
F   Chlamydophila pneumoniae (n=10) 20.0 (2/10) 20.0 (2/10)    0/10 20.0 (2/10)    0/10 10.0 (1/10) 
G   Mycoplasma pneumoniae (n=12) 16.7 (2/12) 33.3 (4/12) 25.0 (3/12) 25.0 (3/12) 25.0 (3/12)    0/12 
H   Typhus (rickettsiosis) (n=7) 14.3 (1/7)      28.6 (2/7)     0/7     0/7     0/7 0/7 
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Table 5.5. Evaluation of the performance of the 6 B. pseudomallei recombinant polypeptides. 
 
Percentage (95% CI)  BPSS1904  BPSL3130  BURPS1710b_0454 BPSS1856 BPSS0897  BPSS1757 
Sensitivity  75  90 66.7 66.7 60  33.3 
  (62.1-85.3)  (79.5-96.2) (53.3-78.3) (53.3-78.3) (46.5-72.4)  (21.7-46.7) 
Specificity  90.2  88.6 94.3 90.2 94.3  97.5 
  (83.6-94.9)  (81.6-93.6) (88.6-97.7) (83.6-94.9) (88.6-97.7)  (93.0-99.5) 
Positive predictive value   79.0  79.4 85.1 76.9 83.7  87.0 
  (66.1-88.6)  (67.9-88.3) (71.7-93.8) (63.2-87.5) (69.3-93.2)  (66.4-97.1) 
Negative predictive value  88.1  94.8 85.3 84.7 82.9  75.0 
   (81.1-93.2)  (89.0-98.1) (78.2-90.8) (77.5-90.5) (75.6-88.7)  (67.6-81.5) 
Positive likelihood ratio   7.69  7.91 11.71 6.83 10.54  13.67 
  (4.40-13.42)  (4.79-13.04) (5.68-24.59) (3.98-12.04) (4.99-22.29)  (4.23-44.19) 
Negative likelihood ratio  0.28  0.11 0.35 0.37 0.42  0.68 
   (0.18-043)  (0.05-0.24) (0.25-0.51) (0.26-0.53) (0.31-0.58)  (0.57-0.82) 
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5.4  Discussion 
5.4.1 Shotgun genomic expression library as a tool for the screening of 
immunogens 
In the past, several attempts have been made to identify potential immunodominant 
antigens of B. pseudomallei, including proteomic-based biotinylation and 
immunoscreening approaches (Harding et al., 2007), bioinformatics prediction tools 
(Thompson et al., 2008) and protein array (Felgner et al., 2009; Suwannasaen et al., 
2011).  Although several immunogenic proteins in B. pseudomallei have been identified 
such as GroEL (Woo et al.,  2001), OmpA (Hara et al., 2009) and Elongation factor-Tu 
(Nieves et al., 2010), these immunogens have not been further evaluated as potential 
serodiagnostic markers.  
 
In the present study, shotgun genomic expression approach was chosen and utilized to 
facilitate the discovery of candidate antigens.  This is due to the fact that shotgun 
expression method is more economical and less demanding compared to an array of 
platforms available commercially,  for example, genome-wide proteome or immunogen 
arrays that allow the selection of candidates from a large number of proteins in 
Mycobacterium tuberculosis (Sartain et al., 2006) and Francisella tularensis (Sundaresh 
et al., 2007).   
 
The introduction of recombinant expression, DNA vectors and purification of protein 
expressed in E. coli in NovaTope System provides a valuable tool for antigen discovery 
research.  Most polypeptides are relatively stable and can be produced by inserting a 
desired sequence of interest into expression vector and producing large quantities of 
polypeptides, thus avoiding the problem of batch to batch variation.   
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This approach offered an effective and quicker strategy to thoroughly examine the short 
peptides or polypeptides expressed corresponding to a contiguous amino acid sequence 
fragment of a protein.   In particular, the small foreign sequence of B. pseudomallei with 
an average insert size of 50 to 300 bp is stably expressed as part of a fusion containing 
the T7 gene 10 protein.  This fusion method ensures that DNA fragment encoding 
protein will be efficiently transcribed and translated under the control of T7 RNA 
polymerase in E. coli NovaBlue DE3, which prevents the target sequence from 
breakdown by cellular proteases.   
 
In addition, this system offers an advantage as the protein isolated will not be a full-
length, but it will correspond only to a polypeptide representing the antibody-binding 
site involved in the recognition. The full-length of pure recombinant proteins are prone 
to degradation and misfolding, but the production of recombinant polypeptides is much 
easier and reproducible production with minimal batch-to-batch variation.  This system 
allows the production of desired homogeneous antigenic polypeptides in large quantities 
from the bacterial recombinant and easily applied to other formats such as ELISA. 
 
The polypeptide epitopes may allow for distinct specificities and subsequently avoiding 
unimportant and/or unwanted epitope present in whole protein.   In other words, the use 
of essential sequences only on peptides is a straightforward approach to capture antigen-
specific antibodies from serum samples.  More recently, Casey et al. (2006) and Al-
Khodari et al. (2011) provided evidence to suggest the potential for the use of peptide as 
an alternative to the complex antigens for serological detection of Epstein-Barr virus 
infection and tuberculosis, respectively.  In contrast with the isolation of native antigen 
by handling a live infectious B. pseudomallei organism, production of recombinant 
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polypeptides without the need to use the entire pathogen, thus reducing the associated 
risk.   
 
From a diagnostic perspective, relevant peptides are those that show significant ability 
to be recognized by any of the melioidosis-positive sera.  In fact, the natural variation is 
expected to be occurred in immune response against B. pseudomallei.  The reasons for 
heterogeneity of immune response are not known, but could be explained for example, 
by differences in the mode of acquisition, strain differences in the organisms, difference 
in the magnitude of the infecting bacterial load, as well as its immunological memory 
(previous exposure to different antigens).  Therefore, the best search is to use of pooled 
sera from multiple patients as mentioned in Section 5.3.2 in panning procedures for 
minimizing individual patient variations in the immune response. 
 
As a result, the effectiveness of the shotgun expression library with an average insert 
size of 50 to 300 bp expressing partial ORF, permitted the identification of 
immunogenic polypeptides that reacted with pooled positive sera from melioidosis 
patients (Section 5.3.4), see Figure 5.5 for a summary.  This approach had been used 
successfully in the identification of useful immunodominant polypeptides of 
Mycobacterium tuberculosis (Bisen et al., 2003). 
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Figure 5.5. Summary of the experiments carried out in this study. 
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5.4.2  Analysis of the identified potential immunogenic polypeptides 
By combining shotgun expression library and immunoscreening assay, 6 polypeptides 
that had not been described previously, i.e., BPSS1904, BPSL3130, 
BURPS1710b_0454, BPSS1856, BPSS0897 and BPSS1757 were successfully 
identified.  These 6 new polypeptides reported here exhibited immunogenicity during 
human infection which was verified by western blot anlaysis (Section 5.3.4).   So, it is 
tempting to hypothesize that these candidate polypeptides are probably displayed on the 
surface of the bacterium and might play an important role in the interaction with host 
cells during in vivo infection, and are thus referred to as immunogenic polypeptides.  
They also deserve further investigation as attractive immunodiagnostic candidates. 
 
The hypothesis prompted us to predict subcellular location of these immunogenic 
polypeptides using PSORTb V3.0.  Five of the polypeptides consist of cytoplasmic 
localized proteins while another one located in the cytoplasmic membrane.  These 
results are in good agreement with previous study, Su and coworkers (2008) reported 
that a large portion of immunogenic proteins involved in human infection consists of 
cytoplasmic proteins (30%) and cytoplasmic membrane (24%).  It is still unclear why a 
cytoplasmic protein generated a humoral response, but the authors propose that these 
proteins are released into surrounding during destruction of the bacterial cells by 
phagocytes, antimicrobial drugs or complement-mediated killing and then exposed to 
the immune system (Su et al.,  2008). 
 
Based on bioinformatics database, these 6 immunogenic polypeptides are predicted to 
be involved in secondary metabolite biosynthesis, cell envelope biogenesis as well as 
hypothetical proteins of unknown function(s) (Table 5.3).  The majority of these 
immunogenic polypeptides were located on chromosome 2 (Table 5.3).   So, the finding 
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was in concordance with those reported previously whereby chromosome 2 has been 
suggested to be associated with genes required for adaptation and survival in different 
niches (Holden et al., 2004) as mentioned in Section 2.2.2. 
 
It has to be assumed that such polypeptides exhibit moonlighting activities (Henderson 
and Martin, 2011), i.e., have more than one biological action. Their detection may 
enhance our understanding of the pathogenicity of B. pseudomallei.  Supporting this, 2 
immunogens BPSS1904 and BPSS0897 have previously been described might be 
involved in the adaptation process during the early stationary phase of growth 
(Wongtrakoongate et al., 2011) and in response to salt stress associated with T3SS 
genes (Pumirat et al., 2010), respectively.  BPSS1856 has homology to Streptomyces 
coelicolor putative phosphotransferase that might play a role in carbon metabolism 
(Kamionka et al., 2002) while BURPS1710b_0454 is predicted to regulate cell envelope 
biogenesis.  
 
5.4.3  Evaluation of the efficacy of recombinant polypeptides for 
serodiagnosis of melioidosis 
To the best of our knowledge, these 6 immunogenic polypeptides have not been 
previously evaluated as serodiagnostic antigens for melioidosis.  Indeed, the cocktail of 
recombinant polypeptides may have contained contaminants with low impurities 
derived from E. coli NovaBlue (DE3) or pSCREEN T vector and could have influenced 
the specificity of the assay.  Consequently, the 6 immunogens were purified and their 
diagnostic values were assessed by using ELISA format in this study.  The main 
advantages of ELISA are their simplicity, speed (many serum samples can be tested in 
parallel) and generation of quantitative results in a short time frame compared to colony 
blot assay, which is cumbersome and poorly standardized.   
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In ELISA assay, our panel of polypeptides can detect IgG and IgM antibodies typically 
produced in human subjects after infection with B. pseudomallei.  The best overall 
performance was achieved using BPSS1904 and BPSL3130 with sensitivities, 
specificities, positive and negative predictive values of above 75% (Table 5.5).   It is 
therefore suggested that both polypeptides are potential candidate antigens.  Still, cross-
reactive responses were observed with disease-control sera in this study and this 
observation also has been reported by other studies (Chen et al., 2003; Hara et al.,  
2013).  A possible reason for antibody response to these cross-reactions may be due to 
B. pseudomallei containing immunologic epitopes similar to other microorganisms.  For 
example, BPSS1757 showed the identified antigenic cross-reactivity site to leptospira 
bacteria as indicated in Figure 5.6.  
 
 
 
 
 
Figure 5.6.   Alignment of amino acid sequences. 
         The similarities among strains are marked as *. 
 
 
 
 
 
 
 
 
BPSL1757   LDDAGVTACCDKMIKQRKDS I S QFEAAGRTDLVEK      
Leptospira   LT DT SVMQILKTNYKRRKDTALEYDKANRPDLS S K         
                           *    *      *                    *   * * *                  *   *  * *     * 
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Thus far, investigation of recombinant antigens for serodiagnosis of B. pseudomallei 
infection using ELISA format have only been analyzed in 3 studies, i.e., each from 
Taiwan (Chen et al., 2003); Australia (Allwood et al., 2008) and Malaysia (Hara et al., 
2013).  Different recombinant antigens were overexpressed, purified and evaluation 
have provided varying results with moderate to good sensitivities, specificities and 
diagnostic odd ratio (DOR) (Figure 5.7).  DOR measures the diagnostic accuracy of a 
given diagnostic test by summarizing function of specificity and sensitivity (Glas et al., 
2003).  A DOR of 1 represent the test does not discriminate between patients with the 
disease and those without it. 
 
The value of DOR ranged from 5.08 to 1067.50, with higher values indicating better 
discriminatory test performance.  The recombinant OmpA ELISA assays demonstrated 
high sensitivity (95%), specificity (98%) and DOR (1067.50) (Allwood et al., 2008).  
However, a very weak positive response was reported by authors as the means ELISA 
readings obtained for tested samples were as low as 0.061 at dilution 1:125 and 0.041 at 
dilution 1:250.  The observation herein may not constitute a true positive in a clinical 
situation and further investigation is needed.  Another study from non-endemic area, 
Taiwan, also demonstrated good ELISA results in sensitivity (94%), specificity (96%) 
and DOR (385) by using recombinant truncated flagellin, but the assay was not 
evaluated using sera from endemic regions (Chen et al., 2003). 
 Chapter 5 
151 
 
 
 
 
 
 
 
 
 
 
 
 
 
        Figure 5.7.  Sensitivities, specificities and diagnostic odds ratio. 
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Interestingly, another group of investigators have shown that using multiple antigens 
(TssD-5, Omp3, smBpF4 and Omp85) improved sensitivity of 88.2% and DOR of 
161.25 while retaining good specificity compared to results when the antigens were 
used  separately (Hara et al., 2013).  In this study, serum samples from melioidosis 
patients reacted with, at least, one recombinant antigen, therefore it is tempting to 
hypothesize that the use of 2 (BPS1904 and BPSL3130) or all recombinant 
immunogenic polypeptides as a combination antigen could be able to detect anti-
B.pseudomallei  antibodies in all the serum samples used in this study.  It is believed 
that the use of combination antigens will minimize individual variation and may further 
enhance sensitivity and DOR of assay. 
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5.5  Concluding discussion and future prospects 
Overall, the systematic stepwise shotgun genomic expression library screening and 
ELISA assay enabled the identification of 2 potential immunodominant polypeptides, B. 
pseudomallei, i.e., BPSS1904 and BPSL3130, although their sensitivities were only 
moderate.  Still, assays based on the detection of immune responses to melioidosis are 
attractive additional test for diagnosis of infection with B. pseudomallei.  
 
Thus, it is suggested that further analysis using both BPSS1904 and BPSL3130 in 
combination, would probably be the superior potential serodiagnostic antigens for 
melioidosis.  As single antigen tests did not have sufficient analytical sensitivity, the use 
of a combination of several polypeptides may minimize variations among individuals in 
their immune response and further enhance sensitivity and DOR of the assays.   
 
In addition, synthetic peptides in their pure forms corresponded to the desired sequence 
of BPSS1904 and BPSL3130 could be used in future experiments in order to enhance 
sensitivity and specificity by lowering the background of the assay.  On the other hand, 
recruitment of more samples for further evaluation is needed to obtain a thorough 
diagnostic profile.   
 
 
 
 
 
 
 Chapter 5 
154 
5.6  Limitations of the study 
Some limitations have been noted here although the expreimental design was carefully 
planned.  It is unavoidable that in the shotgun library, the DNA sequence is not known 
from the start and the clones must be sequenced to obtain an identity.  Another 
drawback was that only 1/6 inserts will be in the correct reading frame in the starting 
DNA by using DNase shotgun procedure.   
 
 
 
 References 
155 
 
References  
 
ABBINK, F. C., ORENDI, J. M. & DE BEAUFORT, A. J. 2001. Mother-to-child 
transmission of Burkholderia pseudomallei. N Engl J Med, 344, 1171-2. 
ALICE, A. F., LOPEZ, C. S., LOWE, C. A., LEDESMA, M. A. & CROSA, J. H. 2006. 
Genetic and transcriptional analysis of the siderophore malleobactin 
biosynthesis and transport genes in the human pathogen Burkholderia 
pseudomallei K96243. J Bacteriol, 188, 1551-66. 
AL-KHODARI, N. Y., AL-ATTIYAH, R. & MUSTAFA, A. S. 2011. Identification, 
diagnostic potential, and natural expression of immunodominant seroreactive 
peptides encoded by five Mycobacterium tuberculosis-specific genomic regions. 
Clin Vaccine Immunol, 18, 477-82. 
ALLWOOD, E. M., DEVENISH, R. J., PRESCOTT, M., ADLER, B. & BOYCE, J. D. 
2011. Strategies for Intracellular Survival of Burkholderia pseudomallei. Front 
Microbiol, 2, 170. 
ALLWOOD, E. M., LOGUE, C. A., HAFNER, G. J., KETHEESAN, N., NORTON, R. 
E., PEAK, I. R. & BEACHAM, I.R. 2008. Evaluation of recombinant antigens 
for diagnosis of melioidosis. FEMS Immunol Med Microbiol, 54, 144-53. 
ALTUN, Z. F., & HALL, D.H. 2005. Hermaphrodite anatomy. In Altun, Z. F., & Hall, 
D.H. (Eds.), WormAtlas.  
AMORNCHAI, P., CHIERAKUL, W., WUTHIEKANUN, V., 
MAHAKHUNKIJCHAROEN, Y., PHETSOUVANH, R., CURRIE, B. J., 
NEWTON, P. N., VAN VINH CHAU, N., WONGRATANACHEEWIN, S., 
DAY, N. P. & PEACOCK, S. J. 2007. Accuracy of Burkholderia pseudomallei 
identification using the API 20NE system and a latex agglutination test. J Clin 
Microbiol, 45, 3774-6. 
ANUNTAGOOL, A., INTACHOTE, P., NAIGOWIT, P. & SIRISINHA, S. 1996. 
Rapid antigen detection assay for identification of Burkholderia (Pseudomonas) 
pseudomallei infection. J Clin Microbiol, 34, 975-6. 
ANUNTAGOOL, N., NAIGOWIT, P., PETKANCHANAPONG, V., ARAMSRI, P., 
PANICHAKUL, T. & SIRISINHA, S. 2000. Monoclonal antibody-based rapid 
identification of Burkholderia pseudomallei in blood culture fluid from patients 
with community-acquired septicaemia. J Med Microbiol, 49, 1075-8. 
ANUNTAGOOL, N., RUGDECH, P. & SIRISINHA, S. 1993. Identification of specific 
antigens of Pseudomonas pseudomallei and evaluation of their efficacies for 
diagnosis of melioidosis. J Clin Microbiol, 31, 1232-6. 
 
 References 
156 
APPASSAKIJ, H., SILPAPOJAKUL, K. R., WANSIT, R. & PORNPATKUL, M. 1990. 
Diagnostic value of the indirect hemagglutination test for melioidosis in an 
endemic area. Am J Trop Med Hyg, 42, 248-53. 
ARJCHAROEN, S., WIKRAIPHAT, C., PUDLA, M., LIMPOSUWAN, K., WOODS, 
D. E., SIRISINHA, S. & UTAISINCHAROEN, P. 2007. Fate of a Burkholderia 
pseudomallei lipopolysaccharide mutant in the mouse macrophage cell line 
RAW 264.7: possible role for the O-antigenic polysaccharide moiety of 
lipopolysaccharide in internalization and intracellular survival. Infect Immun, 75, 
4298-304. 
ASHCROFT, N. & GOLDEN, A. 2002. CDC-25.1 regulates germline proliferation in 
Caenorhabditis elegans. Genesis, 33, 1-7. 
ASHDOWN, L. R. 1979. An improved screening technique for isolation of 
Pseudomonas pseudomallei from clinical specimens. Pathology, 11, 293-7. 
ATTREE, O. & ATTREE, I. 2001. A second type III secretion system in Burkholderia 
pseudomallei: who is the real culprit? Microbiology, 147, 3197-9. 
BADRAN, S., PEDERSEN, T. I., ROED, C., LUNDING, S., BIRK, N., 
VESTERGAARD, H., RODER, B., LILLELUND, H. K., KURTZHALS, J. A., 
KEMP, M. & CHRISTENSEN, J. J. 2010. Imported melioidosis in Danish 
travellers: a diagnostic challenge. Scand J Infect Dis, 42, 445-9. 
BALDER, R., LIPSKI, S., LAZARUS, J. J., GROSE, W., WOOTEN, R. M., HOGAN, 
R. J., WOODS, D. E. & LAFONTAINE, E. R. 2010. Identification of 
Burkholderia mallei and Burkholderia pseudomallei adhesins for human 
respiratory epithelial cells. BMC Microbiol, 10, 250. 
BISEN, P. S., GARG, S. K., TIWARI, R. P., TAGORE, P. R., CHANDRA, R., 
KARNIK, R., THAKER, N., DESAI, N., GHOSH, P.K., FRAZIANO, M. & 
COLIZZI, V. 2003. Analysis of the shotgun expression library of the 
Mycobacterium tuberculosis genome for immunodominant polypeptides: 
potential use in serodiagnosis. Clin Diagn Lab Immunol, 10, 1051-8. 
BODDEY, J. A., DAY, C. J., FLEGG, C. P., ULRICH, R. L., STEPHENS, S. R., 
BEACHAM, I. R., MORRISON, N. A. & PEAK, I. R. 2007. The bacterial gene 
lfpA influences the potent induction of calcitonin receptor and osteoclast-related 
genes in Burkholderia pseudomallei-induced TRAP-positive multinucleated 
giant cells. Cell Microbiol, 9, 514-31. 
BODDEY, J. A., FLEGG, C. P., DAY, C. J., BEACHAM, I. R. & PEAK, I. R. 2006. 
Temperature-regulated microcolony formation by Burkholderia pseudomallei 
requires pilA and enhances association with cultured human cells. Infect Immun, 
74, 5374-81. 
BOWERS, J. R., ENGELTHALER, D. M., GINTHER, J. L., PEARSON, T., 
PEACOCK, S. J., TUANYOK, A., WAGNER, D. M., CURRIE, B. J. & KEIM, 
P. S. 2010. BurkDiff: a real-time PCR allelic discrimination assay for 
Burkholderia pseudomallei and B. mallei. PLoS One, 5, e15413. 
 
 References 
157 
BRENNER, S. 1974. The genetics of Caenorhabditis elegans. Genetics, 77, 71-94. 
BRUCE, H. S. 2002. Melioidosis: an important emerging infectious disease - a military 
problem? ADF Health, 3, 13-21. 
BROWN, N. F., BODDEY, J. A., FLEGG, C. P. & BEACHAM, I. R. 2002. Adherence 
of Burkholderia pseudomallei cells to cultured human epithelial cell lines is 
regulated by growth temperature. Infect Immun, 70, 974-80. 
BURTNICK, M. N., BRETT, P. J., HARDING, S. V., NGUGI, S. A., RIBOT, W. J., 
CHANTRATITA, N., SCORPIO, A., MILNE, T. S., DEAN, R. E., FRITZ, D. 
L., PEACOCK, S. J., PRIOR, J. L., ATKINS, T. P. & DESHAZER, D. 2011. 
The cluster 1 type VI secretion system is a major virulence determinant in 
Burkholderia pseudomallei. Infect Immun, 79, 1512-25. 
BURTNICK, M. N., BRETT, P. J., NAIR, V., WARAWA, J. M., WOODS, D. E. & 
GHERARDINI, F. C. 2008. Burkholderia pseudomallei type III secretion 
system mutants exhibit delayed vacuolar escape phenotypes in RAW 264.7 
murine macrophages. Infect Immun, 76, 2991-3000. 
CAMPOS, C. G., BORST, L. & COTTER, P. A. 2013. Characterization of BcaA, a 
putative classical autotransporter protein in Burkholderia pseudomallei. Infect 
Immun, 81, 1121-8. 
CASEY, J. L., COLEY, A. M., STREET, G., PARISI, K., DEVINE, P. L. & FOLEY, 
M. 2006. Peptide mimotopes selected from a random peptide library for 
diagnosis of Epstein-Barr virus infection. J Clin Microbiol, 44, 764-71. 
CHAN, S. W., ONG, G. I. & NATHAN, S. 2004. Neutralizing chimeric mouse-human 
antibodies against Burkholderia pseudomallei protease: expression, purification 
and characterization. J Biochem Mol Biol, 37, 556-64. 
CHANCHAMROEN, S., KEWCHAROENWONG, C., SUSAENGRAT, W., ATO, M. 
& LERTMEMONGKOLCHAI, G. 2009. Human polymorphonuclear neutrophil 
responses to Burkholderia pseudomallei in healthy and diabetic subjects. Infect 
Immun, 77, 456-63. 
CHANTRATITA, N., MEUMANN, E., THANWISAI, A., LIMMATHUROTSAKUL, 
D., WUTHIEKANUN, V., WANNAPASNI, S., TUMAPA, S., DAY, N. P. & 
PEACOCK, S. J. 2008. Loop-mediated isothermal amplification method 
targeting the TTS1 gene cluster for detection of Burkholderia pseudomallei and 
diagnosis of melioidosis. J Clin Microbiol, 46, 568-73. 
CHANTRATITA, N., WUTHIEKANUN, V., BOONBUMRUNG, K., 
TIYAWISUTSRI, R., VESARATCHAVEST, M., LIMMATHUROTSAKUL, 
D., CHIERAKUL, W., WONGRATANACHEEWIN, S., PUKRITIYAKAMEE, 
S., WHITE, N. J., DAY, N. P. & PEACOCK, S. J. 2007. Biological relevance of 
colony morphology and phenotypic switching by Burkholderia pseudomallei. J 
Bacteriol, 189, 807-17. 
CHAROENSAP, J., UTAISINCHAROEN, P., ENGERING, A. & SIRISINHA, S. 2009. 
Differential intracellular fate of Burkholderia pseudomallei 844 and 
Burkholderia thailandensis UE5 in human monocyte-derived dendritic cells and 
macrophages. BMC Immunol, 10, 20. 
 References 
158 
CHATFIELD, C. H., MULHERN, B. J., BURNSIDE, D. M., & CIANCIOTTO, N. P. 
2011. Legionella pneumophila LbtU acts as a novel, TonB-independent receptor 
for the legiobactin siderophore. J Bacteriol, 193, 1563-75. 
CHEN, Y., WONG, J., SUN, G. W., LIU, Y., TAN, G. Y., & GAN, Y. H. 2011. 
Regulation of type VI secretion system during Burkholderia pseudomallei 
infection. Infect Immun, 79, 3064-73. 
CHEN, Y. S., HSIAO, Y. S., LIN, H. H., YEN, C. M., CHEN, S. C. & CHEN, Y. L. 
2006. Immunogenicity and anti-Burkholderia pseudomallei activity in Balb/c 
mice immunized with plasmid DNA encoding flagellin. Vaccine, 24, 750-8. 
CHEN, Y. S., SHIUAN, D., CHEN, S. C., CHYE, S. M., & CHEN, Y. L. 2003. 
Recombinant truncated flagellin of Burkholderia pseudomallei as a molecular 
probe for diagnosis of melioidosis. Clin Diagn Lab Immunol, 10, 423-5. 
CHENG, A. C. & CURRIE, B. J. 2005. Melioidosis: epidemiology, pathophysiology, 
and management. Clin Microbiol Rev, 18, 383-416. 
CHENG, A. C., JACUPS, S. P., WARD, L. & CURRIE, B. J. 2008. Melioidosis and 
Aboriginal seasons in northern Australia. Trans R Soc Trop Med Hyg, 102 Suppl 
1, S26-9. 
CHENG, A. C., O'BRIEN, M., FREEMAN, K., LUM, G. & CURRIE, B. J. 2006. 
Indirect hemagglutination assay in patients with melioidosis in northern 
Australia. Am J Trop Med Hyg, 74, 330-4. 
CHENTHAMARAKSHAN, V., KUMUTHA, M. V., VADIVELU, J. & 
PUTHUCHEARY, S. D. 2001a. Distribution of immunoglobulin classes and 
IgG subclasses against a culture filtrate antigen of Burkholderia pseudomallei in 
melioidosis patients. J Med Microbiol, 50, 55-61. 
CHENTHAMARAKSHAN, V., VADIVELU, J., & PUTHUCHEARY, S. D. 2001b. 
Detection of immunoglobulins M and G using culture filtrate antigen of 
Burkholderia pseudomallei. Diagn Microbiol Infect Dis, 39, 1-7. 
CHIENG, S., CARRETO, L. & NATHAN, S. 2012. Burkholderia pseudomallei 
transcriptional adaptation in macrophages. BMC Genomics, 13, 328. 
CHIERAKUL, W., WINOTHAI, W., WATTANAWAITUNECHAI, C., 
WUTHIEKANUN, V., RUGTAENGAN, T., RATTANALERTNAVEE, J., 
JITPRATOOM, P., CHAOWAGUL, W., SINGHASIVANON, P., WHITE, N. 
J., DAY, N. P. & PEACOCK, S. J. 2005. Melioidosis in 6 tsunami survivors in 
southern Thailand. Clin Infect Dis, 41, 982-90. 
CHOI, K. H., MIMA, T., CASART, Y., RHOLL, D., KUMAR, A., BEACHAM, I. R. 
& SCHWEIZER, H. P. 2008. Genetic tools for select-agent-compliant 
manipulation of Burkholderia pseudomallei. Appl Environ Microbiol, 74, 1064-
75. 
CHOY, J. L., MAYO, M., JANMAAT, A. & CURRIE, B. J. 2000. Animal melioidosis 
in Australia. Acta Trop, 74, 153-8. 
 References 
159 
CHUA, K. L., CHAN, Y. Y. & GAN, Y. H. 2003. Flagella are virulence determinants 
of Burkholderia pseudomallei. Infect Immun, 71, 1622-9. 
CHUAH, S. C., GILMORE, G. & NORTON, R. E. 2005. Rapid serological diagnosis of 
melioidosis: an evaluation of a prototype immunochromatographic test. 
Pathology, 37, 169-71. 
CHUANG, Y. P., FANG, C. T., LAI, S. Y., CHANG, S. C. & WANG, J. T. 2006. 
Genetic determinants of capsular serotype K1 of Klebsiella pneumoniae causing 
primary pyogenic liver abscess. J Infect Dis, 193, 645-54. 
CHUAYGUD, T., TUNGPRADABKUL, S., SIRISINHA, S., CHUA, K. L. & 
UTAISINCHAROEN, P. 2008. A role of Burkholderia pseudomallei flagella as 
a virulent factor. Trans R Soc Trop Med Hyg, 102 Suppl 1, S140-4. 
CUCCUI, J., EASTON, A., CHU, K. K., BANCROFT, G. J., OYSTON, P. C., 
TITBALL, R. W. & WREN, B. W. 2007. Development of signature-tagged 
mutagenesis in Burkholderia pseudomallei to identify genes important in 
survival and pathogenesis. Infect Immun, 75, 1186-95. 
CULLINANE, M., GONG, L., LI, X., LAZAR-ADLER, N., TRA, T., WOLVETANG, 
E., PRESCOTT, M., BOYCE, J. D., DEVENISH, R. J. & ADLER, B. 2008. 
Stimulation of autophagy suppresses the intracellular survival of Burkholderia 
pseudomallei in mammalian cell lines. Autophagy, 4, 744-53. 
CURRIE, B. J., DANCE, D. A. & CHENG, A. C. 2008. The global distribution of 
Burkholderia pseudomallei and melioidosis: an update. Trans R Soc Trop Med 
Hyg, 102 Suppl 1, S1-4. 
CURRIE, B. J., FISHER, D. A., HOWARD, D. M., BURROW, J. N., LO, D., SELVA-
NAYAGAM, S., ANSTEY, N. M., HUFFAM, S. E., SNELLING, P. L., 
MARKS, P. J., STEPHENS, D. P., LUM, G. D., JACUPS, S. P. & KRAUSE, V. 
L. 2000a. Endemic melioidosis in tropical northern Australia: a 10-year 
prospective study and review of the literature. Clin Infect Dis, 31, 981-6. 
CURRIE, B., HOWARD, D., NGUYEN, V. T., WITHNALL, K. & MERIANOS, A. 
1993. The 1990-1991 outbreak of melioidosis in the Northern Territory of 
Australia: clinical aspects. Southeast Asian J Trop Med Public Health, 24, 436-
43. 
CURRIE, B. J., FISHER, D. A., HOWARD, D. M., BURROW, J. N., 
SELVANAYAGAM, S., SNELLING, P. L., ANSTEY, N. M. & MAYO, M. J. 
2000b. The epidemiology of melioidosis in Australia and Papua New Guinea. 
Acta Trop, 74, 121-7. 
CURRIE, B. J. & JACUPS, S. P. 2003. Intensity of rainfall and severity of melioidosis, 
Australia. Emerg Infect Dis, 9, 1538-42. 
CURRIE, B. J., JACUPS, S. P., CHENG, A. C., FISHER, D. A., ANSTEY, N. M., 
HUFFAM, S. E. & KRAUSE, V. L. 2004. Melioidosis epidemiology and risk 
factors from a prospective whole-population study in northern Australia. Trop 
Med Int Health, 9, 1167-74. 
 References 
160 
CURRIE, B. J., MAYO, M., ANSTEY, N. M., DONOHOE, P., HAASE, A. & KEMP, 
D. J. 2001. A cluster of melioidosis cases from an endemic region is clonal and 
is linked to the water supply using molecular typing of Burkholderia 
pseudomallei isolates. Am J Trop Med Hyg, 65, 177-9. 
CUZZUBBO, A. J., CHENTHAMARAKSHAN, V., VADIVELU, J., 
PUTHUCHEARY, S. D., ROWLAND, D. & DEVINE, P. L. 2000. Evaluation 
of a new commercially available immunoglobulin M and immunoglobulin G 
immunochromatographic test for diagnosis of melioidosis infection. J Clin 
Microbiol, 38, 1670-1. 
D'CRUZE, T., GONG, L., TREERAT, P., RAMM, G., BOYCE, J. D., PRESCOTT, M., 
ADLER, B. & DEVENISH, R. J. 2011. Role for the Burkholderia pseudomallei 
type three secretion system cluster 1 bpscN gene in virulence. Infect Immun, 79, 
3659-64. 
DANCE, D. A., DAVIS, T. M., WATTANAGOON, Y., CHAOWAGUL, W., 
SAIPHAN, P., LOOAREESUWAN, S., WUTHIEKANUN, V. & WHITE, N. J. 
1989. Acute suppurative parotitis caused by Pseudomonas pseudomallei in 
children. J Infect Dis, 159, 654-60. 
DERIS, Z. Z., HASAN, H. & SITI SURAIYA, M. N. 2010. Clinical characteristics and 
outcomes of bacteraemic melioidosis in a teaching hospital in a northeastern 
state of Malaysia: a five-year review. J Infect Dev Ctries, 4, 430-5. 
DESHAZER, D., BRETT, P. J., CARLYON, R. & WOODS, D. E. 1997. Mutagenesis 
of Burkholderia pseudomallei with Tn5-OT182: isolation of motility mutants 
and molecular characterization of the flagellin structural gene. J Bacteriol, 179, 
2116-25. 
DHARAKUL, T., SONGSIVILAI, S., ANUNTAGOOL, N., CHAOWAGUL, W., 
WONGBUNNATE, S., INTACHOTE, P. & SIRISINHA, S. 1997. Diagnostic 
value of an antibody enzyme-linked immunosorbent assay using affinity-
purified antigen in an area endemic for melioidosis. Am J Trop Med Hyg, 56, 
418-23. 
DHARAKUL, T., SONGSIVILAI, S., VIRIYACHITRA, S., LUANGWEDCHAKARN, 
V., TASSANEETRITAP, B. & CHAOWAGUL, W. 1996. Detection of 
Burkholderia pseudomallei DNA in patients with septicemic melioidosis. J Clin 
Microbiol, 34, 609-14. 
DHARAKUL, T., SONGSIVILAI, S., SMITHIKARN, S., THEPTHAI, C. & 
LEELAPORN, A. 1999. Rapid identification of Burkholderia pseudomallei in 
blood cultures by latex agglutination using lipopolysaccharide-specific 
monoclonal antibody. Am J Trop Med Hyg, 61, 658-62. 
 
 
 
 
 References 
161 
DRUAR, C., YU, F., BARNES, J. L., OKINAKA, R. T., CHANTRATITA, N., BEG, 
S., STRATILO, C. W., OLIVE, A. J., SOLTES, G., RUSSELL, M. L., 
LIMMATHUROTSAKUL, D., NORTON, R. E., NI, S. X., PICKING, W. D., 
JACKSON, P. J., STEWART, D. I., TSVETNITSKY, V., PICKING, W. L., 
CHERWONOGRODZKY, J. W., KETHEESAN, N., PEACOCK, S. J. & 
WIERSMA, E. J. 2008. Evaluating Burkholderia pseudomallei Bip proteins as 
vaccines and Bip antibodies as detection agents. FEMS Immunol Med Microbiol, 
52, 78-87. 
EKPO, P., RUNGPANICH, U., PONGSUNK, S., NAIGOWIT, P. & 
PETKANCHANAPONG, V. 2007. Use of protein-specific monoclonal 
antibody-based latex agglutination for rapid diagnosis of Burkholderia 
pseudomallei infection in patients with community-acquired septicemia. Clin 
Vaccine Immunol, 14, 811-2. 
ESSEX-LOPRESTI, A. E., BODDEY, J. A., THOMAS, R., SMITH, M. P., HARTLEY, 
M. G., ATKINS, T., BROWN, N. F., TSANG, C. H., PEAK, I. R., HILL, J., 
BEACHAM, I. R. & TITBALL, R. W. 2005. A type IV pilin, PilA, Contributes 
To Adherence of Burkholderia pseudomallei and virulence in vivo. Infect 
Immun, 73, 1260-4. 
EZZEDINE, K., HEENEN, M. & MALVY, D. 2007. Imported cutaneous melioidosis in 
traveler, Belgium. Emerg Infect Dis, 13, 946-7. 
FELGNER, P. L., KAYALA, M. A., VIGIL, A., BURK, C., NAKAJIMA-SASAKI, R., 
PABLO, J., MOLINA, D. M., HIRST, S., CHEW, J. S., WANG, D., TAN, G., 
DUFFIELD, M., YANG, R., NEEL, J., CHANTRATITA, N., BANCROFT, G., 
LERTMEMONGKOLCHAI, G., DAVIES, D. H., BALDI, P., PEACOCK, S. & 
TITBALL, R. W. 2009. A Burkholderia pseudomallei protein microarray 
reveals serodiagnostic and cross-reactive antigens. Proc Natl Acad Sci U S A, 
106, 13499-504. 
GAL, D., MAYO, M., SMITH-VAUGHAN, H., DASARI, P., MCKINNON, M., 
JACUPS, S. P., URQUHART, A.I., HASSELL, M. & CURRIE, B.J. 2004. 
Contamination of hand wash detergent linked to occupationally acquired 
melioidosis. Am J Trop Med Hyg, 71, 360-362. 
GALYOV, E. E., BRETT, P. J., & DESHAZER, D. 2010. Molecular insights into 
Burkholderia pseudomallei and Burkholderia mallei pathogenesis. Annu Rev 
Microbiol, 64, 495-517. 
GAN, Y. H., CHUA, K. L., CHUA, H. H., LIU, B., HII, C. S., CHONG, H. L. & TAN, 
P. 2002. Characterization of Burkholderia pseudomallei infection and 
identification of novel virulence factors using a Caenorhabditis elegans host 
system. Mol Microbiol, 44, 1185-97. 
GILMORE, G., BARNES, J., KETHEESAN, N. & NORTON, R. 2007. Use of antigens 
derived from Burkholderia pseudomallei, B. thailandensis, and B. cepacia in the 
indirect hemagglutination assay for melioidosis. Clin Vaccine Immunol, 14, 
1529-31. 
 References 
162 
GLAS, A. S., LIJMER, J. G., PRINS, M. H., BONSEL, G. J., & BOSSUYT, P. M. 
2003. The diagnostic odds ratio: a single indicator of test performance. J Clin 
Epidemiol, 56, 1129-35. 
GLASS, M. B. & POPOVIC, T. 2005. Preliminary evaluation of the API 20NE and 
RapID NF plus systems for rapid identification of Burkholderia pseudomallei 
and B. mallei. J Clin Microbiol, 43, 479-83. 
GONG, L., CULLINANE, M., TREERAT, P., RAMM, G., PRESCOTT, M., ADLER, 
B., BOYCE, J. D. & DEVENISH, R. J. 2011. The Burkholderia pseudomallei 
type III secretion system and BopA are required for evasion of LC3-associated 
phagocytosis. PLoS One, 6, e17852. 
GORI, A. H., AHMED, K., MARTINEZ, G., MASAKI, H., WATANABE, K. & 
NAGATAKE, T. 1999. Mediation of attachment of Burkholderia pseudomallei 
to human pharyngeal epithelial cells by the asialoganglioside GM1-GM2 
receptor complex. Am J Trop Med Hyg, 61, 473-5. 
GRAVATO-NOBRE, M. J., & HODGKIN, J. 2005. Caenorhabditis elegans as a model 
for innate immunity to pathogens. Cell Microbiol, 7, 741-51. 
HALDER, D., ZAINAL, N., WAH, C. M. & HAQ, J. A. 1998. Neonatal meningitis and 
septicaemia caused by Burkholderia pseudomallei. Ann Trop Paediatr, 18, 161-
4. 
HARA, Y., CHIN, C. Y., MOHAMED, R., PUTHUCHEARY, S. D., & NATHAN, S. 
2013. Multiple-antigen ELISA for melioidosis - a novel approach to the 
improved serodiagnosis of melioidosis. BMC Infect Dis, 13, 165. 
HARA, Y., MOHAMED, R. & NATHAN, S. 2009. Immunogenic Burkholderia 
pseudomallei outer membrane proteins as potential candidate vaccine targets. 
PLoS One, 4, e6496. 
HARLEY, V. S., DANCE, D. A., DRASAR, B. S. & TOVEY, G. 1998a. Effects of 
Burkholderia pseudomallei and other Burkholderia species on eukaryotic cells 
in tissue culture. Microbios, 96, 71-93. 
HARLEY, V. S., DANCE, D. A., TOVEY, G., MCCROSSAN, M. V. & DRASAR, B. 
S. 1998b. An ultrastructural study of the phagocytosis of Burkholderia 
pseudomallei. Microbios, 94, 35-45. 
HARDING, S. V., SARKAR-TYSON, M., SMITHER, S. J., ATKINS, T. P., OYSTON, 
P. C., BROWN, K. A., LIU, Y., WAIT, R. & TITBALL, R.W. 2007. The 
identification of surface proteins of Burkholderia pseudomallei. Vaccine, 25, 
2664-72. 
HASSAN, M. R., PANI, S. P., PENG, N. P., VORALU, K., VIJAYALAKSHMI, N., 
MEHANDERKAR, R., AZIZ, N. A. & MICHAEL, E. 2010. Incidence, risk 
factors and clinical epidemiology of melioidosis: a complex socio-ecological 
emerging infectious disease in the Alor Setar region of Kedah, Malaysia. BMC 
Infect Dis, 10, 302. 
 References 
163 
HENDERSON, B., & MARTIN, A. 2011. Bacterial virulence in the moonlight: 
multitasking bacterial moonlighting proteins are virulence determinants in 
infectious disease. Infect Immun, 79, 3476-91. 
HENG, B. H., GOH, K. T., YAP, E. H., LOH, H. & YEO, M. 1998. Epidemiological 
surveillance of melioidosis in Singapore. Ann Acad Med Singapore, 27, 478-84. 
HO, M., SCHOLLAARDT, T., SMITH, M. D., PERRY, M. B., BRETT, P. J., 
CHAOWAGUL, W. & BRYAN, L. E. 1997. Specificity and functional activity 
of anti-Burkholderia pseudomallei polysaccharide antibodies. Infect Immun, 65, 
3648-53. 
HOLDEN, M. T., TITBALL, R. W., PEACOCK, S. J., CERDENO-TARRAGA, A. M., 
ATKINS, T., CROSSMAN, L. C., PITT, T., CHURCHER, C., MUNGALL, K., 
BENTLEY, S. D., SEBAIHIA, M., THOMSON, N. R., BASON, N., 
BEACHAM, I. R., BROOKS, K., BROWN, K. A., BROWN, N. F., CHALLIS, 
G. L., CHEREVACH, I., CHILLINGWORTH, T., CRONIN, A., CROSSETT, 
B., DAVIS, P., DESHAZER, D., FELTWELL, T., FRASER, A., HANCE, Z., 
HAUSER, H., HOLROYD, S., JAGELS, K., KEITH, K. E., MADDISON, M., 
MOULE, S., PRICE, C., QUAIL, M. A., RABBINOWITSCH, E., 
RUTHERFORD, K., SANDERS, M., SIMMONDS, M., SONGSIVILAI, S., 
STEVENS, K., TUMAPA, S., VESARATCHAVEST, M., WHITEHEAD, S., 
YEATS, C., BARRELL, B. G., OYSTON, P. C. & PARKHILL, J. 2004. 
Genomic plasticity of the causative agent of melioidosis, Burkholderia 
pseudomallei. Proc Natl Acad Sci U S A, 101, 14240-5. 
HOW, S. H., NG, K. H., JAMALLUDIN, A. R., SHAH, A. & RATHOR, Y. 2005. 
Melioidosis in Pahang, Malaysia. Med J Malaysia, 60, 606-13. 
HOWARD, K. & INGLIS, T. J. 2003. Novel selective medium for isolation of 
Burkholderia pseudomallei. J Clin Microbiol, 41, 3312-6. 
HOWE, C., SAMPATH, A. & SPOTNITZ, M. 1971. The pseudomallei group: a review. 
J Infect Dis, 124, 598-606. 
INGLIS, T. J., CHIANG, D., LEE, G. S. & CHOR-KIANG, L. 1998. Potential 
misidentification of Burkholderia pseudomallei by API 20NE. Pathology, 30, 
62-4. 
INGLIS, T. J., GARROW, S. C., HENDERSON, M., CLAIR, A., SAMPSON, J., 
O'REILLY, L. & CAMERON, B. 2000a. Burkholderia pseudomallei traced to 
water treatment plant in Australia. Emerg Infect Dis, 6, 56-9. 
INGLIS, T. J., MERRITT, A., CHIDLOW, G., ARAVENA-ROMAN, M. & 
HARNETT, G. 2005. Comparison of diagnostic laboratory methods for 
identification of Burkholderia pseudomallei. J Clin Microbiol, 43, 2201-6. 
INGLIS, T. J., RIGBY, P., ROBERTSON, T. A., DUTTON, N. S., HENDERSON, M. 
& CHANG, B. J. 2000b. Interaction between Burkholderia pseudomallei and 
Acanthamoeba species results in coiling phagocytosis, endamebic bacterial 
survival, and escape. Infect Immun, 68, 1681-6. 
 References 
164 
INGLIS, T. J., ROBERTSON, T., WOODS, D. E., DUTTON, N. & CHANG, B. J. 
2003. Flagellum-mediated adhesion by Burkholderia pseudomallei precedes 
invasion of Acanthamoeba astronyxis. Infect Immun, 71, 2280-2. 
IRAZOQUI, J. E., NG, A., XAVIER, R. J. & AUSUBEL, F. M. 2008. Role for beta-
catenin and HOX transcription factors in Caenorhabditis elegans and 
mammalian host epithelial-pathogen interactions. Proc Natl Acad Sci U S A, 105, 
17469-74. 
ISMAIL, G., NOOR EMBI, M., OMAR, O., ALLEN, J. C. & SMITH, C. J. 1987. A 
competitive immunosorbent assay for detection of Pseudomonas pseudomallei 
exotoxin. J Med Microbiol, 23, 353-7. 
JANSSON, H. B. 1994. Adhesion of Conidia of Drechmeria coniospora to 
Caenorhabditis elegans Wild Type and Mutants. J Nematol, 26, 430-5. 
JONES, A. L., BEVERIDGE, T. J. & WOODS, D. E. 1996. Intracellular survival of 
Burkholderia pseudomallei. Infect Immun, 64, 782-90. 
JONES, A. L., DESHAZER, D. & WOODS, D. E. 1997. Identification and 
characterization of a two-component regulatory system involved in invasion of 
eukaryotic cells and heavy-metal resistance in Burkholderia pseudomallei. Infect 
Immun, 65, 4972-7. 
JONES, S. M., ELLIS, J. F., RUSSELL, P., GRIFFIN, K. F. & OYSTON, P. C. 2002. 
Passive protection against Burkholderia pseudomallei infection in mice by 
monoclonal antibodies against capsular polysaccharide, lipopolysaccharide or 
proteins. J Med Microbiol, 51, 1055-62. 
KAESTLI, M., RICHARDSON, L. J., COLMAN, R. E., TUANYOK, A., PRICE, E. P., 
BOWERS, J. R., MAYO, M., KELLEY, E., SEYMOUR, M. L., SAROVICH, D. 
S., PEARSON, T., ENGELTHALER, D. M., WAGNER, D. M., KEIM, P. S., 
SCHUPP, J. M. & CURRIE, B. J. 2012. Comparison of TaqMan PCR assays for 
detection of the melioidosis agent Burkholderia pseudomallei in clinical 
specimens. J Clin Microbiol, 50, 2059-62. 
KAMIONKA, A., PARCHE, S., NOTHAFT, H., SIEPELMEYER, J., JAHREIS, K., & 
TITGEMEYER, F. 2002. The phosphotransferase system of Streptomyces 
coelicolor. Eur J Biochem, 269, 2143-50. 
KANAI, K., SUZUKI, Y., KONDO, E., MAEJIMA, Y., MIYAMOTO, D., SUZUKI, T. 
& KURATA, T. 1997. Specific binding of Burkholderia pseudomallei cells and 
their cell-surface acid phosphatase to gangliotetraosylceramide (asialo GM1) 
and gangliotriaosylceramide (asialo GM2). Southeast Asian J Trop Med Public 
Health, 28, 781-90. 
KANG, Y., NORRIS, M. H., WILCOX, B. A., TUANYOK, A., KEIM, P. S. & 
HOANG, T. T. 2011. Knockout and pullout recombineering for naturally 
transformable Burkholderia thailandensis and Burkholderia pseudomallei. Nat 
Protoc, 6, 1085-104. 
KELLEY, L. A. & STERNBERG, M. J. 2009. Protein structure prediction on the Web: 
a case study using the Phyre server. Nat Protoc, 4, 363-71. 
 References 
165 
KESPICHAYAWATTANA, W., RATTANACHETKUL, S., WANUN, T., 
UTAISINCHAROEN, P. & SIRISINHA, S. 2000. Burkholderia pseudomallei 
induces cell fusion and actin-associated membrane protrusion: a possible 
mechanism for cell-to-cell spreading. Infect Immun, 68, 5377-84. 
KIRATISIN, P., SANTANIRAND, P., CHANTRATITA, N. & KAEWDAENG, S. 
2007. Accuracy of commercial systems for identification of Burkholderia 
pseudomallei versus Burkholderia cepacia. Diagn Microbiol Infect Dis, 59, 277-
81. 
KIYAMA, Y., MIYAHARA, K., & OHSHIMA, Y. 2012. Active uptake of artificial 
particles in the nematode Caenorhabditis elegans. J Exp Biol, 215, 1178-1183. 
KOH, T. H., YONG NG, L. S., FOON HO, J. L., SNG, L. H., WANG, G. C. & TZER 
PIN LIN, R. V. 2003. Automated identification systems and Burkholderia 
pseudomallei. J Clin Microbiol, 41, 1809. 
KONGSAENGDAO, S., BUNNAG, S. & SIRIWIWATTNAKUL, N. 2005. Treatment 
of survivors after the tsunami. N Engl J Med, 352, 2654-5. 
KORBSRISATE, S., TOMARAS, A. P., DAMNIN, S., CKUMDEE, J., SRINON, V., 
LENGWEHASATIT, I., VASIL, M. L. & SUPARAK, S. 2007. Characterization 
of two distinct phospholipase C enzymes from Burkholderia pseudomallei. 
Microbiology, 153, 1907-15. 
KOTHE, M., ANTL, M., HUBER, B., STOECKER, K., EBRECHT, D., STEINMETZ, 
I. & EBERL, L. 2003. Killing of Caenorhabditis elegans by Burkholderia 
cepacia is controlled by the cep quorum-sensing system. Cell Microbiol, 5, 343-
51. 
KUNAKORN, M., BOONMA, P., KHUPULSUP, K. & PETCHCLAI, B. 1990. 
Enzyme-linked immunosorbent assay for immunoglobulin M specific antibody 
for the diagnosis of melioidosis. J Clin Microbiol, 28, 1249-53. 
KUNAKORN, M. & MARKHAM, R. B. 1995. Clinically practical seminested PCR for 
Burkholderia pseudomallei quantitated by enzyme immunoassay with and 
without solution hybridization. J Clin Microbiol, 33, 2131-5. 
KVITKO, B. H., GOODYEAR, A., PROPST, K. L., DOW, S. W. & SCHWEIZER, H. 
P. 2012. Burkholderia pseudomallei known siderophores and hemin uptake are 
dispensable for lethal murine melioidosis. PLoS Negl Trop Dis, 6, e1715. 
LAUW, F. N., SIMPSON, A. J., PRINS, J. M., SMITH, M. D., KURIMOTO, M., VAN 
DEVENTER, S. J., SPEELMAN, P., CHAOWAGUL, W., WHITE, N. J. & 
VAN DER POLL, T. 1999. Elevated plasma concentrations of interferon (IFN)-
gamma and the IFN-gamma-inducing cytokines interleukin (IL)-18, IL-12, and 
IL-15 in severe melioidosis. J Infect Dis, 180, 1878-85. 
LEE, S. H., OOI, S. K., MAHADI, N. M., TAN, M. W., & NATHAN, S. 2011. 
Complete killing of Caenorhabditis elegans by Burkholderia pseudomallei is 
dependent on prolonged direct association with the viable pathogen. PLoS One, 
6, e16707. 
 References 
166 
LEW, A. E. & DESMARCHELIER, P. M. 1994. Detection of Pseudomonas 
pseudomallei by PCR and hybridization. J Clin Microbiol, 32, 1326-32. 
LIMMATHUROTSAKUL, D., CHANTRATITA, N., TEERAWATTANASOOK, N., 
PIRIYAGITPAIBOON, K., THANWISAI, A., WUTHIEKANUN, V., DAY, N. 
P., COOPER, B. & PEACOCK, S. J. 2011. Enzyme-linked immunosorbent 
assay for the diagnosis of melioidosis: better than we thought. Clin Infect Dis, 52, 
1024-8. 
LIMMATHUROTSAKUL, D., CHAOWAGUL, W., CHIERAKUL, W., 
STEPNIEWSKA, K., MAHARJAN, B., WUTHIEKANUN, V., WHITE, N. J., 
DAY, N. P. & PEACOCK, S. J. 2006. Risk factors for recurrent melioidosis in 
northeast Thailand. Clin Infect Dis, 43, 979-86. 
LIMMATHUROTSAKUL, D., KOH, G.C.K.W., PEACOCK. S.J. & CURRIE, B.J. 
2012.  Chronic melioidosis, relapse and latency.  In Ketheesan, N. (Eds.), 
Melioidosis: a century of observation and research (pp.120-129). Amsterdam, 
Netherlands: Elsevier. 
LIMMATHUROTSAKUL, D., WONGRATANACHEEWIN, S., 
TEERAWATTANASOOK, N., WONGSUVAN, G., CHAISUKSANT, S., 
CHETCHOTISAKD, P., CHAOWAGUL, W., DAY, N. P. & PEACOCK, S. J. 
2010. Increasing incidence of human melioidosis in Northeast Thailand. Am J 
Trop Med Hyg, 82, 1113-7. 
LIN, T. L., LEE, C. Z., HSIEH, P. F., TSAI, S. F. & WANG, J. T. 2008. 
Characterization of integrative and conjugative element ICEKp1-associated 
genomic heterogeneity in a Klebsiella pneumoniae strain isolated from a 
primary liver abscess. J Bacteriol, 190, 515-26. 
LO, T. J., ANG, L. W., JAMES, L. & GOH, K. T. 2009. Melioidosis in a tropical city 
state, Singapore. Emerg Infect Dis, 15, 1645-7. 
LOPRASERT, S., SALLABHAN, R., WHANGSUK, W. & MONGKOLSUK, S. 2002. 
The Burkholderia pseudomallei oxyR gene: expression analysis and mutant 
characterization. Gene, 296, 161-9. 
LOWE, P., ENGLER, C. & NORTON, R. 2002. Comparison of automated and 
nonautomated systems for identification of Burkholderia pseudomallei. J Clin 
Microbiol, 40, 4625-7. 
LUHACHACK, L. G., VISVIKIS, O., WOLLENBERG, A. C., LACY-HULBERT, A., 
STUART, L. M. & IRAZOQUI, J. E. 2012. EGL-9 controls C. elegans host 
defense specificity through prolyl hydroxylation-dependent and -independent 
HIF-1 pathways. PLoS Pathog, 8, e1002798. 
LUMJIAKTASE, P., DIGGLE, S. P., LOPRASERT, S., TUNGPRADABKUL, S., 
DAYKIN, M., CAMARA, M., WILLIAMS, P. & KUNAKORN, M. 2006. 
Quorum sensing regulates dpsA and the oxidative stress response in 
Burkholderia pseudomallei. Microbiology, 152, 3651-9. 
MALCZEWSKI, A. B., OMAN, K. M., NORTON, R. E. & KETHEESAN, N. 2005. 
Clinical presentation of melioidosis in Queensland, Australia. Trans R Soc Trop 
Med Hyg, 99, 856-60. 
 References 
167 
MAROHN, M. E., SANTIAGO, A. E., SHIREY, K. A., LIPSKY, M., VOGEL, S. N. & 
BARRY, E. M. 2012. Members of the Francisella tularensis phagosomal 
transporter subfamily of major facilitator superfamily transporters are critical for 
pathogenesis. Infect Immun, 80, 2390-401. 
MATHAI, E., JESUDASON, M. V. & ANBARASU, A. 2003. Indirect 
immunofluorescent antibody test for the rapid diagnosis of melioidosis. Indian J 
Med Res, 118, 68-70. 
MCCORMICK, J. B., SEXTON, D. J., MCMURRAY, J. G., CAREY, E., HAYES, P. 
& FELDMAN, R. A. 1975. Human-to-human transmission of Pseudomonas 
pseudomallei. Ann Intern Med, 83, 512-3. 
MEUMANN, E. M., NOVAK, R. T., GAL, D., KAESTLI, M. E., MAYO, M., 
HANSON, J. P., SPENCER, E., GLASS, M. B., GEE, J. E., WILKINS, P. P. & 
CURRIE, B. J. 2006. Clinical evaluation of a type III secretion system real-time 
PCR assay for diagnosing melioidosis. J Clin Microbiol, 44, 3028-30. 
MILLAN, J. M., MAYO, M., GAL, D., JANMAAT, A. & CURRIE, B. J. 2007. 
Clinical variation in melioidosis in pigs with clonal infection following possible 
environmental contamination from bore water. Vet J, 174, 200-2. 
MUANGMAN, S., KORBSRISATE, S., MUANGSOMBUT, V., SRINON, V., 
ADLER, N. L., SCHROEDER, G. N., FRANKEL, G. & GALYOV, E. E. 2011. 
BopC is a type III secreted effector protein of Burkholderia pseudomallei. 
FEMS Microbiol Lett, 323, 75-82. 
MUANGSOMBUT, V., SUPARAK, S., PUMIRAT, P., DAMNIN, S., 
VATTANAVIBOON, P., THONGBOONKERD, V. & KORBSRISATE, S. 
2008. Inactivation of Burkholderia pseudomallei bsaQ results in decreased 
invasion efficiency and delayed escape of bacteria from endocytic vesicles. Arch 
Microbiol, 190, 623-31. 
MULLER, C. M., CONEJERO, L., SPINK, N., WAND, M. E., BANCROFT, G. J. & 
TITBALL, R. W. 2012. Role of RelA and SpoT in Burkholderia pseudomallei 
virulence and immunity. Infect Immun, 80, 3247-55. 
NAIGOWIT, P., KURATA, T., WANGROONGSUB, P., PETKANJANAPONG, V., 
KONDO, E. & KANAI, K. 1993. Application of indirect immunofluorescence 
microscopy to colony identification of Pseudomonas pseudomallei. Asian Pac J 
Allergy Immunol, 11, 149-54. 
NANDI, T., & TAN, P. 2012. The Burkholderia pseudomallei genome – an emerging 
model for microbial complexicity and pathogen virulence. In Ketheesan, N. 
(Eds.), Melioidosis: a century of observation and research (pp.68-81). 
Amsterdam, Netherlands: Elsevier 
NATHAN, S., LI, H., MOHAMED, R. & EMBI, N. 2002. Phage display of 
recombinant antibodies toward Burkholderia pseudomallei exotoxin. J Biochem 
Mol Biol Biophys, 6, 45-53. 
NGAUY, V., LEMESHEV, Y., SADKOWSKI, L. & CRAWFORD, G. 2005. 
Cutaneous melioidosis in a man who was taken as a prisoner of war by the 
Japanese during World War II. J Clin Microbiol, 43, 970-2. 
 References 
168 
NIEVES, W., HEANG, J., ASAKRAH, S., HONER ZU BENTRUP, K., ROY, C. J. & 
MORICI, L. A. 2010. Immunospecific responses to bacterial elongation factor 
Tu during Burkholderia infection and immunization. PLoS One, 5, e14361. 
NORAZAH, A., ROHANI, M. Y., CHANG, P. T. & KAMEL, A. G. 1996. Indirect 
hemagglutination antibodies against Burkholderia pseudomallei in normal blood 
donors and suspected cases of melioidosis in Malaysia. Southeast Asian J Trop 
Med Public Health, 27, 263-6. 
NORRIS, M. H., PROPST, K. L., KANG, Y., DOW, S. W., SCHWEIZER, H. P. & 
HOANG, T. T. 2011. The Burkholderia pseudomallei Delta asd mutant exhibits 
attenuated intracellular infectivity and imparts protection against acute 
inhalation melioidosis in mice. Infect Immun, 79, 4010-8. 
NOVAK, R. T., GLASS, M. B., GEE, J. E., GAL, D., MAYO, M. J., CURRIE, B. J. & 
WILKINS, P. P. 2006. Development and evaluation of a real-time PCR assay 
targeting the type III secretion system of Burkholderia pseudomallei. J Clin 
Microbiol, 44, 85-90. 
NOYAL, M. J., HARISH, B. N., BHAT, V. & PARIJA, S. C. 2009. Neonatal 
melioidosis: a case report from India. Indian J Med Microbiol, 27, 260-3. 
O'BRIEN, M., FREEMAN, K., LUM, G., CHENG, A. C., JACUPS, S. P., & CURRIE, 
B. J. 2004. Further evaluation of a rapid diagnostic test for melioidosis in an area 
of endemicity. J Clin Microbiol, 42, 2239-40. 
O'QUINN, A. L., WIEGAND, E. M. & JEDDELOH, J. A. 2001. Burkholderia 
pseudomallei kills the nematode Caenorhabditis elegans using an endotoxin-
mediated paralysis. Cell Microbiol, 3, 381-93. 
OOI, S. K., LIM, T. Y., LEE, S. H. & NATHAN, S. 2012. Burkholderia pseudomallei 
kills Caenorhabditis elegans through virulence mechanisms distinct from 
intestinal lumen colonization. Virulence, 3, 485-96. 
ORTIZ-MARTIN, I., MACHO, A. P., LAMBERSTEN, L., RAMOS, C., & BEUZON, 
C. R. 2006. Suicide vectors for antibiotic marker exchange and rapid generation 
of multiple knockout mutants by allelic exchange in Gram-negative bacteria. J 
Microbiol Methods, 67, 395-407. 
PAGALAVAN, L. 2005. Melioidosis: the Johor Bahru experience. Med J Malaysia, 60, 
599-605. 
PEACOCK, S. J., CHIENG, G., CHENG, A. C., DANCE, D. A., AMORNCHAI, P., 
WONGSUVAN, G., TEERAWATTANASOOK, N., CHIERAKUL, W., DAY, 
N. P. & WUTHIEKANUN, V. 2005. Comparison of Ashdown's medium, 
Burkholderia cepacia medium, and Burkholderia pseudomallei selective agar 
for clinical isolation of Burkholderia pseudomallei. J Clin Microbiol, 43, 5359-
61. 
PEACOCK, S. J., SCHWEIZER, H. P., DANCE, D. A., SMITH, T. L., GEE, J. E., 
WUTHIEKANUN, V., DESHAZER, D., STEINMETZ, I., TAN, P. & CURRIE, 
B. J. 2008. Management of accidental laboratory exposure to Burkholderia 
pseudomallei and B. mallei. Emerg Infect Dis, 14, e2. 
 References 
169 
PETKANJANAPONG, V., NAIGOWIT, P., KONDO, E. & KANAI, K. 1992. Use of 
endotoxin antigens in enzyme-linked immunosorbent assay for the diagnosis of 
P. pseudomallei infections (melioidosis). Asian Pac J Allergy Immunol, 10, 145-
50. 
PILATZ, S., BREITBACH, K., HEIN, N., FEHLHABER, B., SCHULZE, J., 
BRENNEKE, B., EBERL, L. & STEINMETZ, I. 2006. Identification of 
Burkholderia pseudomallei genes required for the intracellular life cycle and in 
vivo virulence. Infect Immun, 74, 3576-86. 
PONGSUNK, S., THIRAWATTANASUK, N., PIYASANGTHONG, N. & EKPO, P. 
1999. Rapid identification of Burkholderia pseudomallei in blood cultures by a 
monoclonal antibody assay. J Clin Microbiol, 37, 3662-7. 
POWELL, J. R., & AUSUBEL, F. M. 2008. Models of Caenorhabditis elegans 
infection by bacterial and fungal pathogens. Methods Mol Biol, 415, 403-27. 
PROPST, K. L., MIMA, T., CHOI, K. H., DOW, S. W. & SCHWEIZER, H. P. 2010. A 
Burkholderia pseudomallei delta purM mutant is avirulent in immunocompetent 
and immunodeficient animals: candidate strain for exclusion from select-agent 
lists. Infect Immun, 78, 3136-43. 
PUMIRAT, P., CUCCUI, J., STABLER, R. A., STEVENS, J. M., MUANGSOMBUT, 
V., SINGSUKSAWAT, E., STEVENS, M. P., WREN, B. W. & 
KORBSRISATE, S. 2010. Global transcriptional profiling of Burkholderia 
pseudomallei under salt stress reveals differential effects on the Bsa type III 
secretion system. BMC Microbiol, 10, 171. 
PUTHUCHEARY, S. D. & NATHAN, S. A. 2006. Comparison by electron microscopy 
of intracellular events and survival of Burkholderia pseudomallei in monocytes 
from normal subjects and patients with melioidosis. Singapore Med J, 47, 697-
703. 
PUTHUCHEARY, S. D. 2009. Melioidosis in Malaysia. Med J Malaysia, 64, 266-74. 
PUTHUCHEARY, S. D., ANUAR, A. S., & TEE, T. S. 2010. Burkholderia 
thailandensis whole cell antigen cross-reacts with B. pseudomallei antibodies 
from patients with melioidosis in an immunofluorescent assay. Southeast Asian 
J Trop Med Public Health, 41, 395-400. 
PUTHUCHEARY, S. D., PARASAKTHI, N. & LEE, M. K. 1992. Septicaemic 
melioidosis: a review of 50 cases from Malaysia. Trans R Soc Trop Med Hyg, 86, 
683-5. 
PUTHUCHEARY, S. D., PUAH, S. M., CHAI, H. C., THONG, K. L. & CHUA, K. H. 
2012a. Molecular investigation of virulence determinants between a virulent 
clinical strain and an attenuated strain of Burkholderia pseudomallei. J Mol 
Microbiol Biotechnol, 22, 198-204. 
PUTHUCHEARY, S. D., & SAM, I. C. 2012b. Why is the response rate slow in 
ceftazidime therapy for melioidosis? Expert Rev Anti Infect Ther, 10,5-7. 
 
 References 
170 
PUTHUCHEARY S. D., & VADIVELU J. 2002. Clinical Manifestations, In: Human 
Melioidosis Singapore University Press, Singapore  pp:33-43 
RALPH, A., MCBRIDE, J. & CURRIE, B. J. 2004. Transmission of Burkholderia 
pseudomallei via breast milk in northern Australia. Pediatr Infect Dis J, 23, 
1169-71. 
RAMSAY, S. 2012. Medical imaging in melioidosis. In Ketheesan, N. (Eds.), 
Melioidosis: a century of observation and research (pp.174-180). Amsterdam, 
Netherlands: Elsevier. 
RATTANATHONGKOM, A., SERMSWAN, R. W. & WONGRATANACHEEWIN, S. 
1997. Detection of Burkholderia pseudomallei in blood samples using 
polymerase chain reaction. Mol Cell Probes, 11, 25-31. 
RECKSEIDLER, S. L., DESHAZER, D., SOKOL, P. A. & WOODS, D. E. 2001. 
Detection of bacterial virulence genes by subtractive hybridization: 
identification of capsular polysaccharide of Burkholderia pseudomallei as a 
major virulence determinant. Infect Immun, 69, 34-44. 
RECKSEIDLER-ZENTENO, S. L., DEVINNEY, R. & WOODS, D. E. 2005. The 
capsular polysaccharide of Burkholderia pseudomallei contributes to survival in 
serum by reducing complement factor C3b deposition. Infect Immun, 73, 1106-
15. 
REYRAT, J. M., PELICIC, V., GICQUEL, B. & RAPPUOLI, R. 1998. 
Counterselectable markers: untapped tools for bacterial genetics and 
pathogenesis. Infect Immun, 66, 4011-7. 
RHOLL, D. A., TRUNCK, L. A. & SCHWEIZER, H. P. 2008. In vivo Himar1 
transposon mutagenesis of Burkholderia pseudomallei. Appl Environ Microbiol, 
74, 7529-35. 
ROBERTSON, J., LEVY, A., SAGRIPANTI, J. L. & INGLIS, T. J. 2010. The survival 
of Burkholderia pseudomallei in liquid media. Am J Trop Med Hyg, 82, 88-94. 
ROLIM, D. B., VILAR, D. C., SOUSA, A. Q., MIRALLES, I. S., DE OLIVEIRA, D. 
C., HARNETT, G., O'REILLY, L., HOWARD, K., SAMPSON, I. & INGLIS, T. 
J. 2005. Melioidosis, northeastern Brazil. Emerg Infect Dis, 11, 1458-60. 
ROTZ, L. D., KHAN, A. S., LILLIBRIDGE, S. R., OSTROFF, S. M., & HUGHES, J. 
M. 2002. Public health assessment of potential biological terrorism agents. 
Emerg Infect Dis, 8, 225-30. 
RUGDECH, P., ANUNTAGOOL, N. & SIRISINHA, S. 1995. Monoclonal antibodies 
to Pseudomonas pseudomallei and their potential for diagnosis of melioidosis. 
Am J Trop Med Hyg, 52, 231-5. 
SAM, I. C. & PUTHUCHEARY, S. D. 2007. Melioidosis and rainfall in Kuala Lumpur, 
Malaysia. J Infect, 54, 519-20. 
SAMBROOK J. AND RUSSELL D.W. 2001. Molecular cloning: a laboratory manual 
(Volume 2). Cold Spring Harbor Laboratory Press. 
 References 
171 
SAMOSORNSUK, N., LULITANOND, A., SAENLA, N., ANUNTAGOOL, N., 
WONGRATANACHEEWIN, S. & SIRISINHA, S. 1999. Short report: 
evaluation of a monoclonal antibody-based latex agglutination test for rapid 
diagnosis of septicemic melioidosis. Am J Trop Med Hyg, 61, 735-7. 
SANTANIRAND, P., HARLEY, V. S., DANCE, D. A., DRASAR, B. S. & 
BANCROFT, G. J. 1999. Obligatory role of gamma interferon for host survival 
in a murine model of infection with Burkholderia pseudomallei. Infect Immun, 
67, 3593-600. 
SARKAR-TYSON, M., THWAITE, J. E., HARDING, S. V., SMITHER, S. J., 
OYSTON, P. C., ATKINS, T. P. & TITBALL, R. W. 2007. Polysaccharides and 
virulence of Burkholderia pseudomallei. J Med Microbiol, 56, 1005-10. 
SARTAIN, M. J., SLAYDEN, R. A., SINGH, K. K., LAAL, S. & BELISLE, J. T. 2006. 
Disease state differentiation and identification of tuberculosis biomarkers via 
native antigen array profiling. Mol Cell Proteomics, 5, 2102-13. 
SAUER, J. D., BACHMAN, M. A. & SWANSON, M. S. 2005. The phagosomal 
transporter A couples threonine acquisition to differentiation and replication of 
Legionella pneumophila in macrophages. Proc Natl Acad Sci U S A, 102, 9924-9. 
SCHWEIZER, H. P. & PEACOCK, S. J. 2008. Antimicrobial drug-selection markers 
for Burkholderia pseudomallei and B. mallei. Emerg Infect Dis, 14, 1689-92. 
SERMSWAN, R. W., WONGRATANACHEEWIN, S., ANUNTAGOOL, N. & 
SIRISINHA, S. 2000. Comparison of the polymerase chain reaction and 
serologic tests for diagnosis of septicemic melioidosis. Am J Trop Med Hyg, 63, 
146-9. 
SHALOM, G., SHAW, J. G. & THOMAS, M. S. 2007. In vivo expression technology 
identifies a type VI secretion system locus in Burkholderia pseudomallei that is 
induced upon invasion of macrophages. Microbiology, 153, 2689-99. 
SHIVERS, R. P., PAGANO, D. J., KOOISTRA, T., RICHARDSON, C. E., REDDY, K. 
C., WHITNEY, J. K., KAMANZI, O., MATSUMOTO, K., HISAMOTO, N. & 
KIM, D. H. 2010. Phosphorylation of the conserved transcription factor ATF-7 
by PMK-1 p38 MAPK regulates innate immunity in Caenorhabditis elegans. 
PLoS Genet, 6, e1000892. 
SIFRI, C. D., BEGUN, J., AUSUBEL, F. M. & CALDERWOOD, S. B. 2003. 
Caenorhabditis elegans as a model host for Staphylococcus aureus pathogenesis. 
Infect Immun, 71, 2208-17. 
SIRISINHA, S., ANUNTAGOOL, N., DHARAKUL, T., EKPO, P., 
WONGRATANACHEEWIN, S., NAIGOWIT, P., PETCHCLAI, B., 
THAMLIKITKUL, V. & SUPUTTAMONGKOL, Y. 2000. Recent 
developments in laboratory diagnosis of melioidosis. Acta Trop, 74, 235-45. 
SITTHIDET, C., KORBSRISATE, S., LAYTON, A. N., FIELD, T. R., STEVENS, M. 
P. & STEVENS, J. M. 2011. Identification of motifs of Burkholderia 
pseudomallei BimA required for intracellular motility, actin binding, and actin 
polymerization. J Bacteriol, 193, 1901-10. 
 References 
172 
SIVALINGAM, S.P., ULETT, G.C. & NELSON, M. 2012. Model of infection. In 
Ketheesan, N. (Eds.), Melioidosis: a century of observation and research 
(pp.242-256). Amsterdam, Netherlands: Elsevier. 
SONG, Y., XIE, C., ONG, Y. M., GAN, Y. H. & CHUA, K. L. 2005. The BpsIR 
quorum-sensing system of Burkholderia pseudomallei. J Bacteriol, 187, 785-90. 
SPLETTSTOESSER, W. D., FRANGOULIDIS, D. & PUTHUCHEARY, S. D. 2008. 
Validation and comparison of an extrapolysaccharide (EPS)-based in-house 
ELISA and the PanBio melioidosis rapid cassette test-kits for serodiagnosis of 
melioidosis in a non-endemic area. Trans R Soc Trop Med Hyg, 102 Suppl 1, 
S45-6. 
STANTON, A. T. & FLETCHER, W. 1921. Melioidosis, a new disease of the tropics. 
Trans. Fourth Congr Far East Assoc. Trop. Med., 2, 196-8. 
STANTON, A. T. & FLETCHER, W. 1932. Melioidosis. In Studies from the Institute 
for Medical Research, Federated Malay States London: John Bale and Danielson 
Ltd. 21. 
STEINMETZ, I., REGANZEROWSKI, A., BRENNEKE, B., HAUSSLER, S., 
SIMPSON, A. & WHITE, N. J. 1999. Rapid identification of Burkholderia 
pseudomallei by latex agglutination based on an exopolysaccharide-specific 
monoclonal antibody. J Clin Microbiol, 37, 225-8. 
STEVENS, J. M., GALYOV, E. E. & STEVENS, M. P. 2006. Actin-dependent 
movement of bacterial pathogens. Nat Rev Microbiol, 4, 91-101. 
STEVENS, J. M., ULRICH, R. L., TAYLOR, L. A., WOOD, M. W., DESHAZER, D., 
STEVENS, M. P. & GALYOV, E. E. 2005a. Actin-binding proteins from 
Burkholderia mallei and Burkholderia thailandensis can functionally 
compensate for the actin-based motility defect of a Burkholderia pseudomallei 
bimA mutant. J Bacteriol, 187, 7857-62. 
STEVENS, M. P., FRIEBEL, A., TAYLOR, L. A., WOOD, M. W., BROWN, P. J., 
HARDT, W. D. & GALYOV, E. E. 2003. A Burkholderia pseudomallei type III 
secreted protein, BopE, facilitates bacterial invasion of epithelial cells and 
exhibits guanine nucleotide exchange factor activity. J Bacteriol, 185, 4992-6. 
STEVENS, M. P., HAQUE, A., ATKINS, T., HILL, J., WOOD, M. W., EASTON, A., 
NELSON, M., UNDERWOOD-FOWLER, C., TITBALL, R. W., BANCROFT, 
G. J. & GALYOV, E. E. 2004. Attenuated virulence and protective efficacy of a 
Burkholderia pseudomallei bsa type III secretion mutant in murine models of 
melioidosis. Microbiology, 150, 2669-76. 
STEVENS, M. P., STEVENS, J. M., JENG, R. L., TAYLOR, L. A., WOOD, M. W., 
HAWES, P., MONAGHAN, P., WELCH, M. D. & GALYOV, E. E. 2005b. 
Identification of a bacterial factor required for actin-based motility of 
Burkholderia pseudomallei. Mol Microbiol, 56, 40-53. 
STEVENS, M. P., WOOD, M. W., TAYLOR, L. A., MONAGHAN, P., HAWES, P., 
JONES, P. W., WALLIS, T. S. & GALYOV, E. E. 2002. An Inv/Mxi-Spa-like 
type III protein secretion system in Burkholderia pseudomallei modulates 
intracellular behaviour of the pathogen. Mol Microbiol, 46, 649-59. 
 References 
173 
STIERNAGLE, T. (Ed.). (1999). Maintenance of C. elegans. New York: Oxford 
University Press. 
SU, Y. C., WAN, K. L., MOHAMED, R., & NATHAN, S. 2008. A genome level 
survey of Burkholderia pseudomallei immunome expressed during human 
infection. Microbes Infect, 10, 1335-45. 
SUN, G. W., LU, J., PERVAIZ, S., CAO, W. P. & GAN, Y. H. 2005. Caspase-1 
dependent macrophage death induced by Burkholderia pseudomallei. Cell 
Microbiol, 7, 1447-58. 
SUNDARESH, S., RANDALL, A., UNAL, B., PETERSEN, J. M., BELISLE, J. T., 
HARTLEY, M. G., DUFFIELD, M., TITBALL, R. W., DAVIES, D. H., 
FELGNER, P. L. & BALDI, P. 2007. From protein microarrays to diagnostic 
antigen discovery: a study of the pathogen Francisella tularensis. 
Bioinformatics, 23, i508-18. 
SUPAPROM, C., WANG, D., LEELAYUWAT, C., THAEWPIA, W., SUSAENGRAT, 
W., KOH, V., OOI, E. E., LERTMEMONGKOLCHAI, G. & LIU, Y. 2007. 
Development of real-time PCR assays and evaluation of their potential use for 
rapid detection of Burkholderia pseudomallei in clinical blood specimens. J Clin 
Microbiol, 45, 2894-901. 
SUPARAK, S., KESPICHAYAWATTANA, W., HAQUE, A., EASTON, A., 
DAMNIN, S., LERTMEMONGKOLCHAI, G., BANCROFT, G. J. & 
KORBSRISATE, S. 2005. Multinucleated giant cell formation and apoptosis in 
infected host cells is mediated by Burkholderia pseudomallei type III secretion 
protein BipB. J Bacteriol, 187, 6556-60. 
SUPUTTAMONGKOL, Y., HALL, A. J., DANCE, D. A., CHAOWAGUL, W., 
RAJCHANUVONG, A., SMITH, M. D. & WHITE, N. J. 1994. The 
epidemiology of melioidosis in Ubon Ratchatani, northeast Thailand. Int J 
Epidemiol, 23, 1082-90. 
SUWANNASAEN, D., MAHAWANTUNG, J., CHAOWAGUL, W., 
LIMMATHUROTSAKUL, D., FELGNER, P. L., DAVIES, H., BANCROFT, G. 
J., TITBALL, R. W. & LERTMEMONGKOLCHAI, G. 2011. Human immune 
responses to Burkholderia pseudomallei characterized by protein microarray 
analysis. J Infect Dis, 203, 1002-11. 
SUZUKI, T., MURAI, T., FUKUDA, I., TOBE, T., YOSHIKAWA, M. & 
SASAKAWA, C. 1994. Identification and characterization of a chromosomal 
virulence gene, vacJ, required for intercellular spreading of Shigella flexneri. 
Mol Microbiol, 11, 31-41. 
TAN, K. S., CHEN, Y., LIM, Y. C., TAN, G. Y., LIU, Y., LIM, Y. T., MACARY, P. & 
GAN, Y. H. 2010. Suppression of host innate immune response by Burkholderia 
pseudomallei through the virulence factor TssM. J Immunol, 184, 5160-71. 
TAN, M. W., MAHAJAN-MIKLOS, S. & AUSUBEL, F. M. 1999. Killing of 
Caenorhabditis elegans by Pseudomonas aeruginosa used to model mammalian 
bacterial pathogenesis. Proc Natl Acad Sci U S A, 96, 715-20. 
 
 References 
174 
TANDHAVANANT, S., THANWISAI, A., LIMMATHUROTSAKUL, D., 
KORBSRISATE, S., DAY, N. P., PEACOCK, S. J. & CHANTRATITA, N. 
2010. Effect of colony morphology variation of Burkholderia pseudomallei on 
intracellular survival and resistance to antimicrobial environments in human 
macrophages in vitro. BMC Microbiol, 10, 303. 
The C. ELEGANS SEQUENCING CONSORTIUM, 1998. Genome sequence of the 
nematode C. elegans: a platform for investigating biology. Science, 282, 2012-8.  
THEPTHAI, C., SMITHTIKARN, S., SUKSUWAN, M., SONGSIVILAI, S. & 
DHARAKUL, T. 2005. Serodiagnosis of melioidosis by a competitive enzyme-
linked immunosorbent assay using a lipopolysaccharide-specific monoclonal 
antibody. Asian Pac J Allergy Immunol, 23, 127-32. 
THOMPSON, D. B., CRANDALL, K., HARDING, S. V., SMITHER, S. J., KITTO, G. 
B., TITBALL, R. W. & BROWN, K. A. 2008. In silico analysis of potential 
diagnostic targets from Burkholderia pseudomallei. Trans R Soc Trop Med Hyg, 
102 Suppl 1, S61-5. 
THONGDEE, M., GALLAGHER, L. A., SCHELL, M., DHARAKUL, T., 
SONGSIVILAI, S. & MANOIL, C. 2008. Targeted mutagenesis of 
Burkholderia thailandensis and Burkholderia pseudomallei through natural 
transformation of PCR fragments. Appl Environ Microbiol, 74, 2985-9. 
TOMASO, H., PITT, T. L., LANDT, O., AL DAHOUK, S., SCHOLZ, H. C., 
REISINGER, E. C., SPRAGUE, L. D., RATHMANN, I. & NEUBAUER, H. 
2005. Rapid presumptive identification of Burkholderia pseudomallei with real-
time PCR assays using fluorescent hybridization probes. Mol Cell Probes, 19, 9-
20. 
TUANYOK, A. 2012. Genomic islands in Burkholderia pseudomallei. In Ketheesan, N. 
(Eds.), Melioidosis: a century of observation and research (pp.82-86). 
Amsterdam, Netherlands: Elsevier. 
TUANYOK, A., LEADEM, B. R., AUERBACH, R. K., BECKSTROM-STERNBERG, 
S. M., BECKSTROM-STERNBERG, J. S., MAYO, M., WUTHIEKANUN, V., 
BRETTIN, T. S., NIERMAN, W. C., PEACOCK, S. J., CURRIE, B. J., 
WAGNER, D. M. & KEIM, P. 2008. Genomic islands from five strains of 
Burkholderia pseudomallei. BMC Genomics, 9, 566. 
TUANYOK, A., TOM, M., DUNBAR, J. & WOODS, D. E. 2006. Genome-wide 
expression analysis of Burkholderia pseudomallei infection in a hamster model 
of acute melioidosis. Infect Immun, 74, 5465-76. 
ULRICH, R. L., DESHAZER, D., BRUEGGEMANN, E. E., HINES, H. B., OYSTON, 
P. C. & JEDDELOH, J. A. 2004. Role of quorum sensing in the pathogenicity of 
Burkholderia pseudomallei. J Med Microbiol, 53, 1053-64. 
UTAISINCHAROEN, P., ANUNTAGOOL, N., LIMPOSUWAN, K., CHAISURIYA, 
P. & SIRISINHA, S. 2003. Involvement of beta interferon in enhancing 
inducible nitric oxide synthase production and antimicrobial activity of 
Burkholderia pseudomallei-infected macrophages. Infect Immun, 71, 3053-7. 
 References 
175 
UTAISINCHAROEN, P., ARJCHAROEN, S., LENGWEHASATIT, I., 
LIMPOSUWAN, K. & SIRISINHA, S. 2005. Burkholderia pseudomallei 
invasion and activation of epithelial cells requires activation of p38 mitogen-
activated protein kinase. Microb Pathog, 38, 107-12. 
UTAISINCHAROEN, P., ARJCHAROEN, S., LIMPOSUWAN, K., 
TUNGPRADABKUL, S. & SIRISINHA, S. 2006. Burkholderia pseudomallei 
RpoS regulates multinucleated giant cell formation and inducible nitric oxide 
synthase expression in mouse macrophage cell line (RAW 264.7). Microb 
Pathog, 40, 184-9. 
UTAISINCHAROEN, P., TANGTHAWORNCHAIKUL, N., 
KESPICHAYAWATTANA, W., ANUNTAGOOL, N., CHAISURIYA, P. & 
SIRISINHA, S. 2000. Kinetic studies of the production of nitric oxide (NO) and 
tumour necrosis factor-alpha (TNF-alpha) in macrophages stimulated with 
Burkholderia pseudomallei endotoxin. Clin Exp Immunol, 122, 324-9. 
UTAISINCHAROEN, P., TANGTHAWORNCHAIKUL, N., 
KESPICHAYAWATTANA, W., CHAISURIYA, P. & SIRISINHA, S. 2001. 
Burkholderia pseudomallei interferes with inducible nitric oxide synthase (iNOS) 
production: a possible mechanism of evading macrophage killing. Microbiol 
Immunol, 45, 307-13. 
VADIVELU, J. & PUTHUCHEARY, S. D. 2000. Diagnostic and prognostic value of 
an immunofluorescent assay for melioidosis. Am J Trop Med Hyg, 62, 297-300. 
VADIVELU, J., PUTHUCHEARY, S. D., GENDEH, G. S. & PARASAKTHI, N. 1995. 
Serodiagnosis of melioidosis in Malaysia. Singapore Med J, 36, 299-302. 
VALADE, E., THIBAULT, F. M., GAUTHIER, Y. P., PALENCIA, M., POPOFF, M. 
Y. & VIDAL, D. R. 2004. The PmlI-PmlR quorum-sensing system in 
Burkholderia pseudomallei plays a key role in virulence and modulates 
production of the MprA protease. J Bacteriol, 186, 2288-94. 
VANAPORN, M., WAND, M., MICHELL, S. L., SARKAR-TYSON, M., IRELAND, 
P., GOLDMAN, S., KEWCHAROENWONG, C., RINCHAI, D., 
LERTMEMONGKOLCHAI, G. & TITBALL, R. W. 2011. Superoxide 
dismutase C is required for intracellular survival and virulence of Burkholderia 
pseudomallei. Microbiology, 157, 2392-400. 
VASU, C., VADIVELU, J. & PUTHUCHEARY, S. D. 2003. The humoral immune 
response in melioidosis patients during therapy. Infection, 31, 24-30. 
WAJANAROGANA, S., NIMNUCH, P., THONGMEE, A. & KRITSIRIWUTHINAN, 
K. 2013. Potential of recombinant flagellin fragment from Burkholderia 
thailandensis as an antigen for melioidosis antibody detection by indirect ELISA. 
Mol Cell Probes, 27, 98-102. 
WALSH, A. L., SMITH, M. D., WUTHIEKANUN, V., SUPUTTAMONGKOL, Y., 
DESAKORN, V., CHAOWAGUL, W. & WHITE, N. J. 1994. 
Immunofluorescence microscopy for the rapid diagnosis of melioidosis. J Clin 
Pathol, 47, 377-9. 
 References 
176 
WANG, C. Y., YAP, B. H. & DELILKAN, A. E. 1993. Melioidosis pneumonia and 
blast injury. Chest, 103, 1897-9. 
WARAWA, J., & WOODS, D. E. 2005. Type III secretion system cluster 3 is required 
for maximal virulence of Burkholderia pseudomallei in a hamster infection 
model. FEMS Microbiol Lett, 242, 101-8. 
WEISSERT, C., DOLLENMAIER, G., RAFEINER, P., RIEHM, J. & SCHULTZE, D. 
2009. Burkholderia pseudomallei misidentified by automated system. Emerg 
Infect Dis, 15, 1799-801. 
WEST, T. E., CHIERAKUL, W., CHANTRATITA, N., LIMMATHUROTSAKUL, D., 
WUTHIEKANUN, V., EMOND, M. J., HAWN, T. R., PEACOCK, S. J. & 
SKERRETT, S. J. 2012. Toll-like receptor 4 region genetic variants are 
associated with susceptibility to melioidosis. Genes Immun, 13, 38-46. 
WHITE, N. J. 2003. Melioidosis. Lancet, 361, 1715-22. 
WHITE, J. G., SOUTHGATE, E., THOMSON, J. N., & BRENNER, S. 1986. The 
structure of the nervous system of the nematode Caenorhabditis elegans. Philos 
Trans R Soc Lond B Biol Sci, 314, 1-340. 
WIERSINGA, W. J., CURRIE, B. J. & PEACOCK, S. J. 2012. Melioidosis. N Engl J 
Med, 367, 1035-44. 
WIERSINGA, W. J., VAN DER POLL, T., WHITE, N. J., DAY, N. P. & PEACOCK, 
S. J. 2006. Melioidosis: insights into the pathogenicity of Burkholderia 
pseudomallei. Nat Rev Microbiol, 4, 272-82. 
WIERSINGA, W. J., WIELAND, C. W., DESSING, M. C., CHANTRATITA, N., 
CHENG, A. C., LIMMATHUROTSAKUL, D., CHIERAKUL, W., 
LEENDERTSE, M., FLORQUIN, S., DE VOS, A. F., WHITE, N., DONDORP, 
A. M., DAY, N. P., PEACOCK, S. J. & VAN DER POLL, T. 2007. Toll-like 
receptor 2 impairs host defense in gram-negative sepsis caused by Burkholderia 
pseudomallei (Melioidosis). PLoS Med, 4, e248. 
WONG, K. T., PUTHUCHEARY, S. D. & VADIVELU, J. 1995. The histopathology of 
human  melioidosis. Histopathology, 26, 51-5. 
WONGRATANACHEEWIN, S., KESPICHAYAWATTANA, W., INTACHOTE, P., 
PICHYANGKUL, S., SERMSWAN, R. W., KRIEG, A. M. & SIRISINHA, S. 
2004. Immunostimulatory CpG oligodeoxynucleotide confers protection in a 
murine model of infection with Burkholderia pseudomallei. Infect Immun, 72, 
4494-502. 
WONGTRAKOONGATE, P., ROYTRAKUL, S., YASOTHORNSRIKUL, S. & 
TUNGPRADABKUL, S. 2011. A proteome reference map of the causative 
agent of melioidosis Burkholderia pseudomallei. J Biomed Biotechnol, 2011, 
530926. 
WOO, P. C., LEUNG, P. K., WONG, S. S., HO, P. L. & YUEN, K. Y. 2001. groEL 
encodes a highly antigenic protein in Burkholderia pseudomallei. Clin Diagn 
Lab Immunol, 8, 832-6. 
 References 
177 
WUTHIEKANUN, V., AMORNCHAI, P., CHIERAKUL, W., CHENG, A. C., WHITE, 
N. J., PEACOCK, S. J. & DAY, N. P. 2004. Evaluation of immunoglobulin M 
(IgM) and IgG rapid cassette test kits for diagnosis of melioidosis in an area of 
endemicity. J Clin Microbiol, 42, 3435-7. 
WUTHIEKANUN, V., CHIERAKUL, W., LANGA, S., CHAOWAGUL, W., 
PANPITPAT, C., SAIPAN, P., THOUJAIKONG, T., DAY, N. P. & PEACOCK, 
S. J. 2006a. Development of antibodies to Burkholderia pseudomallei during 
childhood in melioidosis-endemic northeast Thailand. Am J Trop Med Hyg, 74, 
1074-5. 
WUTHIEKANUN, V., CHIERAKUL, W., RATTANALERTNAVEE, J., LANGA, S., 
SIRODOM, D., WATTANAWAITUNECHAI, C., WINOTHAI, W., WHITE, N. 
J., DAY, N. & PEACOCK, S. J. 2006b. Serological evidence for increased 
human exposure to Burkholderia pseudomallei following the tsunami in 
southern Thailand. J Clin Microbiol, 44, 239-40. 
WUTHIEKANUN, V., DESAKORN, V., WONGSUVAN, G., AMORNCHAI, P., 
CHENG, A. C., MAHARJAN, B., LIMMATHUROTSAKUL, D., 
CHIERAKUL, W., WHITE, N. J., DAY, N. P. & PEACOCK, S. J. 2005. Rapid 
immunofluorescence microscopy for diagnosis of melioidosis. Clin Diagn Lab 
Immunol, 12, 555-6. 
WUTHIEKANUN, V., SMITH, M. D., DANCE, D. A., WALSH, A. L., PITT, T. L. & 
WHITE, N. J. 1996. Biochemical characteristics of clinical and environmental 
isolates of Burkholderia pseudomallei. J Med Microbiol, 45, 408-12. 
YABUUCHI, E., KOSAKO, Y., OYAIZU, H., YANO, I., HOTTA, H., HASHIMOTO, 
Y., EZAKI, T. & ARAKAWA, M. 1992. Proposal of Burkholderia gen. nov. 
and transfer of seven species of the genus Pseudomonas homology group II to 
the new genus, with the type species Burkholderia cepacia (Palleroni and 
Holmes 1981) comb. nov. Microbiol Immunol, 36, 1251-75. 
YU, Y., KIM, H. S., CHUA, H. H., LIN, C. H., SIM, S. H., LIN, D., DERR, A., 
ENGELS, R., DESHAZER, D., BIRREN, B., NIERMAN, W. C. & TAN, P. 
2006. Genomic patterns of pathogen evolution revealed by comparison of 
Burkholderia pseudomallei, the causative agent of melioidosis, to avirulent 
Burkholderia thailandensis. BMC Microbiol, 6, 46. 
YUEN, C. W., ONG, E. B., MOHAMAD, S., MANAF, U. A. & NAJIMUDIN, N. 2012. 
Construction and characterization of a Burkholderia pseudomallei wzm deletion 
mutant. J Microbiol Biotechnol, 22, 1336-42. 
ZHANG, Y., LU, H., & BARGMANN, C. I. 2005. Pathogenic bacteria induce aversive 
olfactory learning in Caenorhabditis elegans. Nature, 438, 179-184. 
ZHOU, X. H., OBUCHOWSKI, N.A. & MCCLISH D.K. 2011.  Measure of diagnostic 
accuracy. In Statistical methods in diagnostic medicine (pp. 15-56). New Jersey, 
United Statess: John Wiley & Sons. 
ZONG, Z., WANG, X., DENG, Y. & ZHOU, T. 2012. Misidentification of 
Burkholderia pseudomallei as Burkholderia cepacia by the VITEK 2 system. J 
Med Microbiol, 61, 1483-4. 
  
Publications 
178 
 
Publications  
  
1. PUTHUCHEARY, S. D., PUAH, S. M., CHAI, H. C., THONG, K. L. & CHUA, 
K. H. 2012. Molecular investigation of virulence determinants between a 
virulent clinical strain and an attenuated strain of Burkholderia pseudomallei. J 
Mol Microbiol Biotechnol, 22, 198-204. 
  
2. PUAH, S. M., PUTHUCHEARY, S. D., & CHUA, K. H. 2013. Potential 
immunogenic polypeptides of Burkholderia pseudomallei identified by shotgun 
expression library and evaluation of their efficacy for serodiagnosis of 
melioidosis. Int J Med Sci, 10, 539-47. 
 
3. Molecular characterization of putative virulent determinants of Burkholderia 
pseudomallei. (Submitted, 2014) 
 
4. A systematic review for serological antibody detection tests in diagnosis of 
melioidosis. (Manuscript in preparation) 
 
 
 
  
Appendices 
 
179 
APPENDICES 
            
Appendix I:    Sources of chemicals and reagents 
Company Origin Reagents 
  ▪ Bovine serum albumin (BSA) 
▪ Boric acid (H3BO3) 
▪ Ethylenediamine tetraacetate (EDTA) 
▪ Fish gelatin 
▪ Sodium chloride (NaCl) 
▪ Sodium dodecyl sulfate (SDS) 
▪ Tris-base 
▪ Tris, Tris (Hydroxymethyl) aminomethane 
▪ Triton X -100 
▪ Tween-20 
BD USA ▪ Bacto Agar 
▪ Bacto Peptone 
▪ LB agar Miller 
▪ LB broth 
▪ Tryptic soy agar 
Bio-Rad 
laboratories Ltd. 
USA ▪ Acrylamide:bisacrylamide (29:1) (30 % w/v) solution 
▪ Ammonium persulfate (APS) 
▪ N,N,N’,N’-tetramethylethylenediamine (TEMED) 
Carolina USA Caenorhabditis elegans N2 (wild type strain) 
Fermentas Life 
Sciences 
USA ▪ 50 bp and 100 bp DNA molecular weight markers 
▪ DreamTaq DNA polymerase 
GCC UK ▪ Absolute ethanol (EtOH) 
Life 
technologies 
USA ▪ DMEM with L-glutamine 
▪ Fetal Bovine Serum 
▪ Gentamycin 
▪ Penicillin-Streptomycin 
▪ TrypLE 
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Appendix I (Continued) 
Company Origin Reagents 
Merck Germany ▪ Ampicilin 
▪ Carbenicillin 
▪ Chloramphenicol 
▪ Ethidium Bromide (EtBr) 
▪ Glycine 
▪ Potassium dihydrogen phosphate (KH2PO4) 
▪ Magnesium sulphate (MgSO4) 
▪ Sodium hydroxide (NaOH) 
▪ Disodium phosphate (Na2HPO4) 
▪ Phosphate-buffered saline (PBS) 
Nacalai Tesque Japan ▪ Calcium chloride (CaCl2) 
▪ Cholesterol 
▪ Glucose 
▪ Sorbitol 
▪ Sucrose 
▪ Streptomycin 
▪ Trisodium citrate dehydrate (C6H5Na3O7.2H2O) 
New England 
Biolabs (NEB) 
Inc. 
UK ▪ CIP 
▪ Restrictions enzymes EcoRI, NcoI,  Not I 
▪ T4 DNA Ligase 
Pierce USA ▪ AP-conjugated Immunopure® ProteinA/G 
▪ BCIP/NBT phosphatase substrate 
Promega USA ▪ Agarose powder 
▪ Isopropyl b-D-thiogalacpyranoside (IPTG) 
▪ X-gal 
Sigma-Aldrich USA ▪ Kanamycin 
▪ Laemmli buffer 
▪ Tetracycline 
Takara Japan ▪ LA taq polymerase 
VWR USA ▪ Methanol 
▪ Sulfuric acid 
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Appendix II:    Commonly used stock solutions 
 
50 mg/mL Ampicillin 
Ampicillin                                                 0.5 g 
sdH2O to                                                 10 mL 
The stock solution was sterilized by filtration and aliquoted into smaller working 
volumes of 1 ml, which were kept at -20ºC. 
 
50 mg/mL Carbenicillin 
Carbenicillin                                    0.5 g 
sdH2O to                                              10    mL 
The stock solution was sterilized by filtration and aliquoted into smaller working 
volumes of 1 ml, which were kept at -20ºC. 
 
25 mg/mL Chloramphenicol 
Chloramphenicol                                  0.25 g 
Ethanol (100%) to                                            10 mL 
The powder was dissolved in absolute ethanol and sterilized by filtration.  Next, the 
solution was aliquoted into smaller working volumes of 1 ml, which were kept at -20ºC. 
 
25 mg/mL Isopropyl b-D-thiogalacpyranoside (IPTG)  
IPTG                                  0.25 g 
sdH2O to                                                 10 mL 
The stock solution was sterilized by filtration and aliquoted into smaller working 
volumes of 1 ml, which were kept at -20ºC. 
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25 mg/mL Kanamycin  
Kanamycin sulfate                                 0.25 g 
sdH2O to                                                  10 mL 
The stock solution was sterilized by filtration and aliquoted into smaller working 
volumes of 1 ml, which were kept at -20ºC. 
 
50 mg/mL Streptomycin  
Streptomycin                                   0.5 g  
sdH2O to                                                  10 mL 
The stock solution was sterilized by filtration and aliquoted into smaller working 
volumes of 1 ml, which were kept at -20ºC. 
 
5 mg/mL Tetracycline 
Tetracyline                                               0.25 g 
sdH2O to                                                  50 mL 
The stock solution was sterilized by filtration and aliquoted into smaller working 
volumes of 1 ml, which were kept at -20ºC. 
 
20 mg/mL 5-bromo-4-chloro-3-indolyl b-D-galactopyranoside (X-gal) 
X-gal                                     0.2 g  
dimethylformamide                                           10 mL 
The stock solution was mixed well and aliquoted into smaller working volumes of 1 ml 
in microcentrifuge tubes which were wrapped in foil to protect it from light and kept at -
20ºC. 
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Ethanol (EtOH) 
Ethanol was used in various concentrations (v/v), i.e., 70 and 100%.  The stock of 
absolute ethanol was adjusted with sdH2O accordingly. 
 
LB agar 
Difco 
TM
  LB Agar, Miller                          40 g 
sdH2O to                                                    1000 mL 
The powder was completely dissolved in 800 mL of sdH2O by heating with frequent 
agitation.  The volume was then adjusted to 1 liter and sterilized by autoclaving.  
 
LB broth 
Difco 
TM
 LB Broth, Miller                          25 g 
sdH2O to                                                    1000 mL 
The powder was completely dissolved in 800 mL of sdH2O by heating with frequent 
agitation.  The volume was then adjusted to 1 liter and sterilized by autoclaving. 
 
Minimal medium plate 
5 X M9 salts            200    mL 
1 M MgSO4                2    mL 
20% glucose              20    mL 
1 M CaCl2                0.1 mL 
Agar               15    g 
The volume was then adjusted to 1 liter and sterilized by autoclaving. 
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Tryptic Soy Agar (TSA) 
Difco 
TM 
 TSA agar                                 40 g 
sdH2O to                                            1000 mL 
The powder was completely dissolved in 800 mL of sdH2O by heating with frequent 
agitation.  The volume was then adjusted to 1 liter and sterilized by autoclaving. 
 
   
Appendix III:    Caenorhabditis elegans killing assay 
 
Nematode growth agar 
Agar                                     17    g   
NaCl                                       2.9 g            
Peptone                                      2.5 g                     
1 M  CaCl2                                         1 ml            
5 mg/mL Cholesterol                  1 mL         
1 M MgSO4                   1 mL 
1 M KH2PO4                 25 mL 
sdH2O to                                                      1000 ml 
The first 3 reagents were mixed and sterilized by autoclaving.  Next, the last 4 reagents 
were added after the mixture was cooling to 55°C. 
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M9 buffer 
KH2PO4                                         3 g            
Na2HPO4                              6 g         
NaCl                               5 g 
1 M MgSO4                                                       1 mL 
sdH2O to                                                      1000 mL 
The first 3 reagents were mixed and filter sterilized by using a 0.45 µm filter.  Next, 1 
mL of 1 M MgSO4 was added when the solution was cooling to 55°C. 
 
Freezing buffer 
1 M NaCl                                      20 mL            
1 M KH2PO4, pH 6               10 mL 
Glycerol                                                          60 mL 
0.1 M MgSO4              0.6  mL 
 sdH2O to                                                     200  mL 
The first 3 reagents were mixed and sterilized by autoclaving.  Next, 0.6 mL of 0.1 M 
MgSO4 was added under sterile condition when the solution was cooling to 55°C. 
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Appendix IV:    Solutions used in agarose gel electrophoresis (AGE) and sodium  
    dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)  
 
10X Tris-borate EDTA buffer (TBE), pH 8.3 
Tris base                108 g 
Boric acid                     55 g 
0.5 M EDTA                             40 mL 
sdH2O to                        1000 mL 
A 10X TBE stock solution was prepared and stored at room temperature.  It was used as 
soon as possible because precipitation occurred on long storage.  The solution was 
diluted to appropriate strengths, i.e., 5X or 1X for use.   
 
6X Loading Dye (LD) 
Bromophenol blue               0.25 g 
Xylene cyanol              0.25 g 
Glycerol            50      mL 
1 M Tris, pH 8.0             1      mL 
sdH2O to                          100      mL 
The 100 mL stock solution was prepared by mixing all of the above mentioned and 
stored at room temperature.  
 
10 mg/mL Ethidium bromide (EtBr) 
EtBr      0.1 g 
sdH2O to              10    mL 
The stock solution was prepared and stored at room temperature in a bottle wrapped in 
aluminium foil.  EtBr was used at a final concentration of 0.5 µg/mL. 
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10% (w/v) Ammonium persulphate (APS) 
APS                  0.02 g 
sdH2O            200     µL 
The above solution was prepared freshly prior to use.  
 
4X Tris.Cl/SDS (pH 6.8) 
Tris base                6.05 g 
sdH2O            100     mL 
Tris base was dissolved in 40 mL H2O and pH adjusted to pH6.8 with 1 N HCl, later 
H2O was added to 100 mL.  The solution was then filtered through a 0.45 µM filter and 
0.4 g of SDS was added into solution and stored at 4°C.  
 
4X Tris.Cl/SDS (pH 8.8) 
Tris base              91      g 
sdH2O            500     mL 
Tris base was dissolved in 300 mL H2O and pH adjusted to pH8.8 with 1 N HCl, later 
H2O was added to 500 mL.  The solution was then filtered through a 0.45 µM filter and 
2 g of SDS was added into solution and stored at 4°C.  
 
5X SDS running buffer 
Tris base                   15 g 
Glycine                 72 g 
SDS                    5 g 
sdH2O                         1000 mL 
The 1000 mL stock solution was prepared by mixing all of the above mentioned and 
stirred until all dissolved. The solution was diluted to 1X for use.   
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Appendix V:    Solutions used in Colony-blot detection 
 
10% Sodium Dodecyl Sulphate (SDS)                                   
SDS                                      100  g   
sdH2O to                                                       1000 mL 
The solution was adjusted to pH7.2 with HCl. 
 
Denaturing solution 
NaOH                          20     g 
NaCl               87.7  g 
sdH2O to                       1000 mL 
NaOH and NaCl were slowly dissolved in sdH2O and autoclaved at 121ºC for 15 
minutes, and stored at room temperature. 
 
Neutralization solution 
NaCl                87.7 g 
Tris base                   60.6 g 
sdH2O to                          1000 mL 
NaCl and Tris base were slowly dissolved in sdH2O, adjusted to pH7.4 with HCl and 
autoclaved at 121ºC for 15 minutes, and stored at room temperature. 
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20X Saline Sodium Citrate (SSC) 
NaCl             175.3 g 
Sodium citrate.2H2O             88.2 g 
sdH2O to                        1000 mL 
NaCl and sodium citrate.2H2O was slowly dissolved in sdH2O.  The pH of the solution 
was then adjusted to 7.0 with HCl.  The stock solution was autoclaved at 121ºC for 15 
minutes, and stored at room temperature. 
 
Appendix VI:    Solutions used in Western blot analysis 
 
Towbin Transfer buffer 
Tris                   3    g 
Glycine               14.4 g 
SDS       1    g 
Methanol                200 mL 
sdH2O to                           800 mL 
NaCl and sodium citrate.2H2O was slowly dissolved in sdH2O.  The pH of the solution 
was then adjusted to 7.0 with HCl.  The stock solution was autoclaved at 121ºC for 15 
minutes, and stored at room temperature. 
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10X Tris Buffered Saline (TBS), pH 7.5 
Tris HCl                   24    g 
Tris base                  5.6 g 
NaCl                 88    g 
sdH2O to                         1000  mL 
All 3 materials were slowly dissolved in 800 mL sdH2O.  The pH of the solution was 
then adjusted to 7.5 and lastly sdH2O was added to a final volume of 1 liter.   The 
solution was diluted to 1X for use.   
 
1X Tris Buffered Saline 0.05% Tween-20 (TBST), pH 7.5 
One hundred mL of 10X TBS was diluted with 900 mL sdH2O and 0.5 mL of Tween-20 
was then added into the solution. 
 
Blocking buffer 
One percent of gelation was added into 1X PBS prior to the experiment and was used 
immediately. 
 
1X TES 
Tris-HCl                                                        24.23 g  
EDTA                                                             0.19  g 
Sucrose                                                         171.2  g 
sdH2O to               1000 mL 
The solution above was filtered by using a 0.45 µm filter and kept at 4ºC.  The solution 
was diluted to 1/5X TES buffer by adding 1 volume of 1X TES buffer to 4 volumes of 
sdH2O. 
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Appendix VII:    Solutions used in ELISA assay 
 
1X Phosphate Buffered Saline (PBS), pH 7.3-7.5 
OmniPur PBS tablet             1 tablet 
sdH2O to                              100 mL 
The tablet was slowly dissolved in 100 mL sdH2O and stored at room temperature. 
 
1X Phosphate Buffered Saline 0.2% Tween-20 (PBST) 
Of 100 mL of 1X PBS, 0.2 mL of Tween-20 was then added into the solution. 
 
Blocking buffer 
One gram of bovine serum albumin was added into 100 mL of 1X PBST prior to the 
experiment and was used immediately. 
 
Stop buffer  
0.1 M H2SO4 
Sulfuric acid (H2SO4 1M)                                  5.6  mL  
sdH2O to               100     mL 
Sulfuric acid was slowly added to 80 mL sdH2O and mixing well, and was then adjusted 
to final volume of 100 mL.  The solution was then diluted to 1/10X buffer by adding 1 
volume of 1M H2SO4  to 9 volumes of sdH2O. 
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Appendix VIII:    Example of sequencing result 
 Chromatogram of 1229281_2784_Ins_2784R 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Sequence alignment using ClustalW 
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Appendix IX:    Raw data for replication of bacteria in macrophage cells  
 
No Hours Before normalization (cfu) After normalization (%) 
    2 4 8 2 4 8 
1 Bp-CMS 1.13E+07 1.52E+07 1.57E+07 100 134 138 
                
2 BPSL2033::Km 6.89E+06 4.63E+06 2.08E+06 100 67 30 
  Complemented-strains 1.30E+07 1.24E+07 9.84E+06 100 96 76 
                
3 BP1026B_I2780::Km 2.56E+07 1.86E+07 1.14E+07 100 73 44 
  Complemented-strains 2.87E+07 2.68E+07 1.49E+07 100 93 52 
                
4 BP1026B_I2784::Km 8.24E+06 7.36E+06 8.11E+06 100 89 98 
  Complemented-strains 1.26E+07 1.03E+07 7.64E+06 100 82 61 
                
5 BURPS1106A_A0094::Km 1.91E+07 1.06E+07 3.12E+06 100 55 16 
  Complemented-strains 1.72E+07 1.93E+07 6.64E+06 100 113 39 
                
6 BURPS1106A_1131::Km 1.35E+07 8.49E+06 9.77E+06 100 63 72 
  Complemented-strains 5.68E+06 6.27E+06 1.68E+06 100 110 30 
                
7 BURPS1710A_1419::Km 1.31E+07 1.13E+07 5.73E+06 100 87 44 
  Complemented-strains 3.48E+07 2.90E+07 2.92E+07 100 83 84 
                
8 BPSL3147::Km 8.10E+06 6.62E+06 3.74E+06 100 82 46 
  Complemented-strains 1.93E+07 2.14E+07 1.59E+07 100 111 82 
                
 
*Raw data of before normalization represent the mean value obtained from 3 separate   
  experiments and each experiment was performed in 3 technical replicates for each time  
  point. 
 
